¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/4/26 ¤U¤È 07:15:59
²Ä 549 ½g¦^À³
|
¤ß®®©P¤G(4/23)Àò±o³æ¹ç»Ä(Compositions containing tannic acids and uses thereof )ªº¬ü°ê±M§Q®É(10,265,336) Åý¤H·Q°_¹ù¥S¦~ªìªº¤@½g±M¤å [ 108¦~·s¦~·s§Æ±æ: §Ú¹ï SND-7ªº´Á«Ý ] liawbf.pixnet.net/blog/post/48772971 ±M¤å½Í¤Î ²{¦æ§Üºë¯«ÃĪ«ªº°Æ§@¥Î---¥NÁ¯gÔ¸s(MetS) SND-7°£¤F°w¹ï§Üºë¯«ªvÀø , ÁÙ¦³®ø°£©Î´î»´²{¦æÃĪ«¥NÁ¯gÔ¸sªºÂù«§@¥Î 2018/9 Àò±oªº±M§Q Compositions containing benzoate compound and tannic acid for treating central nervous system disorders (10,064,833) ·|¤£·|SND-7¤]¬O³oÓ²Õ¦X , ¥u¤£¹L°t¤è¤ñ¨Ò¤£¦P¦Ó¤w?
1.³æ¹ç»Ä (TA)°§C¦å¿}¤ô¥ , §í¨îªÎDªº½×¤å
³æ¹ç»Ä (TA)¨ë¿E¸²µå¿}Âà¹B¨Ã§í¨î3T3-L1²ÓM¤¤ªº¯×ªÕ²ÓM¤À¤Æ academic.oup.com/jn/article/135/2/165/4663627
ªÎD¬OXºî¦X¼x©MII«¬¿}§¿¯f¡]T2D¡^ªº¥Dn¦MÀI¦]¯À¡CµM¦Ó¡A¤j¦h¼Æ°¿}ÃĪº§Ü¿}§¿¯fÃĪ«¤]¥i«P¶iÅ髼W¥[¡A±q¦Ó´î»´T2Dªº¤@ºØ¯gª¬¡A¦P®É¥[«¾ÉPT2Dªº¥Dn¦MÀI¦]¯À¡C¯×ªÕ²ÓMªº¤À¤Æ©M¼W´Þ¯×ªÕ¥Í¦¨¬O¾ÉPÅ髼W¥[©MªÎDªº¥Dn¾÷¨î¡C«D±`§Æ±æ¶}µo¥Î©ó°§C¦å¿}¤ô¥¦Ó¤£»¤¾É±wªÌ¯×ªÕ§Î¦¨ªºT2DªºÃĪ«©MªvÀø¡C §Ú̶i¤@¨BÀË´ú¨ìTA»¤¾É¯Ø®q¯À¨üÅé¡]IR¡^©MAktªºÁC»Ä¤Æ¡A¥H¤Î¸²µå¿}Âà¹B³J¥Õ4¡]GLUT4¡^ªºÂà¹B¡A¸²µå¿}Âà¹B³J¥Õ4¬O°Ñ»P¯Ø®q¯À¤¶¾Éªº¸²µå¿}Âà¹Bªº«H¸¹¶Ç¾É³~®|ªº³J¥Õ½è¦]¤l¡C§ÚÌÁÙÃÒ©úTA§í¨î¯×ªÕ¥Í¦¨ªºÃöÁä°ò¦]ªºªí¹F¡CP <0.05¡^¡C³o¨Çµ²ªGªí©úTA¥i¥Î©ó¹w¨¾©MªvÀøT2D¤Î¨ä¬ÛÃöªºªÎD¯g¡CTA¥i¯à¦³¥i¯à¦¨¬°¶}µo·s«¬§Ü¿}§¿¯fÃĪ«ªº¥ý¾É¤Æ¦Xª«¡A³o¨ÇÃĪ«¯à°÷¦b¤£¼W¥[ªÎDªº±¡ªp¤U°§C¦å¿}¤ô¥¡C
TAªº2ºØ¬¡©Êªº²Õ¦X¨Ï¨ä«D±`¾A¦X§@¬°ì«¬¤Æ¦Xª«¥Î©ó¶i¤@¨Bªºµ²ºc©M¥\¯à¬ã¨s¡A¥H¶}µoªvÀøX©MT2Dºî¦X¼x¯gª¬ªº·s«¬ÃĪ«¡A¦p°ª¦å¿}¡A°ª¯Ø®q¯À¦å¯g©M°ª¥Ìªo¤Tà¦å¯g¡A¦Ó¤£¦ñÀHÅ髼W¥[¬Æ¦Ü´îªÎ¡C¹ï©ó±w¦³¿}§¿¯f¬ÛÃöÅé«°ÝÃDªº°ª¹F90¢HªºT2D±wªÌ¡A¨ã¦³³oºØ©Ê½è²Õ¦XªºÃĪ«À³¸Ó¬O§ó¦nªº¿ï¾Ü¡C
2.³æ¹ç»Ä(TA) ¦P®É¹w¨¾°ª¦åÀ£©M°ª¯×¦å¯gªº½×¤å
³æ¹ç»Ä(TA)¬O¤j¹«¥D°Ê¯ß¦åºÞ¥·Æ¦Ù©M¨x¤W¥Ö²ÓM¤¤¦åºÞºò±i¯À1«¬¨üÅé©M§C±K«×¯×³J¥Õ¨üÅ骺²Õ´¯S²§©ÊÂù«½Õ¸`¾¯¡G¬}¹î¡§ªk°ê®¯½×¡¨
www.fasebj.org/doi/abs/10.1096/fasebj.31.1_supplement.1005.10
¡§ªk°ê®¯½×(French Paradox)¡¨ªí©ú¬õ¸²µå°s¤¤¦s¦bªº¦UºØ¦h×ô¹ï¤ß¦åºÞ¯e¯fªº«OÅ@§@¥Î¡C³æ¹ç»Ä¡]TA¡^¡A¤@ºØ¥i¤ô¸Ñ¦h×ô¡A¨ã¦³¤£¦PªºÃIJz§@¥Î¡A¦ý¨ä¤ßŦ«OÅ@¾÷¨î©|¤£²M·¡¡C¦b³o¶µ¬ã¨s¤¤¡A§Ú̬ã¨s¤F³æ¹ç»Ä¹ï¦åºÞºò±i¯À1«¬¨üÅé¡]AT1R¡^©M§C±K«×¯×³J¥Õ¨üÅé¡]LDLR¡^ªº¼vÅT¡A³o¨âºØ¥Dn¦]¯À»P°ª¦åÀ£©M°ª¯×¦å¯gµ¥¤ß¦åºÞ¯e¯f¦³Ãö¡C Á`¤§¡A¥»¬ã¨sº¦¸ªí©úTA¤¶¾É³q¹LEGFR¿E¬¡MAP¿E酶¹ïRASMCs©MWB²ÓM¤¤AT1R©MLDLRªº½Õ¸`¦ÜÃö«n¡A¥i³q¹L©ú½T¹v¦VAT1R©MLDLR¦P®É¹w¨¾°ª¦åÀ£©M°ª¯×¦å¯g¡A¦]¦¹¡A´£¨Ñ¹ï¡§ªk°ê®¯½×¡¨ªº¾÷¨î¬}¹î¤O¡C
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/4/24 ¤W¤È 08:40:46
²Ä 548 ½g¦^À³
|
¿D¬w¾ÇªÌ¤]¦³¬ã¨sTA¹ïADªº§@¥Î
ªüº¸¯ý®üÀq¯f¤¤³æ¹ç»Äªº¤À¤l¹vÂI
www.eurekaselect.com/node/149819/article/molecular-targets-of-tannic-acid-in-alzheimers-disease
TAªº´XºØÅé¥~©MÅ餺¼Ò«¬¤wÅã¥ÜTA¹ïADªº¯«¸g«OÅ@§@¥Î¡C°£¤F¨ä±j¤jªº§Ü®ñ¤Æ©M§Üª¢§@¥Î¥~¡A¦³ÃÒ¾Úªí©úTA¤]¬O£]-¤Àªc酶¡]BACE1¡^¬¡©Ê©M³J¥Õ½èªí¹Fªº¤ÑµM§í»s¾¯¡CBACE1¬Ot³dA£]肽²£¥Í©M¨H¿nªº¥Dn酶¡CTAÁÙ¦bÅé¥~¨Ï¯«¸g¬r©Ê¾ý¯»¼Ë³J¥Õ£]¡]A£]¡^ìÅÖºû¤£Ã©w¡C°£¤F¹ïA£]¯ÅÁpªº¼vÅT¥~¡ATAÁÙ¥i¥H§í¨îtau肽ªºÅé¥~»E¶°¡Atau肽¬O²ÓM¤º¯«¸gìÅÖºûÄñµ²¡]NFT¡^ªº®Ö¤ß²Õ¤À¡C
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/4/23 ¤U¤È 04:20:51
²Ä 547 ½g¦^À³
|
¤µ¤éSND-5Àò±o²Õ¦Xª«©M¥Î³~ªº¬ü°ê±M§Q ¹ù¥S°¨¤WÀ°§Ṳ́W¤F¤@°óTAªº½Ò
TA §í¨î¥|ºØ酶 ¦³§U©ó§Ü AD »P¿}§¿¯f
liawbf.pixnet.net/blog/post/48895644
¤å¤¤z¤Î TA ¤ñ²{¦æªvÀøAD »P¿}§¿¯fªºÃĪ« , ¦³§ó¨Îªº[¥b§í¨î¿@«×IC50] ©M [§í¨î±`¼ÆKi] ¸Ô±¡½Ð°Ñ¹ù¥S¤Wz±M¤å ³Ì«á , ¤pªº ¤]n¸òµÛ¹ù¥S³Û [¤ß®®ªºSND-1 , SND-5 , SND-7 ¥[ªo! ]
ÁÂÁ¤j®a! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/4/23 ¤U¤È 12:55:56
²Ä 546 ½g¦^À³
|
¹ï¤£°_! ¦A«×§ó¥¿
³oÓ±M§Q À³¸Ó¥]¬A SND-5 ªº²Õ¦Xª«±M§Q ÁÙ¦³¥¦ªº¥Î³~±M§Q
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/4/23 ¤U¤È 12:39:22
²Ä 545 ½g¦^À³
|
¹ï¤£°_! §ó¥¿³¡¤À¼Æ¦r
Google½Ķªº [ Claims ][ Åv§Qn¨D] ¡G
1.¤@ºØ²Õ¦Xª«¡A¥]§t¡]i¡^³æ¹ç»Ä©Î¨äÃľǤW¥i±µ¨üªºÆQªº²V¦Xª«¡A©M¡]ii¡^¸üÅé¡A¨ä¤¤¸Ó²Õ¦Xª«§t¦³¨ã¦³¤Ö©ó¥|ÓÙ«³æ¹çªº³¡¤À®ò°ò»Ä¤p©ó5¢H ¡A¨ä¤¤¸üÅé¥]¬A¤G®ñ¤Æª¿©Mf¥Ò»Ä¡C
2.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥ 98¢H ªº³æ¹ç»Ä¨ã¦³4-12Ó¨S¹¤l酰°ò³¡¤À¡C
3.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥ 97¢H ªº³æ¹ç»Ä¨ã¦³5-12Ó¨S¹¤l酰°ò³¡¤À¡C
4.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥ 90¢H ªº³æ¹ç»Ä¨ã¦³6-12Ó¨S¹¤l酰°ò³¡¤À¡C
5.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥ 60¢H ªº³æ¹ç»Ä¨ã¦³8-12Ó¨S¹¤l酰°ò³¡¤À¡C
6.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤¦b²Õ¦Xª«¤¤¡A¬ù 10-20¢H ªº³æ¹ç»Ä¨ã¦³5Ó¨S¹¤l酰°ò³¡¤À¡A¬ù 15-25¢H ªº³æ¹ç»Ä¨ã¦³6-7Ó¨S¹¤l酰°ò³¡¤À¡A©M¬ù 55-65¢H ªº³æ¹ç»Ä¡C³æ¹ç»Ä¨ã¦³8-12Ó¨S¹¤l酰°ò³¡¤À¡C
7.¦pÅv§Qn¨D1©Òzªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«¬OÃĪ«²Õ¦Xª«¡AÀç¾iÃĪ«²Õ¦Xª«¡A«O°·¹«~©ÎÂåÀø¹«~¡C
8.Åv§Qn¨D7ªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«¬O¤ù¾¯¡A½¦Ån¡A³n©CÄZª«©Î¾®½¦¡C
9.¤@ºØ§í¨î¨ü¸ÕªÌ¤¤D-®ò°ò»Ä®ñ¤Æ酶¡]DAAO¡^ªº¤èªk¡A¥]¬A¦V¦³¦¹»Ýnªº¨ü¸ÕªÌ¬I¥Î¦³®Ä¶qªºÅv§Qn¨D1ªº²Õ¦Xª«¡C
10.®Ú¾ÚÅv§Qn¨D9©Òzªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¬O±w¦³¡AÃhºÃ±w¦³¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯f¯g©Î»PªÎD¬ÛÃöªº¯f¯g©Î³B©ó¨ä¤¤·ÀIªº¤HÃþ±wªÌ¡C
11.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³CNS¯e¯f©Î³B©ó±w¦³CNS¯e¯fªº·ÀI¤¤¡A©Òz±wªÌ¿ï¦Ûºë¯«¤Àµõ¯g¡Aºë¯«»Ùê¡Aªüº¸¯ý®üÀq¯f¡AÃBù®¸Ã¨§b¡A¦åºÞ©Êè§b¡Aè§b¡C¸ô©öÅé¡A¦Ñ¦~©Êè§b¡A»´«×»{ª¾»Ùê¡A¨}©Ê¿ò§Ñ¡A³¬¦X©ÊÀY³¡·l¶Ë¡A¦Û³¬¯gÃШt»Ùê¡Aªü´µ§B®æºî¦X¯g¡A¯Ü©ÊXºî¦X¼x¡Aª`·N¤O¯Ê³´¦h°Ê»Ùê¡Aª`·N¤O¯Ê³´»Ùê¡A±j¢¯g¡A©â°Ê»Ùê¡A¨àµ£¾Ç²ß»Ùê¡A¸g«e´Áºî¦X¼x¡A§íÆ{¯g¡A««×§íÆ{¯g¡A§Ö·P¯Ê¥F¯g¡A¦Û±þ·N©À©M/©Î¦æ¬°¡AÂù¬Û±¡·P»Ùê¡AµJ¼{¯g¡A®£·W¯g¡A³Ð¶Ë«áÀ³¿E»Ùê¡AºC©Ê»´«×©M¤£¥i¹w´úªºÀ£¤O¡A¶¼¹¥¢½Õ¡A¦¨Å}¯g¡A¤H®æ»Ùê¡A©¬ª÷´Ë¯f¡A¦ë§Ê¹y¯f¡A¦hµo©Êµw¤Æ¯g¡A¦ÙµäÁY°¼¯Áµw¤Æ¯g¡A¹Ï¹p¯Sºî¦X¼x¡A©]¶¡¿ò§¿¯g¡A«DÅöíwµo§@¡A²´Â¥µjÅË¡A§ù¤ó¦ÙÀç¾i¤£¨}¯g¡A¤¤·¡AºC©Ê¯kµh¡A¥]¬Aµhı¹L±Ó©M²§±`©Ê¯kµh¦b¤ºªº¯«¸g©Ê¯kµh¡A¿}§¿¯f©Ê¦hµo©Ê¯«¸g¯f©MºC©Ê¯kµhºî¦X¼x¡C
12.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³©Î¦³±w¦³»PªÎD¦³Ãöªº¯e¯fªº·ÀI¡A©Òz¯e¯f¿ï¦Û¶i¹»Ùê¡A¯«¸g©Ê¹½¹¯g¡A¯«¸g©Ê³g¹¯g¡A¤¤·¡A«a¤ß¯f¡C ¡A¤ßż¯fµo§@¡A¥R¦å©Ê¤ß¤O°IºÜ¡A¥ý¤Ñ©Ê¤ßż¯f¡A°ª¦åÀ£¡A«D°sºë©Ê¯×ªÕ©Ê¨xª¢¡A¯Ø®q¯À©è§Ü¡A°ª§¿»Ä¦å¯g¡A¥Òª¬¸¢¥\¯à´î°h¯g¡A°©Ãö¸`ª¢¡AÁxµ²¥Û¡A¤£¥¥¯g¡AªÎD³q®ð¤£¨¬ºî¦X¼x¡Aªý¶ë©ÊºÎ¯v©I§l¼È°±¡AºC©Êªý¶ë©ÊªÍ¯f©Mý³Ý¡C
13.¦pÅv§Qn¨D10©Òzªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³»PªÎD¬ÛÃöªº¯e¯f©Î³B©ó±w¦³¸Ó¯e¯fªº·ÀI¤¤¡A©ÒzªÎD¯g¬O¿ï¦Û¿}§¿¯f¡A°ª¦å¿}¯g¡A°ª¯×¦å¯g©M°ªÁx©T¾J¦å¯gªºªÎD¯g¡C
14.Åv§Qn¨D9ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¥H¨C¤Ñ¤T¦¸¦Ü¨C¨âÓ¤ë¤@¦¸ªºÀW²v¬I¥Î©Òz²Õ¦Xª«¡C
15.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ»P¤@ºØ©Î¦hºØ¥t¥~ªºÃľ¯¦P®É¡A¤§«e©Î¤§«á¥Î©óªvÀøCNS¯f¯g©Î»PªÎD¬ÛÃöªº¯f¯g¡C
16.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«§t¦³¤Ö©ó1¢Hªº¨ã¦³¤Ö©ó¥|Ó¨S¹¤l酰°ò³¡¤Àªº³æ¹ç»Ä¡C
17.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤³æ¹ç»Äªº²V¦Xª«³q¹L¥]¬A±q´Óª«¨Ó·½´£¨ú³æ¹ç»Ä©M°£¥h¨ã¦³¤Ö©ó¥|Ó¨S¹¤l酰°ò³¡¤Àªº³æ¹ç»Äªº¤èªk»s³Æ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/4/23 ¤U¤È 12:33:09
²Ä 544 ½g¦^À³
|
Google½Ķªº [ Claims ][ Åv§Qn¨D] ¡G
1.¤@ºØ²Õ¦Xª«¡A¥]§t¡]i¡^³æ¹ç»Ä©Î¨äÃľǤW¥i±µ¨üªºÆQªº²V¦Xª«¡A©M¡]ii¡^¸üÅé¡A¨ä¤¤¸Ó²Õ¦Xª«§t¦³¨ã¦³¤Ö©ó¥|ÓÙ«³æ¹çªº³¡¤À®ò°ò»Ä¤p©ó5¢H ¡A¨ä¤¤¸üÅé¥]¬A¤G®ñ¤Æª¿©Mf¥Ò»Ä¡C
2.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥9.8¢Hªº³æ¹ç»Ä¨ã¦³4-12Ó¨S¹¤l酰°ò³¡¤À¡C
3.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥9.7¢Hªº³æ¹ç»Ä¨ã¦³5-12Ó¨S¹¤l酰°ò³¡¤À¡C
4.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥90¢Hªº³æ¹ç»Ä¨ã¦³6-12Ó¨S¹¤l酰°ò³¡¤À¡C
5.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥60¢Hªº³æ¹ç»Ä¨ã¦³8-12Ó¨S¹¤l酰°ò³¡¤À¡C
6.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤¦b²Õ¦Xª«¤¤¡A¬ù10-20¢Hªº³æ¹ç»Ä¨ã¦³5Ó¨S¹¤l酰°ò³¡¤À¡A¬ù15-25¢Hªº³æ¹ç»Ä¨ã¦³6-7Ó¨S¹¤l酰°ò³¡¤À¡A©M¬ù55-65¢Hªº³æ¹ç»Ä¡C³æ¹ç»Ä¨ã¦³8-12Ó¨S¹¤l酰°ò³¡¤À¡C
7.¦pÅv§Qn¨D1©Òzªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«¬OÃĪ«²Õ¦Xª«¡AÀç¾iÃĪ«²Õ¦Xª«¡A«O°·¹«~©ÎÂåÀø¹«~¡C
8.Åv§Qn¨D7ªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«¬O¤ù¾¯¡A½¦Ån¡A³n©CÄZª«©Î¾®½¦¡C
9.¤@ºØ§í¨î¨ü¸ÕªÌ¤¤D-®ò°ò»Ä®ñ¤Æ酶¡]DAAO¡^ªº¤èªk¡A¥]¬A¦V¦³¦¹»Ýnªº¨ü¸ÕªÌ¬I¥Î¦³®Ä¶qªºÅv§Qn¨D1ªº²Õ¦Xª«¡C
10.®Ú¾ÚÅv§Qn¨D9©Òzªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¬O±w¦³¡AÃhºÃ±w¦³¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯f¯g©Î»PªÎD¬ÛÃöªº¯f¯g©Î³B©ó¨ä¤¤·ÀIªº¤HÃþ±wªÌ¡C
11.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³CNS¯e¯f©Î³B©ó±w¦³CNS¯e¯fªº·ÀI¤¤¡A©Òz±wªÌ¿ï¦Ûºë¯«¤Àµõ¯g¡Aºë¯«»Ùê¡Aªüº¸¯ý®üÀq¯f¡AÃBù®¸Ã¨§b¡A¦åºÞ©Êè§b¡Aè§b¡C¸ô©öÅé¡A¦Ñ¦~©Êè§b¡A»´«×»{ª¾»Ùê¡A¨}©Ê¿ò§Ñ¡A³¬¦X©ÊÀY³¡·l¶Ë¡A¦Û³¬¯gÃШt»Ùê¡Aªü´µ§B®æºî¦X¯g¡A¯Ü©ÊXºî¦X¼x¡Aª`·N¤O¯Ê³´¦h°Ê»Ùê¡Aª`·N¤O¯Ê³´»Ùê¡A±j¢¯g¡A©â°Ê»Ùê¡A¨àµ£¾Ç²ß»Ùê¡A¸g«e´Áºî¦X¼x¡A§íÆ{¯g¡A««×§íÆ{¯g¡A§Ö·P¯Ê¥F¯g¡A¦Û±þ·N©À©M/©Î¦æ¬°¡AÂù¬Û±¡·P»Ùê¡AµJ¼{¯g¡A®£·W¯g¡A³Ð¶Ë«áÀ³¿E»Ùê¡AºC©Ê»´«×©M¤£¥i¹w´úªºÀ£¤O¡A¶¼¹¥¢½Õ¡A¦¨Å}¯g¡A¤H®æ»Ùê¡A©¬ª÷´Ë¯f¡A¦ë§Ê¹y¯f¡A¦hµo©Êµw¤Æ¯g¡A¦ÙµäÁY°¼¯Áµw¤Æ¯g¡A¹Ï¹p¯Sºî¦X¼x¡A©]¶¡¿ò§¿¯g¡A«DÅöíwµo§@¡A²´Â¥µjÅË¡A§ù¤ó¦ÙÀç¾i¤£¨}¯g¡A¤¤·¡AºC©Ê¯kµh¡A¥]¬Aµhı¹L±Ó©M²§±`©Ê¯kµh¦b¤ºªº¯«¸g©Ê¯kµh¡A¿}§¿¯f©Ê¦hµo©Ê¯«¸g¯f©MºC©Ê¯kµhºî¦X¼x¡C
12.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³©Î¦³±w¦³»PªÎD¦³Ãöªº¯e¯fªº·ÀI¡A©Òz¯e¯f¿ï¦Û¶i¹»Ùê¡A¯«¸g©Ê¹½¹¯g¡A¯«¸g©Ê³g¹¯g¡A¤¤·¡A«a¤ß¯f¡C ¡A¤ßż¯fµo§@¡A¥R¦å©Ê¤ß¤O°IºÜ¡A¥ý¤Ñ©Ê¤ßż¯f¡A°ª¦åÀ£¡A«D°sºë©Ê¯×ªÕ©Ê¨xª¢¡A¯Ø®q¯À©è§Ü¡A°ª§¿»Ä¦å¯g¡A¥Òª¬¸¢¥\¯à´î°h¯g¡A°©Ãö¸`ª¢¡AÁxµ²¥Û¡A¤£¥¥¯g¡AªÎD³q®ð¤£¨¬ºî¦X¼x¡Aªý¶ë©ÊºÎ¯v©I§l¼È°±¡AºC©Êªý¶ë©ÊªÍ¯f©Mý³Ý¡C
13.¦pÅv§Qn¨D10©Òzªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³»PªÎD¬ÛÃöªº¯e¯f©Î³B©ó±w¦³¸Ó¯e¯fªº·ÀI¤¤¡A©ÒzªÎD¯g¬O¿ï¦Û¿}§¿¯f¡A°ª¦å¿}¯g¡A°ª¯×¦å¯g©M°ªÁx©T¾J¦å¯gªºªÎD¯g¡C
14.Åv§Qn¨D9ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¥H¨C¤Ñ¤T¦¸¦Ü¨C¨âÓ¤ë¤@¦¸ªºÀW²v¬I¥Î©Òz²Õ¦Xª«¡C
15.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ»P¤@ºØ©Î¦hºØ¥t¥~ªºÃľ¯¦P®É¡A¤§«e©Î¤§«á¥Î©óªvÀøCNS¯f¯g©Î»PªÎD¬ÛÃöªº¯f¯g¡C
16.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«§t¦³¤Ö©ó1¢Hªº¨ã¦³¤Ö©ó¥|Ó¨S¹¤l酰°ò³¡¤Àªº³æ¹ç»Ä¡C
17.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤³æ¹ç»Äªº²V¦Xª«³q¹L¥]¬A±q´Óª«¨Ó·½´£¨ú³æ¹ç»Ä©M°£¥h¨ã¦³¤Ö©ó¥|Ó¨S¹¤l酰°ò³¡¤Àªº³æ¹ç»Äªº¤èªk»s³Æ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/4/23 ¤U¤È 12:15:46
²Ä 543 ½g¦^À³
|
SND-5 «nªº¥Î³~±M§Q
®¥³ß¤ß®®èèÀò±oUSPTO±Â»Pªº SND-5 ¥Î³~±M§Q
Compositions containing tannic acids and uses thereof
United States Patent 10,265,336 April 23, 2019
patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22Tsai%3B+Guochuan+Emil%22.INNM.&OS=IN/%22Tsai;+Guochuan+Emil%22&RS=IN/%22Tsai;+Guochuan+Emil%22
1. A composition, comprising (i) a mixture of tannic acids or a pharmaceutically acceptable salt thereof, and (ii) a carrier, wherein the composition contains less than 5% of tannic acids having less than four galloyl moieties, wherein the carrier comprises silicon dioxide and benzoic acid.
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/4/4 ¤U¤È 04:03:25
²Ä 542 ½g¦^À³
|
¿}§¿¯fÀøªk©Î¯à¦³®Ä§í¨îªüº¸¯÷®üÀq¯f¶i®i ¨Ó·½¡G ¥Íª«¨¦ ¡@2019-04-04
med.sina.com/article_detail_103_1_63942.html
ªñ¤é¡A¤@¶µ¥Zµn¦b°ê»ÚÂø»xDiabetes Care¤Wªº¬ã¨s³ø§i¤¤¡A¨Ó¦Û«n¥[¦{¤j¾Çªº¬ì¾Ç®a̳q¹L¬ã¨sµo²{¡A±µ¨ü2«¬¿}§¿¯fÃĪ«ªvÀøªº±wªÌ©Î³\·|¦³®Ä»·Â÷ªüº¸¯÷®üÀq¯f¡C¤å³¹¤¤¬ã¨sªÌªí¥Ü¡A¬Û¤ñ¥¼±w¿}§¿¯fªºÓÅé¦Ó¨¥¡A¥¼±µ¨üªvÀøªº¿}§¿¯f±wªÌ¥X²{ªüº¸¯÷®üÀq¯fªº¸ñ¹³¬O«eªÌªº1.6¿¡C
¬ã¨sªÌDaniel A. Nationªí¥Ü¡A§Ú̪º¬ã¨sµ²ªG±j½Õ¤FºÉ¥i¯à¦¦a¦b¦¨¦~¤H¤¤µo²{¿}§¿¯f©M¨ä¥¦¥NÁ©ʯe¯fªº«n©Ê¡A¦b¿}§¿¯f±wªÌ¤¤¡Aè§b¯g©Mªüº¸¯÷®üÀq¯fªºµo¯f²v®t²§ÅãµM»P±wªÌ¬O§_ªAÃĪ½±µ¬ÛÃö¡C
¬ã¨sªÌNation»¡¹D¡AªvÀø¿}§¿¯fªºÃĪ«©Î³\¦bªýÂ_¤j¸£°h¤Æªº¶i®i¤Wªí²{¥X¤@©w¼vÅT
ªþµù:
³æ¹ç»Äªº¥Î³~±M§Q¤º¤å´£¨ì [¥»¤½¶}¤º®e°ò©ó¥H¤Uµo²{¡G³æ¹ç»Ä¡A¯S§O¬O¨ã¦³¦h©ó¤TÓ¨S¹¤l酰°ò³¡¤Àªº¨º¨Ç¡A¦³®Ä¦a§í¨îDAAOªº¬¡©Ê¡C¦]¦¹¡A§t¦³³oºØ³æ¹ç»Äªº²Õ¦Xª«±N¦³¯q©óªvÀø»PDAAO©M/©Î¨¦®ò»Ä¯à¯«¸g¶Ç»¼¬ÛÃöªº¯e¯f©M¯f¯g¡A¨Ò¦pªÎD¯g¡A¿}§¿¯f¡A°ª¯×¦å¯g©MCNS¯f¯g¡C]
[¥»¤½¶}¤º®eªº¤@Ӥ豯A¤Î²Õ¦Xª«...©M¥]§t¤@ºØ©Î¦hºØ³æ¹ç»Ä©M¸üÅ骺ÂåÀø¹«~¡A¨Ò¦pÃľǤW¥i±µ¨üªº¸üÅé©M/©Î¥i¹¥Îªº¸üÅé¡C³o¨Ç¤ÑµM¦s¦bªº©Î«D¤ÑµM¦s¦bªº¡]¦X¦¨ªº¡^¸üÅé¥i½á¤©²Õ¦Xª«¤¤ªº³æ¹ç»Ä¦UºØ¯q³B¡A¨Ò¦p¡A§ïµ½³æ¹ç»ÄªºÅé¥~©M/©ÎÅ餺éw©Ê¡A´£°ª³æ¹ç»Äªº¥Íª«§Q¥Î«× ¡A¼W¥[³æ¹ç»Äªº¥Íª«¬¡©Ê¡A©M/©Î´î¤Ö°Æ§@¥Î¡C¦X¾Aªº¸üÅé¥]¬A¦ý¤£©ó...©Î¨ä²Õ¦X¡C¦b¤@¨Ç¹ê¨Ò¤¤¡A¸üÅé¥i¥]§tf¥Ò»ÄÆQ¡A¨Ò¦pf¥Ò»Ä¶u¡C ]
¤S
«e½g(541)ªº³ø¾É ¤]´¦¥Ü [¦×®Û¤£¶È¯à§ïµ½2«¬¿}§¿¯f¦å¿}¡A§ó¦³§U©ó½Õ¸`Áx©T¾J¤ô¥¡A¦P®É¤]¯à°§C¿}§¿¯f±wªÌ¿©±w¤ß¦åºÞ¯e¯f¡BµÇŦ°ÝÃD¡B¯«¸g·l¶Ë¡B¤ßŦ¯f¤Î¤¤·µ¥¬ÛÃö¨Öµo¯g·ÀI¡C]
SND-1¤]¥H³æ¹ç»Ä¬°½á§Î¾¯ ¡A³£¬O f¥Ò»Ä¶u + ³æ¹ç»Äªº²Õ¦X ¡A¨âªÌ³£¦³§ïµ½2«¬¿}§¿¯fªº§@¥Î ¡A¤µ¨ä¬Û¥[©Î³£¼W²KÃĮĪº¥i¬Ý©Ê ?
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/28 ¤U¤È 07:06:50
²Ä 541 ½g¦^À³
|
³o»®Æ¼F®`¡I¬ã¨s¡G¦³§U½Õ¸`¦å¿}¤ÎÁx©T¾J 10:442019/03/28 ¤¤®É¹q¤l³ø ³¯·×²»
www.chinatimes.com/realtimenews/20190328003448-260405?chdtv
¿}§¿¯f±wªÌ»Ý§Ò¤f°ª¿}¡B°ªªo¯×¹ª«¡C¥~´C³ø¾É¡A¬ã¨sµo²{¡A¦×®Û¯à´î§C¿}§¿¯f±wªÌ¦Y¿}ªº¼¤±æ¡A§ó¦³§U©ó¦å¿}½Õ¸`¡A¼W¥[¤HÅ骺¯Ø®q¯À±Ó·P©Ê¡A¤]¦³§U©ó½Õ¸`Áx©T¾J¤ô¥¡A´î¤Ö¤ß¦åºÞ¯e¯fªº¾÷²v¡C
®Ú¾Ú¡mDaily Express¡n³ø¾É¡A¦×®Û«Ü¥i¯à¬O±wªÌ¥Î¨Ó´À¥N°ª¿}¹«~ªº¨}¤è¡A¬ã¨sµo²{¡A¦×®Û¯à´î§C±wªÌ¦Y¿}ªº¼¤±æ¡A§ïµ½¦å¿}¤ô¥¡A¨Ã¼W¥[¯Ø®q¯À±Ó·P©Ê¡A¼W¥[¿E¯Àªº¤Àªc¡AÁ{§É¹êÅç¤]Åã¥Ü¡AªA¥Î¦×®Û90¤Ñªº2«¬¿}§¿¯f±wªÌ¡AªÅ¸¡¦å¿}È¥§¡¤U°¤F10.3¢H¦Ü29¢H¡C
³ø¾É«ü¥X¡A¦×®Û¤£¶È¯à§ïµ½2«¬¿}§¿¯f¦å¿}¡A§ó¦³§U©ó½Õ¸`Áx©T¾J¤ô¥¡A¦P®É¤]¯à°§C¿}§¿¯f±wªÌ¿©±w¤ß¦åºÞ¯e¯f¡BµÇŦ°ÝÃD¡B¯«¸g·l¶Ë¡B¤ßŦ¯f¤Î¤¤·µ¥¬ÛÃö¨Öµo¯g·ÀI¡C
¦×®Ûªº¥NÁª« f¥Ò»Ä¶u , ¬OSND-1ªº¥D¦¨¥÷ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/28 ¤U¤È 12:31:28
²Ä 540 ½g¦^À³
|
««×§íÆ{¯g·sÃÄÀòFDA¬ð¯}©ÊÀøªk»{©w ¨Ó·½¡GÃÄ©ú±d¼w¡@2019-03-28
med.sina.com/article_detail_103_2_63440.html
AXS-05¬O¤@ºØ³Ð·s¤fªANMDA¨üÅé«ú§Ü¾¯¡C¥¦¥Ñ¥k¬ü¨Fªâ¡]dextromethorphan¡^©M¦w«D¥Lଡ]bupropion¡^ºc¦¨¡A¨Ã¥B¨Ï¥Î¤FAxsome¤½¥qªº¥NÁ§í¨î§Þ³N¡C¥k¬ü¨Fªâ¬O¤@ºØ«DÄvª§©ÊNMDA¨üÅé«ú§Ü¾¯¡A¥¦¦P®É¤]¬Osigma-1¨üÅé¿E°Ê¾¯¡AµÒÆP«¬¤A酰ÁxÆP¨üÅé«ú§Ü¾¯¡A©M5-ßm¦âÓi©M¥h¥ÒµÇ¤W¸¢¯ÀÂà¹B³J¥Õªº§í»s¾¯¡C¦w«D¥Lଯà°÷´£°ª¥k¬ü¨Fªâªº¥Íª«§Q¥Î«×¡A¦P®É¤]¬O¥h¥ÒµÇ¤W¸¢¯À©M¦h¤ÚÓi¦AÄá¨ú§í»s¾¯¡A©MµÒÆP«¬¤A酰ÁxÆP¨üÅé«ú§Ü¾¯¡C
ªþµù: ¥k¬ü¨Fªâ zh.wikipedia.org/wiki/%E5%8F%B3%E7%BE%8E%E6%B2%99%E8%8A%AC
¥k¬ü¨FªâÀò§åªº¬ü°ê±M§Q 2,676,177¤w©¡º¡¡A¦b1958¦~³Q§å㬰¥i¤£»Ý³B¤è°â½æªºÂí«yÃÄ¡C ÃĪ«ÀݥΠ¥k¬ü¨Fªâ¦³ÃĪ«ÀݥΪº¦MÀI¡AÀݥΪ̱`±`±NÃĪ«¾ãªO§]¤U©Î¾ã²~¤@¶¼¦ÓºÉ¨Ã°t¤W¥i¼Ö©Î¨ä¥L§t¦³©@°Ø¦]ªº¶¼®Æ¥H¨D¿³¾Ä®ÄªG[3]¡C¤¤°ê¤j³°¤@¨Ç´CÅéºÙ¨ä¬°¡u¥i«Ý¦]²Ä¤G¡v[4]¡C
ªø´Á¤j¾¯¶qªºªA¥Î¥i¯à¾ÉP¤ò²Ó¦åºÞ¯Ü¤Æ¡A²Õ´©ö¥X¦å¡A¼W¥[³Ð¶Ëªºµ{«×¡C
¦w«D¥LପºÀݥΠread01.com/zh-tw/oQaRg6.html#.XJxME1Uzapo
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/23 ¤U¤È 05:35:20
²Ä 539 ½g¦^À³
|
¹ù¥Sªº´_¥j·
SND-1¹ïCNS¯e¯f¤§Àø®Ä¾÷Âà
liawbf.pixnet.net/blog/post/48856380
¹ù¥S§i¶D§ÚÌSND-1(NABEN)ªº¤@Ó¯µ¤è ¦P®É¤]½Ð¹ù¥S¥´¶}¶W³sµ² , ¦nÅý¤j®a¤è«K½Æ²ß ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/22 ¤W¤È 08:49:45
²Ä 538 ½g¦^À³
|
£]¾ý¯»¼Ë³J¥Õ¡]Beta-amyloid¡^¤S¥¢±Ñ
Biogen°±¤îªüº¸¯ý®üÀq¯gÃĪ«±ß´Á¹êÅçªÑ»ù¼É¶^ªñ30% 2019¦~03¤ë22¤é05:39 ·s®ö°]¸gºî¦X
finance.sina.com.cn/stock/usstock/c/2019-03-22/doc-ihsxncvh4530697.shtml
3¤ë21¤é¬O¥O¥þ²yÃöª`ªüº¸¯ý®üÀq¤ó¯g¬ã¨sªº¤HÌ¿·Pµh¤ßªº¤@¤Ñ¡C
¡@¡@¬üªÑ½L«eªº¡§Ãz¬µ¯Å¡¨·s»DºÙ¡A¬ü°ê¥Íª«§Þ³N¤½¥qBiogen©M¤é¥»»sÃĤ½¥qEisaiªí¥Ü¡A±N°±¤î¨â¶µªüº¸¯ý®üÀq¤ó¯gªº±ß´ÁÃĪ«¸ÕÅç¡]late-stage trail¡A¤]ºÙ¬°¤T´ÁÁ{§É¸ÕÅç¡^¡A¦P®É°±¤îªºÁÙ¦³¤@¶µ¤G´ÁÁ{§É¸ÕÅ窺¦w¥þ©Ê¬ã¨s¡A¥H¤Î¤@¶µ1b´ÁÁ{§É¸ÕÅ窺¦A«×®i´Á¡C
Biogenªí¥Ü¡A¨â®a¤½¥q°±¤î¸ÕÅç¨Ã«D¦]¬°¦w¥þì¦]¡C°±¤î¸ÕÅ窺¨M©w¬O°ò©ó¿W¥ß¼Æ¾ÚºÊ´ú©eû·|¶i¦æªºµL®Ä¤ÀªRªºµ²ªG¡A¸Ó©eû·|»{¬°¡A¸ÕÅç¦b§¹¦¨«á¤£¤Ó¥i¯àº¡¨¬¨ä¥DnÀø®Ä¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤pÀs¤k10146282 |
µoªí®É¶¡:2019/3/20 ¤U¤È 03:37:10
²Ä 537 ½g¦^À³
|
ªÑ»ù¤w¤½uªÈµ²¡A¤£ª¾¦ó®ÉªÑ»ùÃzµo°µ¬ð¯} |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/20 ¤W¤È 11:10:47
²Ä 536 ½g¦^À³
|
SAGE¤½¥q¶}µoº´Ú²£«á§íÆ{¯g·sÃĤµ¤éÀò§å ¨Ó·½¡GÃÄ©ú±d¼w¡@2019-03-20
med.sina.com/article_detail_103_2_62968.html
¤ë20¤é¡AFDA«Å¥¬¡A§åãSAGE Therapeutics¤½¥q¶}µoªºZulresso¡]brexanolone¡^¤W¥«¡A¥Î©óªvÀø²£«á§íÆ{¯g¡]PPD¡^±wªÌ¡C³o¤@Àøªk±N¦b¸g¹L·ÀIµû¦ô©M½w¸Ñµ¦²¤»{ÃÒ¡]REMS¡^ªºÂåÀø¾÷ºc¤¤¥Ñ¦X®æªºÂåÅ@¤Hûª`®g(ÀR¯ßª`®g60¤p®É)¡CZulresso¦¨¬°²Ä¤@´Ú°w¹ïPPDªºÀò§åÀøªk¡A¥¦¤]¬OSAGE¤½¥q²Ä¤@´ÚÀò±oFDA§å㪺Àøªk¡C
Zulresso¬O¤@ºØGABAA¨üÅ骺§Oºc½Õ¸`¾¯¡A¥¦¥i¥H½Õ¸`¯«¸g¬ðIJ¤º©M¬ðIJ¥~GABAA¨üÅ骺¥\¯à¡C¹ï¯«¸g»¼½è¨üÅ骺§Oºc½Õ¸`¯à°÷±N¨üÅ鬡©Ê½Õ¸`¨ì¤£¦P¤ô¥¡A¦Ó¤£¬O§¹¥þ¿E¬¡©ÎªÌ§í¨î¨üÅé¡CGABAA¨üÅé©MNMDA¨üÅé¤À§O°_¨ì§í¨î©M¨ë¿E¤j¸£¯«¸g¤¸²£¥Í¯«¸g½Ä°Êªº§@¥Î¡C³o¨âºØ¨üÅ鬡©Ê¤§¶¡ªº¥¢¿Å¬O¾ÉP§íÆ{¯gµ¥¦hºØºë¯«¯e¯fªºì¦]¡CZulresso¯à°÷¦³®Ä©M¦w¥þ¦a«ì´_GABAA¨üÅé©MNMDA¨üÅ鬡©Ê¤§¶¡ªº¥¿Å¡CZulresso´¿¸gÀò±oFDA±Â¤©ªº¬ð¯}©ÊÀøªk»{©w©MEMA±Â¤©ªºPRIMEÃÄ«~»{©w¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/18 ¤W¤È 08:47:16
²Ä 535 ½g¦^À³
|
¹ù¥Sªº½×¤å¯Å¤j§@ SND-1 for BDNF , BDNF for SCZ
liawbf.pixnet.net/blog/post/48848142
¹ù¥S¤Þz¾ÇªÌ¬ã¨s , »¡©úºë¯«¤Àµõ¯g(SCZ)¯f¤HªºBDNF¤ô·Ç , ©úÅã¤ñ¥¿±`¤H§C¸¨ ¥BBDNFªº§C¸¨ , ©úÅã¦ñÀHSCZªº¯fµ{´c¤Æ , ¸g¹L§Üºë¯«¯fÃĪ«ªvÀø , ¤]¥i©úÅã´£¤ÉBDNF ¤Sf¥Ò»Ä¯Ç¦b°Êª«¹êÅç¥ç¥i´£¤ÉBDNF , ±N¥i¦¨¬° SND-1 ¦b¤HÅé¸ÕÅç¤W¦³®Ä§ïµ½¸g®É¯f¯gª¬ªºÀø®Ä¤§¤@
¥t¤p§Ì»{¬° , SND-13¬OÄÝ©ó1+1ªºªþ¥[ªvÀø¤è¦¡ , 2a´Áªº¤HÅéÁ{§É¤wÃÒ©ú¦bµØ¤H¦³ÅãµÛ®ÄªG ¦Ü©ó¦b¦è¤è¤H¬O§_¦³¦P¼ËÀø®Ä , ´NÅý2b+3´Áªº¦¨®Ä¨ÓÃÒ©ú
ÁÂÁ¹ù¥Sªº¶Ô©ó¬ã¨s½×¤å©M¤À¨É , Åý¤j®a¹ï¤ß®®·sÃĪº¬ãµo¦³§ó²`¨èªº»{ÃÑ©M¤F¸Ñ
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/17 ¤U¤È 04:39:36
²Ä 534 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼w µeÀsÂI·úªº¸Ñ»¡ ¸g¹L Cliff ¤j®¦¼wªº»¡©ú ¤pªº¤~²VµM²M¿ô¦a¤F¸Ñ---[ ³oÓLi-Sarcosine¦n¹³¨ã¦³¶W¥éÃÄ¡]Supergenerics¡^ªº·§©À ] ±M§Q[ Claims ] ¦³»¡ ³oÓLi-SarcosineªºªvÀø¥\¯à
6.¤@ºØ¥Î©ó´î»´¯«¸gºë¯«¯f¯gª¬ªº¤èªk¡A¥]¬A¦V¦³»Ýnªº¨ü¸ÕªÌ¬I¥Î¦³®Ä¶qªºN-¥Ò°ò¥Ì®ò»Ä¾YÆQ©Î¥]§t¾YÆQªº²Õ¦Xª«¡C 7.¦pÅv§Qn¨D6©Òzªº¤èªk¡A¨ä¤¤©Òz¯«¸gºë¯«¯f¯g¬O¨ã¦³¬¡°Ê¹L«×¯gª¬ªº¯«¸gºë¯«¯f¯g¡C 9.Åv§Qn¨D6ªº¤èªk¡A¨ä¤¤¯«¸gºë¯«¯f¯g¬O¨ã¦³·Pı¹B°Ê¯Ê³´ªº¯«¸gºë¯«¯f¯g¡C 11.®Ú¾ÚÅv§Qn¨D6©Òzªº¤èªk¡A¨ä¤¤©Òz¯«¸gºë¯«¯f¯g¬O¨ã¦³¾Ç²ß©M°O¾Ð¯Ê³´ªº¯«¸gºë¯«¯f¯g¡C 13.Åv§Qn¨D6ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¥Î¥t¥~ªº¯«¸gºë¯«¯f¯gÃľ¯ªvÀø¡C 14.Åv§Qn¨D13ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¿ï¦Û§Üºë¯«¯fÃÄ¡A§Ü§íÆ{ÃÄ¡A±¡ºüéw¾¯¡A§ÜµJ¼{Ãĩκ믫¿³¾Ä¾¯¡C 15.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªº§Üºë¯«¯fÃÄ¡G¤B酰f¡A§h噻嗪¡A¬t¾Ä¤DÀR¡A¾Ä¤DÀR¡A¤þ´â©Ô嗪¡A¥Ò²¸èý嗪¡A¤T¬t©Ô嗪¡A¬ü¯Á¹F嗪¡A¤þ嗪¡A¤T¬t¤þ嗪¡A¥ª±Û¤þ嗪¡A²§¤þ嗪¡A噻¾·¡A´â噻嗪¡A flupentixol¡Athiothixene¡Azuclopenthixol¡Aclozapine¡Aolanzapine¡Arisperidone¡Aquetiapine¡Aziprasidone¡Aamisulpride¡Aasenapine¡Apaliperidone¡Aaripiprazole¡Acannabidiol¡ALY2140023¡Adperperidol¡Apimozide¡Abutaperazine¡Acarphenazine¡Aremoxipride¡Apiperacetazine¡Asulpiride¡Aacamprosate¡Atannic acid¡Aand tetenenazine¡C 16.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªº§Ü§íÆ{ÃÄ¡G³æÓi®ñ¤Æ酶§í»s¾¯¡]MAOI¡^¡A¤TÀô§Ü§íÆ{ÃÄ¡]TCAs¡^¡A¥|Àô§Ü§íÆ{ÃÄ¡]TeCAs¡^¡A¿ï¾Ü©Ê5-ßm¦âÓi¦AÄá¨ú§í»s¾¯¡]SSRIs¡^¡A¥h¥ÒµÇ¤W¸¢¯À¯àÃÄ¡C©M¯S²§©Ê5-ßm¦âÓi¯à§Ü§íÆ{ÃÄ¡]NASSAs¡^¡A¥h¥ÒµÇ¤W¸¢¯À¡]¥h¥ÒµÇ¤W¸¢¯À¡^¦AÄá¨ú§í»s¾¯¡A¥h¥ÒµÇ¤W¸¢¯À - ¦h¤ÚÓi¦AÄá¨ú§í»s¾¯©M5-ßm¦âÓi - ¥h¥ÒµÇ¤W¸¢¯À¦AÄá¨ú§í»s¾¯¡]SNRIs¡^¡C 17.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªº§Ü§íÆ{ÃÄ¡G¬t¦è¥Å¡A©¬Ã¹¦è¥Å¡A¨Ì¥L´¶±[¡A¦è酞´¶Äõ¡AªÙ¦±ªL¡A¬t¥ñ¨F©ú¡A¤å©Ôªk¨¯¡A¦Ì¨º´¶±[¡A«×¬¥¦è¥Å¡A¦Ì´á¥¡A¦Ì¦w¦âªL¡A·çªi¦è¥Å¡A¦w«D¥LଡAªü¦Ì´ÀªL¡A¥h¥Ò´ÀªL¡A´¶Ã¹´ÀªL¡A¦a©õ©¬©ú¡A¦±¦Ì©¬©ú¡Aªü²ö¨F¥¡A¦w«D¥LଡA´â¦Ì©¬©ú¡A¦a©õ©¬©ú¡A¦h¦è¥¡A²§¥dªi肼¡A¤ÏfÀô¤þÓi¡A¦±ÐüଡA©`ªkÐüଡAf¤A肼¡A©Ô°¨µß¯À¡A¾Y¡A¦«ýmà¡A¥[¤Ú¼Q¤B¡A¥d°¨¦è¥¡A¶ø¥d¦è¥¡A¤þ¥³»ÄÆQ¡A°¨´¶´ÀªL¡A·Íªkù©ú¡A¦Ným¶©¡A¶Ü´â¨©Ói¡A²§·Ï肼©M²§¤þ嗪¡C 18.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªººë¯«¿³¾Ä¾¯¡G哌¥Òà¡A¥k±Û噻§h¥Òà¡A²§¤þ°ò哌Ôr¡A¥i¥d¦]¡Af¤þÓi¡A¥Ò°òf¤þÓi¡A¥kf¤þÓi¡A3,4-¨È¥Ò¤G®ñ°ò¥Ò°òf¤þÓi¡A¤Ç²öªL¡Af¥Ò嗪¡A¤G¤A°ò¤þ»Ä¡A´âf¤BÓi¡Aým«£ÖJ¡A¹ïßm°ò³Â¶ÀÆP¡Aªâ¬t©Ô©ú¡A1-¡]2,5-¤G¥Ò®ñ°ò-4-¥Ò°òf°ò¡^-2-®ò°ò¤þÖJ¡A¦w«D¥LଡA¥L¥ÅÃþ¡A²ö¹F«D¥§¡AÂb·}ÆP¡A¥k¬ü¨Fªâ¡Alisdexamfetamine dimesylate¡A²V¦XÆQ¦w«D¥L©ú¡A¦«²ö¦è¥Å¡A¥i¼Ö©wÆQ»ÄÆQ¡AÆQ»ÄÐgªk¨¯©MÂb·}ÆP¡C 19.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O±¡ºüéw¾¯¡A¨ä¿ï¦Û¾Y¡A©Ô²ö¤T嗪¡A¥d°¨¦è¥¡A¦«ýmà¡AÐüým©Z¡A¥d°¨¦è¥©M¤þ¥³»ÄÆQ¡C 20.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªº§ÜµJ¼{ÃÄ¡G¦a¦èÌñ¡Aªü´¶Ðü¨Ú¡A¤TÐü¨Ú¡Aindiplon¡A¤ã¨Ó´¶¶©¡A·Í¦èÌñ¡A¶ø¨F¦èÌñ¡A¤BÁ³ÀôଡAßm嗪¡A¥Ò´â喹ଡA¬ü¦««}©w¡A¨Ì¦««}à¡Aªü¥ßÐü¨Ú¡A´â´á¡A clobenzepam¡Aflurazepam¡Alorazepam¡Aclonazepam¡Aloprazolam¡A«}¹FÐü¨Ú¡Aalpidem¡Aalseroxlon¡Aamphenidone¡Aazacyclonol¡Abromisovalum¡Achlorazepate¡A¶tN-carboamoylaspartate¡Acaptodiamine¡Acapuride¡Acarbcloral¡Acarbromal¡Achloral betaine¡Aenciprazine¡Aflesinoxan¡Aipsapiraone¡Aipsapirone¡Alesopitron¡A¬¥¨F¥¡A¥Ò喹ଡAmethprylon¡Apropanolol¡Atandospirone¡Atrazadone¡Azopiclone©Mzolpidem¡C 21.Åv§Qn¨D13ªº¤èªk¡A¨ä¤¤©Òz¯e¯f¬Oªüº¸¯ý®üÀq¤ó¯f¡]AD¡^¡A¨Ã¥B©Òz¥t¥~ªºÃľ¯¿ï¦Û¦h©`哌»ô¡A¥d¤Ú©Ô¥Å¡A¥[Äõ¥L±Ó¡A¬üª÷è¡A¦Û¨¾J¡Amidafotel¡A¥L§JªL¡A¥q¨Ó¦NÄõ©Mºû¥Í¯ÀE. ³o´N¦n¤ñ¤½¥q©Òµo¥¬¶W¯Å¾Ç¦WÃıM§Qªº·s»D½Z www.syneurx.com/2018/09/10/article13/ ³oÓ±M§Q [ Claims ] ¤¤¤]¦³
2.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤f¥Ò»Äà¤Æ¦Xª«¬Of¥Ò»Ä¶u¤Æ¦Xª«©Îf¥Ò»Ä¾Y¤Æ¦Xª«¡C 7.Åv§Qn¨D1ªº²Õ¦Xª«¡AÁÙ¥]§t¥Î©ó¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯f¯gªº¥t¥~ªºªvÀø¾¯¡C 8.Åv§Qn¨D7ªº²Õ¦Xª«¡A¨ä¤¤©ÒzCNS¯e¯fªº¥t¥~ªvÀø¾¯¿ï¦Û¥Ñ¥d§Q©Ô嗪¡A¥¬哌嗪¡A¤B酰f¡A§h噻嗪¡A¬t¾Ä¤DÀR¡A¾Ä¤DÀR¡A¤þ´â©Ô嗪¡A²¸§Q嗪¡A¤T¬t©Ô嗪¡A¬ü¯Á¹F嗪¡A¤þ嗪¡A¤T¬t¤þ嗪¡A²§¤þ嗪¡A thioxanthene¡Achlorprothixene¡Aflupenthixol¡Athiothixene¡Aclozapine¡Aolanzapine¡Arisperidone¡Aquetiapine¡Aziprasidone¡Aamisulpride¡Aasenapine¡Apaliperidone¡Aaripiprazole¡Alamotrigine¡Adperperidol¡Apimozide¡Abutaperazine¡Acarphenazine¡Aeemoxipride¡Apiperacetazine¡Asulpiride¡Aacamprosate¡Atetrabenazine¡Avilazodone¡Alevomilnacipran¡A¬t¦è¥Å¡A©¬Ã¹¦è¥Å¡A¨Ì¥L´¶±[¡A¦è酞´¶Äõ¡AªÙ¦±ªL¡A¬t¥ñ¨F©ú¡A¤å©Ôªk¨¯¡A¦Ì¨º´¶±[¡A«×¬¥¦è¥Å¡A¦Ì´á¥¡A¦Ì¦w¦âªL¡A·çªi¦è¥Å¡A¦w«D¥LଡAªü¦Ì´ÀªL¡A¥h¥ÒµÇ¤W¸¢¯À¡A¦a©Ô¨ºªL¡A¦a©õ©¬©ú¡A¦±¦Ì©¬©ú¡Aªü²ö¨F¥¡A´â¦Ì©¬©ú¡A¦h¼{¥¡A¤ÏfÀô¤þÓi¡A¥q¨Ó¦NÄõ¡A¦±ÐüଡA©`ªkÐüଡAf¤A肼¡A©Ô°¨¦a¥Ì嗪¡A¾YÆQ¡A¦«ýmà¡A¥[¤Ú¼Q¤B¡A¥d°¨¦è¥¡A¶ø¥d¦è¥¡Aõé¨F©Z¡A°¨´¶´ÀªL¡A¦Ì´á¥¡A·ÍªkÓi¡A¶Ü´â¨©Ói¡A²§·Ï肼¡A²§¤þ嗪¡A¦w«D¥L©ú¡A²V¦XÆQf¤þÓi¡A²ö¹F«D¥§¡Adesoxyn¡A¥Ò°òf¤þÓi¡A¥i¥d¦]¡AÂb·}ÆP¡A¥k±Û哌¥ÒÓi¡A¥k±Û¦w«D¥L©ú¡A哌¥Òà¡Alisdexamfetamine dimesylate¡A¦«²ö¦è¥Å¡A¥i¼Ö©w¡AÐgªk¨¯¡AÂb·}ÆP¡A¤Ç²öªL¡A¦h©`哌»ô¡A¥L§JªL¡A¥d¤Ú©Ô¥Å¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡A³æ¹ç»Ä©M»È§ö¸´£¨úª«¡C¥d°¨¦è¥¡Aoxacarbazepine¡Avalporate¡Amaprotiline¡Amirtazapine¡Abrofaromine¡Amoclobemide¡A²§·Ï肼¡Aiproniazid¡A¦w«D¥L©ú¡A²V¦XÆQf¤þÓi¡A²ö¹F«D¥§¡Adesoxyn¡A¥Ò°òf¤þÓi¡A¥i¥d¦]¡AÂb·}ÆP¡Adexmethylphenidate¡A¥k±Û¦w«D¥L©ú¡A哌¥Òà¡Alisdexamfetamine dimesylate¡Aatomoxetine¡A¥i¼Ö©w¡Aguanfacine¡Aarecoline ¡A¤Ç²öªL¡A¦h©`哌»ô¡A¥L§JªL¡A§Q¤Z´µªº©ú¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡A³æ¹ç»Ä©M»È§ö¸´£¨úª«¡C¥d°¨¦è¥¡Aoxacarbazepine¡Avalporate¡Amaprotiline¡Amirtazapine¡Abrofaromine¡Amoclobemide¡A²§·Ï肼¡Aiproniazid¡A¦w«D¥L©ú¡A²V¦XÆQf¤þÓi¡A²ö¹F«D¥§¡Adesoxyn¡A¥Ò°òf¤þÓi¡A¥i¥d¦]¡AÂb·}ÆP¡Adexmethylphenidate¡A¥k±Û¦w«D¥L©ú¡A哌¥Òà¡Alisdexamfetamine dimesylate¡Aatomoxetine¡A¥i¼Ö©w¡Aguanfacine¡Aarecoline ¡A¤Ç²öªL¡A¦h©`哌»ô¡A¥L§JªL¡A§Q¤Z´µªº©ú¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡A³æ¹ç»Ä©M»È§ö¸´£¨úª«¡C¥L§JªL¡A§Q¤Z´µªº©ú¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡AÂý»Ä©M»È§ö¸´£¨úª«¡C¥L§JªL¡A§Q¤Z´µªº©ú¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡AÂý»Ä©M»È§ö¸´£¨úª«¡C
©Ò¥HLi-SarcosineÀ³¸Ó¤]¬O¶W¥éÃÄ¡]Supergenerics¡^ªº·§©À²Õ¦X
¦A¦¸ÁÂÁ Cliff ¤j®¦¼w
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GCliff10135274 |
µoªí®É¶¡:2019/3/17 ¤W¤È 11:13:51
²Ä 533 ½g¦^À³
|
Äò²q·Q¤j2019/3/12²Ä 531 ½g¦^À³ªº¤º®e¡G¤½¥q·s¨ú±oªº¬ü°ê±M§Q 2019 Mar12 US Patent Pub. No.:2019/0008813 A1 ¡uLithium salts of N-substituted glycine compounds and uses thereof ¡v
³o¬Ý°_¨Ó¹³¬O¡uSarcosineªº¾YÆQ¡v¡A¾Ú»¡¬O¦b¬ãµo¹Lµ{¤¤µL·Nµo²{¥¦¨ã¦³½w¸Ñºë¯«¤Àµõ¯gªº¥¿©Ê¡Bt©Ê¯gª¬¤Î§ïµ½»{ª¾¥\¯à¯Ê·lªº¥\¯à¡CY«ö·Ó³o¦¸2/27½²¸³·|«á©Ò´£¨ìªº¼W±jÃĪ«®ÄªGªº¤èªk¡G°µ¦¨ÆQÃþ©Î¥[¤W»²ÃĪº¤èªk¨Ó¬Ý¡A³oÓLi-Sarcosine¦n¹³¨ã¦³¶W¥éÃÄ¡]Supergenerics¡^ªº·§©À¡]°µ¦¨ÆQÃþ¡^¡C ±M§Q¤º¤åÁÙ´£¨ì¡A©Ò¦³§t¦³Li-Sarcosine¦¨¤ÀªºÃÄÁÙ¥i¥H¦A¶i¤@¨B¥[¤WTannic acid°µ¬°²Ä¤GºØ»s¾¯¨Ó©µ¦ùLi-Sarcosine¦¨¤ÀªºªvÀø¥\¯à¡]§Y¥[¤W»²ÃÄ¡^¡C
¦^·QLiBen¬ONaBenªº¾YÆQ¡]°µ¦¨ÆQÃþ¡^¡FY§âNaBen¥[¤WTannic acid¡]¥[¤W»²ÃÄ¡^´N¦¨¤F¬ü°ê±M§QUS Patent Pub. No.:20180036267¡]2018/02/08¨ú±o±M§Q¡^¡A¬O§_¤]¨ã¦³¶W¥éÃĪº·§©À¡H
¹ï·Ó³o¤@¥÷ªº·s»D½Z¨Ó¬Ý¦ü¥G§ó²M·¡¡G¡uwww.syneurx.com/2018/09/10/article13/¡v
¤£¹LNaBen¡BSarcosine¤´µM¤£¬O¤W¥«ÃĪ«¡A¤W±Ó¤H©Òz¦ü¥G¦³»y¯f¡A©Ò¥HÀ³¸Ó¬O§â²{¦³¥«±¤Wªº¤W¥«ÃĪ«°µ×¹¢¡B±j¤Æ¦¨¬°¶W¥éÃÄ¡A¨Ò¦pClozapine¡]´â´á¥¡^+Tannic acid¬O¤£¬O¤ñ¸û¦X²z¡H
ê©óÓ¤H°¾¨£¡A¥i¯à¦bÅÞ¿è©Î®É§Ç¥ý«á¤W¦³©ÒÂÕ»~¡A¶È¨Ñ°Ñ¦Ò¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¨È10135608 |
µoªí®É¶¡:2019/3/12 ¤U¤È 01:39:22
²Ä 532 ½g¦^À³
|
¬ãµo¦¨ªG¦n®ø®§¤@¥ó¤S¤@¥ó¡A½Ð¤j®a@¤ßµ¥«Ý®É¶¡¨ì¨Ó¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/12 ¤U¤È 01:27:52
²Ä 531 ½g¦^À³
|
¤ß®®èè¤SÀò±o¬ü°ê±M§Q
United States Patent 10,226,442 March 12, 2019
Lithium salts of N-substituted glycine compounds and uses thereof
Abstract The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): ##STR00001## in which R.sup.1, R.sup.2, and R.sup.3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R.sup.1, R.sup.2, and R.sup.3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/10 ¤U¤È 12:27:33
²Ä 530 ½g¦^À³
|
¹ï¤£°_! ²Ä529½g§ó¥¿¬°
¦V¤j®a²`²`¤@Áù°`¹Dºp ¥»ª©¤p§Ì©Ò¶K ²Ä514½g ²Ä517½g ²Ä527½gªºªþµù , ÁÙ¦³¤Íª©²Ä1128½gªº¶K¤å§@¼o ¤p§Ì¬Q¤ÑµL·N¤¤§ä¨ì¤F¤@½g¥Ñ¥_¥d¤j¾Ç(UNC)Rachel Kloss Silverman¥ý¥Í©Ò¼gªº METHODS FOR THE SEQUENTIAL PARALLEL COMPARISON DESIGN ( SPCD )
cdr.lib.unc.edu/indexablecontent/uuid:035047ed-5f26-4cba-884d-b100959ab00d
¸Ô²Ó»¡©ú¤FSPCD ¤Î¨äÀ³¥Î CHAPTER 1: LITERATURE REVIEW ÄÄz²z½× CHAPTER 2: SAMPLE SIZE RE-ESTIMATION AND OTHER MIDCOURSE ADJUSTMENTS WITH SEQUENTIAL PARALLEL COMPARISON DESIGN »¡©ú´Á¤¤¤ÀªR¼Ë¥»¼Æªº«¦ô CHAPTER 3: SEQUENTIAL PARALLEL COMPARISON DESIGN WITH BINARY AND TIME-TO-EVENT OUTCOMES ¨Æ¥ó®É¶¡¤ÀªRªºÀ³¥Î CHAPTER 4: PERMUTATION-BASED INFERENCE FOR SEQUENTIAL PARALLEL COMPARISON DESIGN
APPENDIX 1: FIGURES AND TABLES.................................................................50 REFERENCES.........................................................................64 ¹ï§Ú³oÓ²Îpªù¥~º~¨Ó»¡ ¦nÃø ©Ò¥H¶K¥X¨ÓÅý¤j®a¨Ó¦@¦P§V¤O¬ã¨s §ó´Á«Ý²Îp°ª¤â̪º«ü¾É©M±Ð¾Ç
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/10 ¤W¤È 10:38:06
²Ä 529 ½g¦^À³
|
¦V¤j®a²`²`¤@Áù°`¹Dºp ¥»ª©¤p§Ì©Ò¶K ²Ä514½g ²Ä517½g ²Ä527½gªºªþµù , ÁÙ¦³¤Íª©²Ä1128½gªº¶K¤å§@¼o [ ¤½¦¡¤¤ªºÅv«w=0ªº¸Ü(´N¬O¤£±Ä¥Îrun-in ¶¥¬qªº¼Æ¾Ú) , ·|¤ñ¸û¶Kªñ¼ÒÀÀ , ¦ý§Ṳ́£ª¾¹D½²±Ð±Â¬O¥Î 0.5 , 0.25 ©Î¬O 0 ? ] ¤p§Ì¬Q¤ÑµL·N¤¤§ä¨ì¤F¤@½g¥Ñ¥_¥d¤j¾Ç(UNC)Rachel Kloss Silverman¥ý¥Í©Ò¼gªº METHODS FOR THE SEQUENTIAL PARALLEL COMPARISON DESIGN ( SPCD )
cdr.lib.unc.edu/indexablecontent/uuid:035047ed-5f26-4cba-884d-b100959ab00d
¸Ô²Ó»¡©ú¤FSPCD ¤Î¨äÀ³¥Î CHAPTER 1: LITERATURE REVIEW ÄÄz²z½× CHAPTER 2: SAMPLE SIZE RE-ESTIMATION AND OTHER MIDCOURSE ADJUSTMENTS WITH SEQUENTIAL PARALLEL COMPARISON DESIGN »¡©ú´Á¤¤¤ÀªR¼Ë¥»¼Æªº«¦ô CHAPTER 3: SEQUENTIAL PARALLEL COMPARISON DESIGN WITH BINARY AND TIME-TO-EVENT OUTCOMES ¨Æ¥ó®É¶¡¤ÀªRªºÀ³¥Î CHAPTER 4: PERMUTATION-BASED INFERENCE FOR SEQUENTIAL PARALLEL COMPARISON DESIGN APPENDIX 1: FIGURES AND TABLES.............................................................................50 REFERENCES.........................................................................64 ¹ï§Ú³oÓ²Îpªù¥~º~¨Ó»¡ ¦nÃø ©Ò¥H¶K¥X¨ÓÅý¤j®a¨Ó¦@¦P§V¤O¬ã¨s §ó´Á«Ý²Îp°ª¤â̪º«ü¾É©M±Ð¾Ç ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/8 ¤U¤È 07:59:17
²Ä 528 ½g¦^À³
|
§Ü§íÆ{ÃľԳõ¤ÓºG¯P¡I¦ãº¸«Ø5.6»õ¶RªºÃÄ¥|¶µ¬ã¨s§¡¥¢±Ñ ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2019-03-08
med.sina.com/article_detail_103_2_62137.html
º¸«Ø¡]Allergan ¡^¥H5.6»õ¬ü¤¸¦¬ÁÊNaurex¤½¥qÀò±oªº§Ü§íÆ{¯gÃĪ«rapastinel³Ìªñ¤½§G¤F³Ì·s¬ã¨sµ²ªG¡A¤£©¯ªº¬O¡A¸ÓÃĪ«¤T¶µÃöÁä©Ê¸ÕÅ秡¥¼¯à¹F¨ì¨ä¥Dn²×ÂI¡C§óÁV¿|ªº¬O¡A²Ä¥|¶µ¬ã¨sªº¤¤´Á¤ÀªR¤]Åã¥Ü¥X¡A¥Dn©MÃöÁ䪺¦¸nÁ{§É²×ÂI±NµLªk¹ê²{¡C±µ³sªº¸ÕÅ祢±Ñ¾ÉP rapastinelªº¥¼¨Ó¤@¤ù´ù¯í¡C
¬Û¤ñ¤§¤U¡A´N¦b¦ãº¸«Ø«Å¥¬ÃĪ«¸ÕÅ祢±Ñªº«e¤@¤Ñ¡A¦³¦PÃþ§@¥Î¾÷¨îªºNMDA¨üÅé«ú§Ü¾¯¡X¡X±j¥ÍºX¤U·¨´Ë»sÃÄSpravato¡]esketamine¡^CIII»ó¼QÃú¾¯Àò±o¤F¬ü°êFDA§åã¡AÁp¦X¤fªA§Ü§íÆ{ÃĥΩóÃøªv©Ê§íÆ{¦¨¤H±wªÌªºªvÀø¡C¦¹¦¸§åã¤]¨Ï±oSpravato¦¨¬°¹L¥h30¦h¦~¨ÓºÓ¨ã¦³·s§@¥Î¾÷¨îªº§Ü§íÆ{ÃĪ«¡C¡]¸Ô¨£¡G30¦~ºÓ·s¾÷¨î§Ü§íÆ{ÃÄÀò§å¡I±j¥ÍSpravato±N¥Î©óÃøªv§íÆ{¡^
Rapastinel¬O¤@ºØÀR¯ßª`®g¥ÎN-¥Ò°ò-D¤Ñ¥V®ò»Ä¡]NMDA¡^¨üÅ骺¥|肽½Õ¸`ÃÄ¡A¦ãº¸«Ø¦¹¦¸¶i¦æªºÁ{§É¸ÕÅç¬O´ú¸Õ¸ÓNMDA¨üÅé½Õ¸`¾¯§@¬°««×§íÆ{¯g¡] MDD¡^±wªÌªº»²§UªvÀø®ÄªG¡C¤T¶µ3´Á¬ã¨sÁ`¦@¯Ç¤J¤F1,510¨Ò««×§íÆ{¯g±wªÌ¡C°Ñ»P¤T¶µrapastinel¬ã¨sªº±wªÌ¦~ÄÖ¦b18-65·³¤§¶¡¡A²Å¦X««×§íÆ{¯g¼Ð·Ç¡A°Ñ»PªÌ¥²¶·¦³¦Ü¤Ö¤K¶g¥B«ùÄò®É¶¡¤£¶W¹L18Ӥ몺««×§íÆ{µo§@¡C¦¹¥~¡A²Å¦X±ø¥óªº±wªÌ¥²¶·¹ï§Ü§íÆ{ªvÀø«ùÄòªvÀø¦s¦b³¡¤À°_®Ä¤ÏÀ³¡A¦b¾ãÓ¬ã¨s¤¤¥Héw¾¯¶qÄ~Äò¤fªAªvÀø¡C
¦ãº¸«Ø¦b¬ü°ê·í¦a®É¶¡¶g¤T¡]3¤ë6¤é¡^¤U¤Èªº¤@¥÷Án©ú¤¤ªí¥Ü¡A¦b¨ä¤¤¨â¶µ¸ÕÅ礤¡A±wªÌ¨C¶g¦b¤fªA§Ü§íÆ{ÃÄ°ò¦¤W¤À§Oª`®g¦w¼¢¾¯©ÎRapastinel¡C²Ä¤T¶µ¬ã¨s¦b³]p¤WÃþ¦ü¡A¥u¬O¥¦ÁÙµû¦ô¤F¸û§C¾¯¶qrapastinelªºªvÀø®ÄªG¡C¦b©Ò¦³¤T¶µ¬ã¨s¡]RAP-MD-01¡BRAP-MD-02¡BRAP-MD-03¡^¤¤¡A¸ÓÃĪ«ªº@¨ü©Ê¨}¦n¡A¨S¦³¥ô¦óÀÀºë¯«¯f°Æ§@¥Îªº«H¸¹¡C¦ýÁV¿|ªº¬O¡A¤T¶µ¬ã¨s¤¤rapastinelªvÀø²Õ¦b¥Dn©MÃöÁ䦸n²×ÂI¤W§¡»P¦w¼¢¾¯²ÕµL²Îp¾Ç¤WªºÅãµÛ®t§O¡A§Y¸ÓÃĪ«ªºªvÀø®ÄªG¥i¥H©¿²¤¤£p¡C¦¹¥~¡A²Ä¥|¶µ¬ã¨srapastinel´_µo¹w¨¾¬ã¨sRAP-MD-04ªº¤¤´Á¤ÀªRµ²ªGªí©ú¡A¸ÓÃĪ«µLªk¹F¨ì¥Dn©MÃöÁ䦸n²×ÂI¡C
¦ãº¸«Ø¬ãµo¥DºÞDavid Nicholsonªí¥Ü¡A¦ãº¸«Ø±N¤ÀªR³o¨Ç¼Æ¾Ú¹ï¨ä¥Lrapastinel¸ÕÅçp¹ºªº¼vÅT¡A¨Ã¦b2019¦~¤¤°µ¥X¶i¤@¨Bªº¨M©w¡C
¦bII´ÁÁ{§É¸ÕÅ礤Åã¥Ü¡A¹ï¨ä¥L§Ü§íÆ{ÃĤÏÀ³¤£¨¬ªº««×§íÆ{¯g±wªÌ¡Arapastinel³æÃĪvÀø«á¤@¤Ñ¡A±wªÌ§Ü§íÆ{ÃĮIJv¨³³t±o¨ì´£°ª¡C¦ýÁp¦X¥ÎÃĬã¨s®ÄªG¨Ã¤£¦p¹w´Á¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/8 ¤U¤È 07:48:43
²Ä 527 ½g¦^À³
|
¦ãº¸°· ( Allergan ) §Ü§íÆ{ÃĪ«rapastinel¤TÓ¤T´ÁÁ{§É¥¢±Ñ ¨Ó·½¡G¬ü¤¤ÃÄ·½¡@2019-03-08
med.sina.com/article_detail_103_1_62114.html
Rapastinel¤£¶È¶¶§Q³q¹LÁ{§É«eªº««Ãö¥d¡B¦b¤G´ÁÁ{§É¤]Åã¥Ü¸û¦nÀø®Ä¡C³o±o·PÁ§ܧíÆ{ÃĪ«¬ãµoªº¥t¤@Ó¤j§|¡A§Y¦w¼¢¾¯®ÄÀ³¡C«Ü¦h§íÆ{±wªÌµo¯f®ÉªA¥Î¤°»ò³£¯à½w¸Ñ¯gª¬¡B¤×¨ä¬O¦bÂå°|Àô¹Ò¤U¡A©Ò¥H§Y¨Ï¦³®ÄÃĪ«¦b¹ï·Ó¸ÕÅ礤¤]¥u¦³«Ü¤pªºµ¡¤f¯àÅã¥Ü°Ï¤À¡A¶§©Êµ²ªG«D±`Ãø¥H±o¨ì¡C³Q»{¬°ÄAÂФF§íÆ{ªvÀøªº¦Ê¼~¸Ñ¤ñ¦w¼¢¾¯§ïµ½¤]«D±`¦³¡A·í¦~NEJM¥D½sMarcia Angell¨º¥»¡m»sÃĬɯu¬Û¡n¤@®Ñ¤¤±Mªù´£¨ì³oÓÃĪ«ªº·L¤pÁ{§É§ïµ½
¹ù¥Sªº¤j¤å SNG-12 PK Rapastinel (GLYX-13 ) liawbf.pixnet.net/blog/post/47551911
Á{§Éºôªº´yz This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams (mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.
ºû°ò¦Ê¬ì en.wikipedia.org/wiki/Rapastinel
Rapastinel (INN) (former developmental code names GLYX-13, BV-102) is a novel antidepressant that is under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) that acts as a selective, weak partial agonist (mixed antagonist/agonist) of an allosteric site of the glycine site of the NMDA receptor complex (Emax ≈ 25%). rapastinel is technically an allosteric modulator of the glycine site of the NMDA receptor, and hence is more accurately described as a functional glycine site weak partial agonist.
Allosteric modulator In biochemistry and pharmacology, an allosteric modulator (allo- from the Greek meaning other) is a substance which indirectly influences (modulates) the effects of a primary ligand that directly activates or deactivates the function of a target protein. Targets may be metabotropic, ionotropic and nuclear receptors, enzymes and transporters[. Pure modulators have no direct effect on the function of the protein target. Allosteric agonists are to be distinguished from pure allosteric modulators. They are defined as ligands able to directly activate a receptor by binding to an allosteric agonist binding site distinct from the primary (orthosteric) site.
ªþµù :
Ãø¨ì³o¤S¬O°ª¦w¼¢¾¯®ÄÀ³·Sªºº×? ¶Ç²ÎªºÀH¾÷¤À²Õ·|¦³°ª¦w¼¢¾¯®ÄÀ³ , ¦³ÀuÂI , ¤]¦³¯ÊÂI ÀuÂI¬O : ¨â²Õªº[ÃÄ®Ä]ªí²{ , ³£«Ü¦n¬Ý ¯ÊÂI¬O : ¥´²V¾Ôªºµ²ªG , ¨â²Õ®t²§·|§_¨S¦³¹F¨ì²Îp·N¸q? °²¦p¥Î¤ß®®ªºSPCD , Àu¯ÊÂIè¦n¬Û¤Ï °§C°ª¦w¼¢¾¯®ÄÀ³ , ·|Åý¤ÏÀ³²v°§C , [ÃÄ®Ä]Åã±o¨S¦³¶Ç²Î¤èªk¤À²Õªº¦n¬Ý , ¦ý¬O®t²§¸û®e©ö¹F¨ìÅãµÛ (¦p½²±Ð±ÂÁ|¨Òªº¨â²Õ¤ÏÀ³²v¤ñ ¥Ñ50%/30% ¼W¬° 30%/10% ) ¦A¨Ó Allergan ªº Apimostinel¡]NRX-1074¡^¬O Rapastinel ªºÃþ¦üª«¡A¨ã¦³¬Û¦Pªº§@¥Î¾÷¨î »Papimostinel¤@¼Ë³£¦b§@¬°rapastinelªº¤fªA«áÄò¤Æ¦Xª«ªºAGN-241751 , ·|¤£·|¨ü¨ì¼vÅT , ©Î«ÝÆ[¹î
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p©¯¹B10141538 |
µoªí®É¶¡:2019/3/7 ¤W¤È 11:14:47
²Ä 526 ½g¦^À³
|
SpravatoÁp¦X¤fªA§Ü§íÆ{ÃĪº°Æ§@¥Î¤£¤Ö..¦ý¤´¹LÃö..¥NªíCNS»â°ì·sÃĪº«æ¢©Ê... ¥i¹w´Á«áÄòCNS·s¾÷¨îªºÃÄ«~±N³°Äò©ó¥«³õ¤W¥X²{...¤ß®®·s¾÷Âà·sÃÄȱoµ¥«Ý!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/6 ¤U¤È 06:20:25
²Ä 525 ½g¦^À³
|
30¦~ºÓ·s¾÷¨î§Ü§íÆ{ÃÄÀò§å¡I±j¥ÍSpravato ( esketamine¡^±N¥Î©óÃøªv§íÆ{ ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2019-03-06
med.sina.com/article_detail_103_2_61962.html
¾Ú¦ôp¡A¦b¬ü°ê¡A¤j¬ù¤T¤À¤§¤@ªºÄY«§íÆ{¯g¦¨¤H±wªÌ¬°TRD¡C¦¹¦¸§åã¡A¨ÏSpravato¦¨¬°¹L¥h30¦h¦~¨ÓºÓ¨ã¦³·s§@¥Î¾÷¨îªº§Ü§íÆ{ÃĪ«¡C¦b¬ü°ê¡AFDA¤§«e¤w±Â¤©SpravatoªvÀøTRD©MªvÀø¦ñ¦³ºò¢¦Û±þ·ÀIªºÄY«§íÆ{¯g¬ð¯}©ÊÃĪ«¸ê®æ¡C»P¼Ð·Çªº¤fªAªvÀøÃĪ«¬Û¤ñ¡ASpravato³q¹L»óµÄ¤ºµ¹ÃĪº¤è¦¡¥i´£¨Ñ§Ö³t°_®ÄªºÀu¶Õ¡C»Ýn«ü¥Xªº¬O¡ASpravatoÃĪ«¼ÐÅÒ¤¤ªþ±a¦³¤@«h¶Â®Øĵ§i¡A´£¥Ü·ÀIµû¦ô©M´î¨a¾Ô²¤¡]REMS¡^¥H¤Î¦b¨à¬ì±wªÌ©M¦~»´¦¨¤H¤¤¦Û±þ·Qªk©M¦æ¬°ªº·ÀI¡C(SPRAVATO™ carries a Boxed WARNING regarding a Risk Evaluation and Mitigation Strategy (REMS) and the risk of suicidal thoughts and behaviors in pediatric patients and young adults.)
¬ã¨s¤¤¡ASpravatoÁp¦X¤fªA§Ü§íÆ{Ãij̱`¨£ªº°Æ§@¥Î¥]¬A¡G¸ÑÂ÷¡BÀY·w¡Bäú¤ß¡BÂíÀR¡B¯t·w·P¡BIJı©M·Pı´î®z¡BµJ¼{¡Bºë¤O¤£¨¬¡B¦åÀ£¤É°ª¡B¹Ã¦R©M°s¾K·P¡C
¤@¥¹Spravato³Q½T©w¬°¦X¾AªºªvÀø¤è®×¡A®Ú¾ÚREMS¡A±wªÌ±N¦b¸g»{ÃÒªºªvÀø¤¤¤ß±µ¨üªvÀø¡CSpravato¤£·|ª½±µ³B¤èµ¹±wªÌ¦b®a¨Ï¥Î¡A¸ÓÃıN¥Ñ±wªÌ¦bÂåÀø«O°·´£¨ÑªÌªºª½±µÆ[¹î¤U¶i¦æ¦Û§ÚªAÃÄ¡A¨ÃÆ[¹îÂíÀR¡B¸ÑÂ÷©M¦åÀ£ÅܤƦܤÖ2Ó¤p®É¡Aª½¨ì±wªÌ³Q½T»{¦w¥þ«á¤è¥iÂ÷¶}¡C¦¹¥~¡A±wªÌ¦b±o¨ì¨}¦nªººÎ¯v«á¡Aª½¨ì²Ä¤G¤Ñ¤~¯à¾r¾p©Î¾Þ§@««¬¾÷±ñ¡C©Ò¦³±wªÌ³£±Nµn°O¦bSpravato REMSµù¥U¤¤¤ß¡A¥H¶i¤@¨B´yzÂíÀR¡B¸ÑÂ÷¡BÀݥΩM»~¥Î³y¦¨ÄY«¤£¨}«áªGªº·ÀI¡A¨Ã¤ä«ù¦w¥þ¦a¨Ï¥Î¸ÓÃĪ«¡C¦¹¥~¡A·¨´ËCarePath±N´£¨Ñ¥þ±ªº¤ä«ùp¹º¡AÀ°§U±wªÌ±Ò°ÊSpravatoªvÀø¨Ã«O«ù¸ò踪¡C¡]·s®öÂåÃĽsĶ/newborn¡^
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p©¯¹B10141538 |
µoªí®É¶¡:2019/3/6 ¤U¤È 01:55:47
²Ä 524 ½g¦^À³
|
¦pªG¥H¤½¥q¯ó³Ð´Á...¥¼¤W¥««eªº¨ÆÂÝ...(¨º®É¥¼¤W¥«ªÑ»ù´N¤w¦³200¤¸¥H¤W)... ¦Ó§Ú¥ý«e´£¨ìªºÆ[ÂI¬O..3¦~«e¤ß®®¤W¿³Âd®ÉªºªÑ¥»¤Î©Ó¾P»ùªºq©w..¬O¨Ì·Ó°ê»Ú·sÃÄ»ùÈrNPVµû¦ôªk¥h©w»ù168¤¸.. ----------------------------------------------------------------------------------------------- ¤½¥q¦Û¤W¿³Âd¥H«á¨Ã¥¼¦³¥ô¦ó¼W¸ê...3¦~«e©Ó¾P»ù168¤¸¤W¿³Âd«á...ªÑ¥»¨Ã¥¼¿±µÈ.... ¦pªGn»¡¤jªÑªFÁÈ¿ú...¨º¤£³X·Q·Q¤j¥ß¥úªºì©lªÑªF¨ì²{¦bÁȦh¤Ö? ·sÃĤ½¥q³Ìì©lªºªÑªF©Ó¾áªº¬OÁ{§É©|¥¼¦³¥ô¦ó¹êÁZªº§ë¸ê...·ÀI«Y¼Æ³Ì¤j...¦³¦h¤j©Ó¾á·ÀI¦ÛµM¦³¦h¤j³ø¹S.. ¦Ó²{¦bªº¤ß®®¤w¤£Â_§V¤O±N¦U·sÃıÀ¦Ü2-3´ÁÁ{§É...·ÀI¨t¼Æ»·§C©ó¤½¥q¯ó³Ð´Á...¨ä¹ê¬Ý¤jªÑªFÁȦh¤Ö·N¸q¤£¤j.. ¤j®a§ë¸êªÑ²¼¬Ýªº¬O¤½¥q¸gÀçªÌ¸Û«H¥H¤Î¤½¥q¥¼¨Óªº»ùȦ³¦h¤Ö..¥Ø«eȤ£È±o§ë¸ê... ----------------------------------------------------------------------------------------------- ¤ß®®·sÃĶi«×»·¤ñ¤T¦~«e¤j¦³¶i®i..³o¤T¦~ªÑ¥»¥¼¿±µÈ...ªÑ»ù³Ñ¤U©Ó¾P»ùªº1/3»ù...¬Oȱoªø´Á§ë¸ê... §ë¸êªÌ¦pı±o¤ß®®ªº·sÃĨS¦³¥ô¦ó»ùÈ...©Î°ê»Úµû¦ô·sÃĤ½¥q»ùȪº¤è¦¡¨S¥ô¦ó·N¸q... ¨º«Øij´N§O§ë¸ê·sÃĤ½¥q..¥i¥H¥h§ë¸ê¦³¹ê»ÚEPSªº¤½¥q..¶O¤ß¦b¤ß®®ª©¤W..¥u¬O¦h®ö¶O®É¶¡½}¤F... ----------------------------------------------------------------------------------------------- ¥H¤W...¶È¨Ñªø´Á§ë¸êªº¾Ô¤Ḭ́ѦÒ...¨CÓ§ë¸êªÌ¥i©Ó¾áªº·ÀI¤£¦P...¤Å·í§@Ó¤H§ë¸ê¨Ì¾Ú... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gº©¹CªÌ10144096 |
µoªí®É¶¡:2019/3/6 ¤U¤È 01:14:53
²Ä 523 ½g¦^À³
|
¤p´²¤á §A¦n¡A
³o½g¤µ©P¥Zªº¤å³¹¡A¤½¥q¤w¸gµo¹L«°T¼á²M¹L ¡u¸`¿ý¥»¤½¥qµo¨¥¥þ¬°§ù¼¶¡v
¥þ¤å¦p¤U¡G ========= ²Ä¤T¤Q¥|±ø¡@²Ä26´Ú
1.¶Ç¼½´CÅé¦WºÙ:1001´Á¤µ©P¥Z¤Î¨ä¥L´CÅé³ø¾É
2.³ø¾É¤é´Á:105/02/24
3.³ø¾É¤º®e:
¡u¤ß®®¥ÍÂåªí¥Ü¡A¡u³o»ò°µ¬O§Æ±æ¦h¶Ò¨ì¤@ÂI²{ª÷¡C¡v·í®É¤ß®®¬O¥¼¤½¶}µo¦æ¤½¥q¡A
¨Ì·Ó¡m¤½¥qªk¡n¡A¥un²Å¦Xn¥ó¡A¤½¥q¥i¥H³o»ò°µ¡A¦ý¬O¤½¶}µo¦æ¤§«á¡A¡u§Ṳ́£·|
¦A¥Î¸ê¥»¤½¿nÂà¼W¸ê¡C¡v
4.§ë¸ê¤H´£¨Ñ°T®§·§n:¤£¾A¥Î
5.¤½¥q¹ï¸Óµ¥³ø¾É©Î´£¨Ñ°T®§¤§»¡©ú:
¥»¤½¥q»ùȬ°¦U¶¥¬q§ë¸êªÌ©Ò»{¥i¡A©Ò¦³¸ê¥»§Î¦¨¤ÎªÑÅv¤À°t¡A
§¹¥þ¦X©óªk¥O³W³¹¡A¸`¿ý¥»¤½¥qµo¨¥¥þ¬°§ù¼¶¡C
6.¦]À³±¹¬I:µL
7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:
·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê
±Á{·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p´²¤á10147972 |
µoªí®É¶¡:2019/3/6 ¤U¤È 12:36:01
²Ä 522 ½g¦^À³
|
¤ß®®¨S¦³¼W¸ê¡A¦ý¬O¦³®³¸ê¥»¤½¿n°tªÑ¡A¾ÉPªÑ¥»Åܤj°Ú¡CGoogle¤@¤U´N§ä¨ì¤F
¤jªÑªF̪º¦¨¥»¬O²{¦bªÑ»ùªº¤Q¤À¤§¤@¡A·íªì§ëªº¿ú³£ÁȦ^¨Ó¤F¡C
³Ñ¤U¤pªÑªFè誺µ¥«Ý·sÃĪº®ø®§¡A¤@¦~¤S¤@¦~¹L¥h.... *********************************************************************************************** ¦¨¥ß©ó¤@¤T¦~ªº¤ß®®¥ÍÂå¡A§â±b¤Wªº¸ê¥»¤½¿n·í§@ªÑ§Q®³¨Ó°tªÑµ¹ªÑªF¡A§Ö³t¿±µÈªÑ¥»¡A¡u´X®ÉÅ¥¹L¤½¥q¥Î¸ê¥»¤½¿n¨Ó°tªÑªº¡H¡v¥L½èºÃ¡C ¤@¤»¦~¤@¤ë¡A³o®a¤½¥qªº¥«È¤w½Ä¤W¤G¤¤»õ¤¸¡A¬Û¤ñ¤§¤U¡A¦¨¥ß¤»¤Q¥|¦~ªº¥Ã«HÃÄ«~¡A¦P¼Ë¿n·¥µo®i·sÃÄ¡A¨¯¶Ô¯Ñ¯Ð»sÃIJ£·~¡A¥«È³ºµM¥u¦³¤ß®®¥ÍÂ媺¤T¤À¤§¤G¡C ¤ß®®¥ÍÂ媺§@ªk¬O¡A²Ä¤@¦¸°tªÑ¡AÅý¨C¦ìì©lªÑªF°t¤G¡D¤T¤@±iªÑ²¼¡A¤]´N¬O¤@±iªÑ²¼Åܦ¨¤T¡D¤T¤@±i¡F²Ä¤G¦¸¤S¦A°tµoªÑªF¡³¡D¤¤±iªÑ²¼¡AªÑ¥»¦]¦¹¨³³t¿±µÈ¡A쥻¤ß®®¥ÍÂ媺ªÑªF¤â¤W«ùªÑ¡A´N±q¤@±iÅܦ¨¤±i¡A¦]¦¹·í¤½¥q¥H¤@¤»¤K¤¸¦b¿³Âd¥æ©ö¡AªÑ²¼»ùȤ£¨ì¤T¦~¡A´N¿±µÈ¤K¤Q¿¡C ¤ß®®¥ÍÂåµo¨¥¤H½²¥É´@ªí¥Ü¡A¡u³o»ò°µ¬O§Æ±æ¦h¶Ò¨ì¤@ÂI²{ª÷¡C¡v¥h¦~¤K¤ë¤ß®®¥ÍÂå¶Ò¸ê¤Q¤À§xÃø¡A¬°¤FÅý§ë¸ê¤H¹ïªÑ»ù¡u¦³·P¡v¡A¼W¥[§ë¸ê»ùȤ~³o»ò°µ¡A¡u§Ṳ́]µLªk¹w®Æ«á¨Ó¥Í§ÞªÑ¤jº¦¡C¡v¦o¸ÑÄÀ¡A·í®É¤ß®®¬O¥¼¤½¶}µo¦æ¤½¥q¡A¨Ì·Ó¡m¤½¥qªk¡n¡A¥un²Å¦Xn¥ó¡A¤½¥q¥i¥H³o»ò°µ¡A¦ý¬O¤½¶}µo¦æ¤§«á¡A¡u§Ṳ́£·|¦A¥Î¸ê¥»¤½¿nÂà¼W¸ê¡C¡v
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p©¯¹B10141538 |
µoªí®É¶¡:2019/3/4 ¤U¤È 08:54:09
²Ä 521 ½g¦^À³
|
¤T¦~«eªÑ»ù°ªÂI265¤¸©Î³\¬O·í®É¥Í§Þ¥¿¼ö¦Ó¶Wº¦... ¦ý·í®É¤½¥q¤W¿³Âd©Ó¾P»ù168¤¸ªºq©w¬O¸g¹LrNPV¨Óq»ù... °Ñ¦Ò°ê»Ú¤W¹ï©ó·sÃĤ½¥qµû¦ôªº¤è¦¡...¬O¦³¨ä¥«³õµû¦ô²z½×°ò¦ªº... --------------------------------------------------------------------------------- ·íµM¼vÅTªÑ»ùªºì¦]²³¦h..¨Ò¦p..·sÃĤ½¥qªº¼W¸êª½±µ³y¦¨ªÑ¥»¿±µÈ¦Ó¼vÅT¤FªÑ»ù... ¦ý¤ß®®³o¤T¦~¨«¨Ó...¨Ã¥¼¦³¥ô¦ó¼W¸ê...ªÑ¥»¨Ã¥¼¿±µÈ... ªÑ»ù¥Ñ©Ó¾P»ù168¤¸¦Ü¤µ³Ñ¤U¬ù1/3»ù... --------------------------------------------------------------------------------- ¦b¤½¥q·sÃÄÁ{§É¶i«×«ùÄò¶i®i¤U...¤½¥q»ùȤ£Â_´£¤É...¬O«Üȱoªø´Á§ë¸êªº... ©Î³\¥Ø«e¥«³õ¤Wªº§ë¸ê¤H¤£Ä@·N¶R¥Í§Þ·sÃĪÑ... ¦ýÓ¤Hªº¬Ýªk¥¿¦n¬Û¤Ï...·í¤j®a¨S«H¤ß®É¥¿¬O¥xÆW¥Í§Þ·sÃĪѱNn¸Uµo»ô©ñªº¶}©l... ¹ï©ó»ùȶW¶^ªº·sÃĤ½¥q¥¿¬O·¥¦nªº§ë¸ê®É¾÷... ¥H¤W...¶È¨Ñªø´Á§ë¸êªº¾Ô¤Ḭ́ѦÒ...¨CÓ§ë¸êªÌ¥i©Ó¾áªº·ÀI¤£¦P...¤Å·í§@Ó¤H§ë¸ê¨Ì¾Ú... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p´²¤á10147972 |
µoªí®É¶¡:2019/3/4 ¤U¤È 06:36:37
²Ä 520 ½g¦^À³
|
¤T¦~«e©Ò¦³¥Í§ÞªÑ³£ª£¤W¤Ñ¡A¤ß®®·íµM¥i¥H½Ä¨ì200¦h¡C²{¦bªº¥Í§ÞÃþªÑ¡A´X¥G³£¬O¬Û¹ï§CÀɪº¦ì¸m¡A¥Dn§ë¸ê¤H¤£Ä@·N¶R¥Í§ÞªÑ²¼¡C§ë¸ê¥Í§ÞªÑ¯uªº¬O¤@±øº©º©ªø¸ô¡A¤£¤@©w¦³©Ò¦^³ø¡C²¦³º¨S¦³°tªÑ°t®§¡A¸Ñª¼¥¢±Ñ´N¤@³õªÅ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¨È10135608 |
µoªí®É¶¡:2019/3/4 ¤U¤È 01:26:01
²Ä 519 ½g¦^À³
|
¤p©¯¹B¤j¡G§ë¸ê¤H±¹ïªÑ»ù²{ªp©Ò°µªº¤ß²z¤ÏÀ³µÛ¹ê½ÆÂø¡A¤@»y¹D¯}´N¬O°l°ª±þ§C¡A¹J§Q¦h²r°l¡A¬Æ©Î¤Û·Q¥¼¨ÓªÑ»ù¸¤W¤Ñ»Ú¡A¹J§QªÅ©Î¤£©`¤[½L«h¦Û³]°±·l¥X³õ¡AÓ¤H¦³20¾l¦~ªÑÄÖ¡A¤@¨Ó¸g¾ú¸gÅç±Ð°V»á¦h¡A²`¿Ú´²¤á¤ß²z©M¤j¤á¤âªk¡A¤WӤ뤤¦¯¡A¤ß®®ªÑ»ù¦³¤@ªi¤U±þ¡A§Ú¦b¤¤Â_®É©ß´²¤á¤ßºA¡A¥ý¥X¤â©Ó±µ¤@¨Ç¡A¦ý¥¼´ú±o©³³¡»ù¡AÀH«á´X¤Ñ¦A«×±a¶q¤U±þ¡A§Ú«i´±¥X¤â¦A¶R¶i¤@¦¸¡A²×©ó´ú±oªi¬q©³»ù¡C¤ß®®ªÑ»ù¬O¥Ñ²³¦h§ë¸ê¤HÁp¦X¦æ¬°©Òq©wªº¡A§ÚµL±q¹wª¾°ª§C¡A¦ý¬O§Ú¦Û»{¶R¶iªº»ù¦ì«Üȱo¡A°_½X¤w¬O¤W¿³Âd»ù®æªº1/3»ù¡Aªp¥B¤½¥q¥¿©¹©Z³~µo®i¡A¦³¦ó¤£¥i¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p©¯¹B10141538 |
µoªí®É¶¡:2019/3/4 ¤U¤È 12:18:55
²Ä 518 ½g¦^À³
|
3¦~«e¤ß®®±aµÛ¬ð¯}©ÊÀøªkªºÀu²§·sÃÄÅD¤W¿³Âd¥H©Ó¾P»ù168¤¸ª½¤W265¤¸... 3¦~«á¤ß®®¦U¶µ·sÃĬҦ³¶i®i...¤½¥q𷪺¨B¥ï¤@¨B¤@¨B¦V«e...ªÑ»ù«o¥u³Ñ·íªìªº1/3... §ë¸ê¤ß²z¾Ç¯uªº¬O¬Û·í²`¶ø.... ----------------------------------------------------------------------------------- ·PÁ²q·Q¤j¤À¨ÉÁ{®ÉªÑªF·|ªº¸ê°T¥H¤ÎÄ_¶Qªº¨£¸Ñ... ¤]·PÁ¤j¤á¤jªºÆ[ÂI>>¦]¬°¦¬®×ªº«~½è¦Ó¹ïÁ{§É¹ï¶Hªº¿z¿ï«D±`ÄY®æ¦Ó³y¦¨¦¬®×ªº½wºC... Ó¤H»{¬°...¬°½T«O·sÃĦ¨¥\...ÄY®æ¿z¿ïÁ{§É¹ï¶H¬O¥²¶·ªº... ------------------------------------------------------------------------------------ ȱo´Á«ÝªºQ2-Q3 ´Á¤¤¼Æ¾Ú..¥H¤Î«áÄò±ÂÅv/IPOµ¥µ¥ªº¶i®i...
¥H¤W~~¨Ñªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ~~~¤Å·í§@§ë¸ê¨Ì¾Ú~~·P®¦~~~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/4 ¤W¤È 11:45:38
²Ä 517 ½g¦^À³
|
¤j¤á¤j ±zªºÆ[ÂI¤]¬O¤@ºØ¥i¯à ¤ß®®107 H1ªº¬y°Ê¸ê²£©|¾l 4.38»õ¥x¹ô ¨Ì·Ó¤ß®®ªá¿úªº³t«× ¨C¥b¦~ 0.9»õ¥x¹ô À³¥i¼µ¨ì109 ¤W¥b¦~µ²§ô ¦ý¬O½²±Ð±Â¦b106ªÑªF±`·| ´N¹w§i106¦~©³n¼W¸ê µM¦Ó¨ì²{¦b³£ÁÙ¨S±Ò°Êªº·N«ä ²{ª÷¬y¶qªº¬y¤J¬y¥X³Wµe Á`n¦³¤@Ó¦w¥þªº¾l¸Î °²¦p¬O§ÚÌ¥D¬F ¨Ì§Ú̲{¦b©Ò¨£ªº±¡ªp ¦´N¸Ó¶i¦æ¼W¸ê¤F ¤£¹L§Ṳ́£¬O½²±Ð±Â §Ú̬ݤ£¨ì½²±Ð±Â©Ò¬Ý¨ì¤½¥qªº±ÂÅv½Í§P¶i«× ¤£ª¾¹DÁ{§Éªº¼Æ¾Ú (´N¦p¤p§Ì¬Q¤é©Ò»¡ªº---¨â²Õ¦XpªºÁ`¤ÏÀ³²v ) ³o¨Ç©Î³\³£¼vÅTµÛ½²±Ð±Âªº¨Mµ¦ »¡¤£©w ±ÂÅv½Í§P¶i«×¤wªñ¦¨¼ô ©Ò¥H¤£¼W¸ê ¤S®³¬Q¤Ñ¼ÒÀÀªº¼Æ¾Ú TRR(%)¡KER (%) ¡KCR (%) ¡KER/CR ¡K¹LÃö©Ò»ÝÁ`¼Ë¥»¼Æ (PÈ < 0.05 ) ¡K..12.5¡K...15¡K¡K.10¡K¡K¡K¡K1.5¡K¡K¡K¡K. > 1374 ¡K..15¡K¡K...20¡K¡K.10¡K¡K¡K¡K..2¡K¡K¡K¡K..450 ¡K..20¡K¡K...30¡K¡K.10¡K¡K¡K¡K..3¡K¡K¡K¡K..150 ¡K..25¡K¡K...40¡K¡K.10¡K¡K¡K¡K..4¡K¡K¡K¡K..90 ¡K..30¡K¡K...50¡K¡K.10¡K¡K¡K¡K..5¡K¡K¡K¡K..60
¹ï·Ó²Õªº¤ÏÀ³²v¦b10%ªþªñ¬O«Ü¦³¥i¯àªº ©Ò¥HÁ`¤ÏÀ³²v¦b20% , 25% , 30% ¨ä¹LÃöªº³Ì§CÁ`¼Ë¥»¼Æ ¤À§O¬° 150 , 90 , 60 ½²±Ð±Â©Ò¬Ý¨ìªºÁ`¤ÏÀ³²v »¡¤£©wÅý½²±Ð±Â§PÂ_²{¦bªº¦¬®×¤H¼Æ¤w¸g°÷¤F? ·íÁ`¤ÏÀ³²v¶V°ª ¶V¦³¥¿±´£¦¦¬¤uªº¥i¯à©Ê «e¨Ç®ÉÔ ¤p§Ì¤]¦³¼ÒÀÀ»¡ ¦w¥þ«Y¼Æ > 6 ³o´NÁô§tµÛ ¥¿±´£¦¦¬¤uªº¥i¯à ³o©Î³\©M±ÂÅv¤S¦³¥¿¬ÛÃö
¤p§Ìªº¤ÀªRÁö¦³ÅÞ¿è©Ê ¦ý²×¨s¤´¬O²q´ú °²¦pÅý§Ú̪¾¹DÁ`¤ÏÀ³²v ¬Û«H¤ÀªR·|§ó¶Kªñ¨Æ¹ê ÁÙ¬O¦Ñ¸Ü¤@¥y ¥H¤W»¡ªk¤Á¤Å§@¬°±z§ë¸êªº¨Ì¾Ú
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤j¤á¤H®a10140174 |
µoªí®É¶¡:2019/3/4 ¤W¤È 10:22:02
²Ä 516 ½g¦^À³
|
¦¬®×¶i«×¬O½²±Ð±Â¦b¥D±± , ÀHµÛ¸êª÷°µ¾ãÅé¦Ò¶q½Õ¾ã¡¦ ²q·Q¤j±zªº·N«ä¬O²{¦b¦]¬°¸êª÷¤£°÷,©Ò¥H¦¬®×©ñºC? §ÚÓ¤H¬Oı±o¦]¬°½²±Ð±Â¦]¬°¦¬®×ªº«~½è¦Ó¹ïÁ{§É¹ï¶Hªº¿z¿ï«D±`ÄY®æ¦Ó³y¦¨¦¬®×ªº½wºC¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¨È10135608 |
µoªí®É¶¡:2019/3/3 ¤U¤È 08:13:02
²Ä 515 ½g¦^À³
|
²q·Q¤j¡G¯u¨ØªA§AºëÅPªº¤ÀªR¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/3 ¤U¤È 07:53:03
²Ä 514 ½g¦^À³
|
¤j¤á¤jªº«äºû , ¶Kªñ¤@¯ë¥«³õªº·Qªk , ©Ò¥H2018ªÑªF±`·|·í¤é¤j¾_Àú , ÀH«á½L¶^ , ¦]¥ý«eº¦´T¹O¿ ³o¦¸2019ªÑÁ{·|·í¤é¤]¬O¤U¶^ , µM«á©O? ¤pªº¦³¤@Ó¤£¦Pªº·Qªk , ©h¥BºÙ¬°---è¤H»¡¹Ú¨g·Q¦± . Ó¤Hı±o ¦¬®×¶i«×¬O½²±Ð±Â¦b¥D±± , ÀHµÛ¸êª÷°µ¾ãÅé¦Ò¶q½Õ¾ã . ¥»¨Ó³oÓ¸ê®Æ¤p§Ì¬O¤£·Q¤½¶}ªº , ¤@¨Ó²Ê²¤ , ¤G¨Ó©È¼vÅTªB¤Í ³oÓ¸ê®Æ¬O¥Î¥d¤èÀËÅç¼ÒÀÀªº : ER : ¹êÅç²Õ¤ÏÀ³²v CR : ¹ï·Ó²Õ¤ÏÀ³²v TRR : ¨â²Õ¦X°_¨ÓªºÁ`¤ÏÀ³²v[=(ER+CR)/2] , Âùª¼¶¥¬qÀ³¤]¬Ý±o¨ìªº¼Æ¾Ú? TRR(%)¡KER (%) ¡KCR (%) ¡KER/CR ¡K¹LÃö©Ò»ÝÁ`¼Ë¥»¼Æ (PÈ < 0.05 ) ¡K..7.5¡K¡K..10¡K¡K..5¡K¡K¡K¡K..2¡K¡K¡K¡K.1000 ¡K..10¡K¡K...15¡K¡K..5¡K¡K¡K¡K..3¡K¡K¡K¡K..348 ¡K..12.5¡K...20¡K¡K..5¡K¡K¡K¡K..4¡K¡K¡K¡K..195 ¡K..15¡K¡K...25¡K¡K..5¡K¡K¡K¡K..5¡K¡K¡K¡K..130 ¡K..17.5¡K...30¡K¡K..5¡K¡K¡K¡K..6¡K¡K¡K¡K..110 ¡K..22.5¡K...40¡K¡K..5¡K¡K¡K¡K..8¡K¡K¡K¡K..50
¡K..12.5¡K...15¡K¡K.10¡K¡K¡K¡K1.5¡K¡K¡K¡K. > 1374 ¡K..15¡K¡K...20¡K¡K.10¡K¡K¡K¡K..2¡K¡K¡K¡K..450 ¡K..20¡K¡K...30¡K¡K.10¡K¡K¡K¡K..3¡K¡K¡K¡K..150 ¡K..25¡K¡K...40¡K¡K.10¡K¡K¡K¡K..4¡K¡K¡K¡K..90 ¡K..30¡K¡K...50¡K¡K.10¡K¡K¡K¡K..5¡K¡K¡K¡K..60
¡K..17.5¡K...20¡K¡K.15¡K¡K¡K¡K..1.33¡K¡K.. > 1374 ¡K..20¡K¡K...25¡K¡K.15¡K¡K¡K¡K..1.67¡K¡K..600 ¡K..22.5¡K...30¡K¡K.15¡K¡K¡K¡K..2¡K¡K¡K¡K..300 ¡K..25¡K¡K...35¡K¡K.15¡K¡K¡K¡K..2.33¡K¡K..190 ¡K..27.5¡K...40¡K¡K.15¡K¡K¡K¡K..2.67¡K¡K..140 ¡K..30¡K¡K...45¡K¡K.15¡K¡K¡K¡K..3¡K¡K¡K¡K..100
¡K..22.5¡K...25¡K¡K.20¡K¡K¡K¡K..1.25¡K¡K.. > 1374 ¡K..25¡K¡K...30¡K¡K.20¡K¡K¡K¡K..1.50¡K¡K...650 ¡K..27.5¡K...35¡K¡K.20¡K¡K¡K¡K..1.75¡K.¡K..320 ¡K..30¡K¡K...40¡K¡K.20¡K¡K¡K¡K..2.00¡K.¡K..200 ¡K..32.5¡K...45¡K¡K.20¡K¡K¡K¡K..2.25¡K.¡K..130 ¡K..35¡K¡K...50¡K¡K.20¡K¡K¡K¡K..2.50¡K¡K...100
¡K..40¡K¡K...50¡K¡K.30¡K¡K¡K¡K..1.67¡K¡K...200
Á`¤ÏÀ³²v¦Ü¤Ö¦b´Á¤¤¤ÀªR´N·|ª¾¹D , ©Î³\²{¦b¤]ª¾¹D , ¥u¬O½²±Ð±Â¿ï¾Ü¤£¤½¶} ¬°¤F©ö©ó§PÂ_ , §Ú̱NÁ`¤ÏÀ³²v¬Û¦Pªº©ñ¦b¤@°_¤ñ¸û
TRR(%)¡KER (%) ¡KCR (%) ¡KER/CR ¡K¹LÃö©Ò»ÝÁ`¼Ë¥»¼Æ (PÈ < 0.05 ) ¡K..7.5¡K¡K..10¡K¡K..5¡K¡K¡K¡K..2¡K¡K¡K¡K.1000
¡K..10¡K¡K...15¡K¡K..5¡K¡K¡K¡K..3¡K¡K¡K¡K..348
¡K..12.5¡K...20¡K¡K..5¡K¡K¡K¡K..4¡K¡K¡K¡K..195 ¡K..12.5¡K...15¡K¡K.10¡K¡K¡K¡K1.5¡K¡K¡K¡K. > 1374
¡K..15¡K¡K...25¡K¡K..5¡K¡K¡K¡K..5¡K¡K¡K¡K..130 ¡K..15¡K¡K...20¡K¡K.10¡K¡K¡K¡K..2¡K¡K¡K¡K..450
¡K..17.5¡K...30¡K¡K..5¡K¡K¡K¡K..6¡K¡K¡K¡K..110 ¡K..17.5¡K...20¡K¡K.15¡K¡K¡K¡K..1.33¡K¡K.. > 1374
¡K..20¡K¡K...30¡K¡K.10¡K¡K¡K¡K..3¡K¡K¡K¡K..150 ¡K..20¡K¡K...25¡K¡K.15¡K¡K¡K¡K..1.67¡K¡K..600
¡K..22.5¡K...40¡K¡K..5¡K¡K¡K¡K..8¡K¡K¡K¡K..50 ¡K..22.5¡K...30¡K¡K.15¡K¡K¡K¡K..2¡K¡K¡K¡K..300 ¡K..22.5¡K...25¡K¡K.20¡K¡K¡K¡K..1.25¡K¡K.. > 1374
¡K..25¡K¡K...40¡K¡K.10¡K¡K¡K¡K..4¡K¡K¡K¡K..90 ¡K..25¡K¡K...35¡K¡K.15¡K¡K¡K¡K..2.33¡K¡K..190 ¡K..25¡K¡K...30¡K¡K.20¡K¡K¡K¡K..1.50¡K¡K...650
¡K..27.5¡K...40¡K¡K.15¡K¡K¡K¡K..2.67¡K¡K..140 ¡K..27.5¡K...35¡K¡K.20¡K¡K¡K¡K..1.75¡K.¡K..320
¡K..30¡K¡K...50¡K¡K.10¡K¡K¡K¡K..5¡K¡K¡K¡K..60 ¡K..30¡K¡K...45¡K¡K.15¡K¡K¡K¡K..3¡K¡K¡K¡K..100 ¡K..30¡K¡K...40¡K¡K.20¡K¡K¡K¡K..2.00¡K.¡K..200
¡K..32.5¡K...45¡K¡K.20¡K¡K¡K¡K..2.25¡K.¡K..130
¡K..35¡K¡K...50¡K¡K.20¡K¡K¡K¡K..2.50¡K¡K...100
¡K..40¡K¡K...50¡K¡K.30¡K¡K¡K¡K..1.67¡K¡K...200
Ó¤H¹ê¦b¤£§Æ±æ±N¹ï·Ó²Õ¤ÏÀ³²v(CR)>20%®³¨Ó¤ÀªR ½²±Ð±Â¤£¬OÁ|¤F¤@Ó¤£«ç»ò«ê·í¦ý¤S¶K¤Áªº¤ñ³ë¶Ü ¨âÓ¤kªB¤Í , ¤@Ó±`¨£± , ¥t¤@Ó¸ûªø®É¶¡¤~¨£± , ¨Ó»¡©úSPCD¸ÕÅ窺¦w¼¢¾¯®ÄÀ³ ¤]´N¬O»¡ , Âùª¼ÀH¾÷¶¥¬qªº±wªÌ , ³£¬O¨Ó¦Ûrun-in ¶¥¬qªA¥Î¦w¼¢¾¯ªº¤£¤ÏÀ³ªÌ(PANSS§ïµ½´T«×¥¼¹F20%ªÌ) ³o¨Ç¥H«eªA¥Î¦w¼¢¾¯´N¤£¤ÏÀ³ªº±wªÌ , ¦bÂùª¼ÀH¾÷¶¥¬q , Y¦AªA¥Î¦w¼¢¾¯, ·|Åܦ¨¤ÏÀ³ªÌ¶Ü? À³¸Ó¤£°ª§a ¦ý³o¨Ç±wªÌY¦bÂùª¼ÀH¾÷¶¥¬q , §ïªANaBen , °£¤FNaBenªºÃĮĥ~ , ¥i¯àÁÙ·|¦³©M¤§«eªA¥Î¦w¼¢¾¯¤£¤@¼Ëªº·P¨ü²£¥Í? ³oÀ³¬O½²±Ð±Â¨âÓ¤kªB¤ÍªºÂA¬¡¤ñ³ëªººë¯« ©Ò¥H , ¹ï·Ó²Õªº¤ÏÀ³²v20% , ©Î¥i©¿²¤¤£¬Ý °²¦p¹ï·Ó²Õªº¤ÏÀ³²v¤j©óµ¥©ó20%ªº¤£¬Ý , ¨º»ò Á`¤ÏÀ³²vY¦b25%(§t)¥H¤W , «hÁ`¼Ë¥»¼Æ©Î¥i¦b200¥H¤U Ó¤H¬O¶É¦V©ó¥Î¹ï·Ó²Õ¤ÏÀ³²v(CR)=10%¨Ó¤ÀªR ¤]´N¬O³o²Õ¼ÒÀÀ ¡K..12.5¡K...15¡K¡K.10¡K¡K¡K¡K1.5¡K¡K¡K¡K. > 1374 ¡K..15¡K¡K...20¡K¡K.10¡K¡K¡K¡K..2¡K¡K¡K¡K..450 ¡K..20¡K¡K...30¡K¡K.10¡K¡K¡K¡K..3¡K¡K¡K¡K..150 ¡K..25¡K¡K...40¡K¡K.10¡K¡K¡K¡K..4¡K¡K¡K¡K..90 ¡K..30¡K¡K...50¡K¡K.10¡K¡K¡K¡K..5¡K¡K¡K¡K..60 °²Y¬O³o¼Ë ©Î³\¨º¤Ñ¬ð³QDSMB¡]data and safety monitoring board¡F¸ê®Æ¤Î¦w¥þºÊ´ú©eû·|¡^³qª¾¦¬¤u , ´N¦p¦P½÷·çªºCDK 4/6§í¨î¾¯Ibrance ¤@¼Ë , ©Î³\¤]¤£·|ı±o³Y²§?
½²±Ð±Â¦³ÄYÂÔªº¤ÀªR¤èªk §ÚÌ°µ§ë¸ê§PÂ_ªº´N¥u¯à¥Î²Ê²¤ªº¤è¦¡¨Ó¼ÒÀÀ , ¼ÖÆ[©Î«O¦u·íµM¦s¥G±z§ÚÓ¤Hªº®³®º ¤p§Ì¤]¥u¯àÄYµÂªº»¡ , ¥H¤W¼ÒÀÀ±À´ú©ÎÂ÷¨Æ¹ê¬Æ»· , ¤Á¤Å§@¬°±z§ë¸êªº¨Ì¾Ú
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gseniorbbs10144999 |
µoªí®É¶¡:2019/3/3 ¤U¤È 06:05:46
²Ä 513 ½g¦^À³
|
¤£·|º¦ªºì¦] 1.¨S¦³ÃD§÷ 2.ÀsÀYªÑ--¤¤¸Îªº¾P°âª¬ªp¤]¤£¦n
Y¬O³W¹º¥xÆW¤W¥«ÂdÀ³¸Ó´N¬O¨«IPOÄw¸ê¡An¶Ò±o¤ñ¸û¦hªº¸êª÷ªÑ»ù¶Õ¥²n°ª¡A©Ò¥HÀ³¸Ó·|¦³ÃD§÷ª£§@ªÑ»ù¤~¹ï¡C³Ì±ß©ú¦~À³¸Ó´N·|¬Ý¨ì¤F.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤j¤á¤H®a10140174 |
µoªí®É¶¡:2019/3/3 ¤U¤È 01:43:46
²Ä 512 ½g¦^À³
|
²{¦bªÑ»ù§C°g¥Dnªºì¦]À³¸Ó¬O ¦¬®×³t«×ªº½wºC. SND-13¦¬®×±µªñ¨â¦~,n¨ì¤µ¦~ªº²Ä¤T©u¤~°µ¨ä¤¤¤ÀªR, ¥Nªín¨ì²Ä¤T©uªº¦¬®×¤~¦³170´X¤H.¦pªG¨ì®É¤Sn¼W¥[¦¬®×¤H¼Æ,¨º½Ð°Ý³o¤£¬On¦Ü¤Ö¦Aµ¥¤T¦~¥H¤W¤~·|¦³µ²ªG¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/3 ¤W¤È 09:30:43
²Ä 511 ½g¦^À³
|
¤p¨È¤jªº³o¬q¸Ü [ ¤½¥q¦pªG¥H±ÂÅvÃÄ«~±M§Qªº¤è¦¡¨Ó¨ú±o¥Ø«e©Ò»Ý¸êª÷¡A¬O³Ì§Ö³t¤]¬O³Ì·ÓÅUªÑªFÅv¯qªº³~®| ] Åý¤p§Ì·Q°_½²±Ð±Â·|¤¤¦bÁ¿z±ÂÅv®É¤@¬q@¤H´M¨ýªº¸Ü ±ÂÅvªºÁ`ª÷ÃB«Ü¤j ¦ý¬Oñ¬ùª÷¥u¦³¤@ÂI , ³o¨Ã¤£¯àº¡¨¬·í«e¤½¥q¸êª÷ªº»Ý¨Dª¬ªp ±z¬O§_»{¬° , ³o¬OY¤zÃļt¶}¥Xªº±ø¥ó¦ÓÅý½²±Ð±Â«H¤â©à¨Óªº¤@Ó¨Ò¤l??? ÁÙ¬O§Ú·Q¤Ó¦h , ·Q¨ì¦Û¤vµØ¾v³B³B ¤j®a¦h«Ü²H©wÀRÀq , ½Ðì½Ì¤pªº¤@¦A¤j¼L¤Ú¨¥¤£¤Î¸q
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¨È10135608 |
µoªí®É¶¡:2019/3/2 ¤U¤È 10:03:26
²Ä 510 ½g¦^À³
|
¤ß¤ÍÌ¡G¦h¦~¸gÅ穾§i§Ú¡A³ß®®È±oµ¥«Ý¡A¨I¤£¦í®ð¶]µu缐¡A«Ü¦³¥i¯à¿ù¥¢¨}¾÷¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¨È10135608 |
µoªí®É¶¡:2019/3/2 ¤U¤È 09:55:10
²Ä 509 ½g¦^À³
|
Ó¤H»{¬°¤½¥q¦³¦h¶µ¤T´Á·sÃÄ¥¿µ¥«Ýµu¡B¤¤¡Bªø´Á°õ¦æÁ{§É¸ÕÅç¡AÄw±¹¸êª÷¬O·í«en°È¡A·sÃĤT´ÁÁ{§É©Ò»Ý¸g¶O¡A¤@¯ë·sÃÄ°_½X±on85»õ¡A©t¨àÃĶȻÝ15»õ°_¡A¦¨¥»¬Û¥h¬Æ»·¡A¤½¥q¦pªG¥H±ÂÅvÃÄ«~±M§Qªº¤è¦¡¨Ó¨ú±o¥Ø«e©Ò»Ý¸êª÷¡A¬O³Ì§Ö³t¤]¬O³Ì·ÓÅUªÑªFÅv¯qªº³~³w¡A¦³³oµ§¸êª÷Ѻª`Á{§É¸ÕÅç©Ò»Ý¡Aµ¥«Ý¶i«×Àò±o¨}¦nµ²ªG¡A¦A±µÄò¥Ó½ÐIPO¤W¥«Âd¡Bµo¦æ¼W¸êªÑ¡AÄw±o¤¤Ä~¸êª÷¡A¦A±µ¦AÀy½Ä¨ë¥¦¶µ¤G¡B¤T´ÁÁ{§É¡A³v³À°ê»Ú·sÃÄ¥«³õ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gseniorbbs10144999 |
µoªí®É¶¡:2019/3/2 ¤U¤È 09:54:37
²Ä 508 ½g¦^À³
|
¥u¦³®t¥|Ӥ뤽¥q¬°¤°»ò¨º»ò«æ©O?¦X²zªº§PÂ_À³¸Ó¬O±ÂÅv®×¤w¸g´X¥G¤jP©è©w............
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¨È10135608 |
µoªí®É¶¡:2019/3/2 ¤U¤È 08:49:35
²Ä 507 ½g¦^À³
|
²q·Q¤j¡GÁÂÁ§A¶}¤Fª÷¤f¡A¹D¥X¥l¶}Á{®É·|¥Dnªº¥Î·N¡A§Ú¥»¨Æ¤£°÷¡A¤£´±»¥¨¥²q´ú¡A¦ý¤]¦p¦P§A©Ò²q´ú¤@¼Ë¡A¥u¬O´e¦b¤ß𥚃¦Û§Ú·Pı¶}¤ß¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/2 ¤U¤È 07:32:04
²Ä 506 ½g¦^À³
|
¬ü¤j ±zªºÅU¼{ , ½²±Ð±Â¤]ª¾¹D³o¨ÇºÞ¨î , ÁÙ»¡©È¸êª÷·|¶×¤£¥X¨Ó ¥L¤]ª¾¹D¥Ø«e¤ß®®ªºª¬ªp , ©|¥¼²Å¦X¬ü°ê»´äªº¤W¥«±ø¥ó ©Ò¥H¥L¤]»¡ , ¥H¦b¥xÆW¤W¥«Âdªº¾÷·|©~«e ·|¤¤¥LÁÙ¤ÀªR , ¥x¬ü´äºªº¥«ªp©M§ë¸êªÌªk¤H¦ÛµM¤H¤Î¸êª÷¨Ó·½ªº¦û¤ñ ¬Û«H½²±Ð±Â·|¦b¦UºØ±ø¥ó¤Î¸êª÷»Ý¨Dªº½w«æùØ°µ¤@Ó¿ï¾Ü Ó¤H·Pı , ¤ß®®¦b¥xÆW¤W¥«Âdªº¾÷·|º¡¤jªº µ¥¸êª÷¨ì¦ì(µL½×±ÂÅv©Î¨ä¥L¤è¦¡ªº¼W¸ê) , §Ú·Q¤ß®®Á{§É´N·|°_¸¤F?! ¤ß®®¦]¸êª÷¦]¯À , ´XÓ3´ÁÁ{§É³£¼È®É¥´¦í ªÑªF±`·|»¡nªº¼W¸ê , ª½¨ì²{¦b³£ÁÙ¥¼¦³°Ê§@ ¤]¦³ªÑªF´£°Ý , ±ÂÅvµ¹ SyneuRx Neuroscience , ¬°¦ó¤£µ¥¨ì2019ªºªÑªF±`·| , ¦Ó´£«e4Ó¤ë¥l¶}ªÑÁ{·|? ¤£¹L½²±Ð±Â¨Sª½±µ¨¥©ú , ¥u»¡·íµM¶V§Ö¶V¦n Ãø¹D¬On§Ú̲q´ú±ÂÅv®×¤wªñ¦¨¼ô¤F???
²q´úªº¶¢²á ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªY½à¼Æ¦r¬ü10147157 |
µoªí®É¶¡:2019/3/2 ¤U¤È 06:41:00
²Ä 505 ½g¦^À³
|
¤¤°ê¬OÓÄY®æ¥~¶×ºÞ¨îªº°ê®a
2016¦~«e¦b¦X®æ¹Ò¥~¾÷ºc§ë¸êªÌ¹Ò¤ºÃÒ¨é§ë¸êºÞ²z¼È¦æ¿ìªk¤¤ ¦³©Ò¿×ªº¶×¥X¤ñ¨Ò¨î(¤]´N¬O¥~¶×ºÞ¨î) 2016¦~¦Ü2018¦~¤~ÃP¸j ¨ú®ø¶×¥X¤ñ¨Ò¨î©M¨ú®ø¦³ÃöÂê©w´Án¨D
¦Ü©óÓ¤H¤è± Ó¤HÁʶצ³¹ê¦æ¦~«×Á`ÃBºÞ²z¡A¦~«×Á`ÃB¥Ø«e¤À别¬°¨C¤H¨C¦~µ¥È5¸U¬ü¤¸
ºÞ²z¼h¦pªGn¦bº(¬ì³Ðª©)IPOn¦n¦nªº·Q¤@·Q ³oºØ¥~¶×ºÞ¨îµ{«×¡A¿ú¶i¥h¤F¬O¤£¬O®e©ö¥X±o¨Ó
»´ä¥¼¨Ó¤]¥i¯à³Qµø¬°¸êª÷°k¥Xªºº|¬} ¦³¤°»ò¤£§Qªº·s¬Fµ¦¹ê¬I¤]¤£·N¥~
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/2 ¤U¤È 03:23:56
²Ä 504 ½g¦^À³
|
¤ÀªR®v¡G¤µ¦~80¦Ü90®a¥ø·~µn³°¬ì³ÐªO
2019-03-02 14:21Áp¦X³ø °OªÌ§õ¥òºû¢¬§Y®É³ø¾É
2¤ë28¤éµ²§ô¼x¨D·N¨£¡A¤j³°ÃҺʷ|¤µ¤Ñâ±á¤õ³tµo¥¬¬ì³ÐªO¸ÕÂIµù¥U¨î³W«h¡AIPO¨ü²z§Y±N±Ò°Ê¡A°êª÷ÃҨ麮uµ¦²¤¤ÀªR®v§õ¥ß®pªí¥Ü¡A«ö·Ó³oÓ³t«×¡A¹wp¬ì³ÐªO³Ì§Ö7¤ë1¤é¹B§@±Ò°Ê¡Aº§å20¦Ü25®a¥ª¥k¡A¤µ¦~¥þ¦~µo¦æ80¦Ü90®a¥ª¥k¡C
§õ¥ß®p»{¬°¡Aº§åµo¦æ¥Dn¶°¤¤¦b¤T¤jÃþ¦æ·~¡G°ªºÝ»s³y¡B¥b¾ÉÅé¡BÂåÃÄ¡C«ö·Ó¨C®a¿Ä¸êÃB¤H¥Á¹ô3.5»õ¤¸´úºâ¡A¥þ¦~IPO¿Ä¸êÃB¤H¥Á¹ô300»õ¤¸¥ª¥k¡C
³]¥ß¬ì³ÐªO¨Ã¸ÕÂIµù¥U¨î³W«h www.sse.com.cn/lawandrules/sserules/tib/
¤W®ü证¨é¥æ©ö©Ò¬ì创ªOªÑ²¼发¦æ¤W¥«审®Ö规则 www.sse.com.cn/lawandrules/sserules/tib/review/a/20190302/a9be0ddb9baed2b57e35f436b4b752d4.pdf
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/3/2 ¤W¤È 11:15:33
²Ä 503 ½g¦^À³
|
20190227¤ß®®ªÑªFÁ{®É·|«ÂI . ³q¹L±ÂÅv©M¸Ñ°£Äv·~¸T¤î¨î
¥Ñ½²±Ð±Âªº¤@®u¸Ü , ¥i¥H²`²`ªº»â·| , ½²±Ð±Â¤£¶ÈÂå¾Ç»â°ì±M·~»â¥ý·~¬É(¾Ç¬É»â¥ý·~¬É¤Q¦~) , ¹ï©óÂåÃÄ¥«³õ©M¸ê¥»¥«³õªº¹B§@¤]¦p¼Æ®a¬Ã , ª¾¤§¬Æ¸Ô
¥H¤U¬O½²±Ð±Â·|«á½Í¸Üªº«ÂIºKn : . SND-13¹wpQ3´Á¤¤¤ÀªR , ¤£¹L½²±Ð±Â¤]n¤j®a§O¤Ó°ª¿³ , ´Á¤¤¤ÀªR¨Ã¤£¬O¸Ñª¼ , ¦®¦bµû¦ôn¤£n¼W¥[¦¬®×¤H¼Æ ; Ó¤Hı±o½²±Ð±Â¥i¯à¹îı³o¼Ëªº»¡ªk©Î·|¤Þµo¤j®a¹L«×¼ÖÆ[ªº¹w´Á , ²¦³º¨S¦³¦nªº¼Æ¾Ú , ¸Ñª¼¨º¦³°ª¿³¥i¨¥ , ©Ò¥H¤SÁ¿zÁ{§É«áÄò¥i¯àªºµ{§Ç¥H¬°¥¿Å ªþµù : ²{¦b©Î³\ª¾¹DÁ`¤ÏÀ³²v , ¨º´N¬O½²±Ð±Â¦b¸ÑÄÀSPCDªº¸ÕÅç³]p , ¹êÅç²Õªº¤ÏÀ³²v¥i¯à±q50% °¬°30% , ¹ï·Ó²Õªº¤ÏÀ³²v©Î±q30% °¬°10% , ¨º»ò , ¨â²Õªº¤ÏÀ³²v¤ñȱN¥Ñ¶Ç²ÎPD³]pªº1.67 (50%/30%)¸õ¤É¬°SPCD³]pªº 3 ( 30%/10%) , ¤ÏÀ³²v¤ñȪº©Ô¶}¥NªíµÛ¨â²ÕÀø®Äªº®t¶ZÅܤj ¡C ¤p§Ì¹Á¸Õ¥Î348¤H¨Ó²Ê²¤¼ÒÀÀ¥d¤èÀËÅç , ±o¨ì¶Ç²ÎPD³]pªºPȬù¬°0.000128 (¤ÏÀ³²v¤ñÈ 1.67 , ¼Ë¥»¼Æ 348 ) , Y¬°SPCD³]p , PȬù¬°0.00085 (¤ÏÀ³²v¤ñÈ 3 , ¼Ë¥»¼Æ 182 (=348*3/4*0.7) , ¨âªÌPȬÛY , µM¹ù¥S¦b¥Lªº¤j§@¤¤ (liawbf.pixnet.net/blog/post/47542314 ) ´£¨ì¥L¬Ý¹Lªº¾ÇªÌ¬ã¨s , ¨Ï¥ÎSPCD , ®ÄªG¶q¥i¥H´£¤É 2 ~ 3 ¦¨ , ²Îp¦ÒÅç¤O¥i¥H¼W¥[ 1 ~ 5 ¦¨ . Y±N¼Ë¥»¼Æ¥Î³Ì¤jÈ(1374)¨Ó¼ÒÀÀ®É , ±o¨ì¶Ç²ÎPD³]pªºPȬù¬° 4.5 E -14 (¤ÏÀ³²v¤ñÈ 1.67 , ¼Ë¥»¼Æ 1374 ) , Y¬°SPCD³]p , PȬù¬° 2.16 E -11 (¤ÏÀ³²v¤ñÈ 3 , ¼Ë¥»¼Æ 721 (=1374*3/4*0.7) , ¥i¨£¼Ë¥»¼Æ¹ïPȪº¼vÅT¬Æ²` , ¨âªÌPÈÁö®t¤d¿ , ¦ý¹ï³oºØ¶W¤pPÈ , ¤@¼Ë³£¬O¼g¦¨ p < 0.00001 ( ¼ÒÀÀ©Ò¥Îªº°Ñ¼Æ¥²©w»P¹ê»Úªº¼ÆȦ³©Ò¥X¤J , ¤Á¤Å§@¬°§ë¸ê¨Ì¾Ú ) . SND-5 , SNA-1 pµe Q2 ~ Q3 °e¥ó¥Ó½Ð¤G´ÁÁ{§É , ¨ä¤¤SND-5¬O¤¤¡B¬ü¨â¦a¦P®É°e¥ó . SNG-12 ²Ä¤T´ÁÁ{§É¸ÕÅç±N¼W¥[²Ä¤@Ó¬P´Áªºµû¦ô®ÉÂI . SND-5 ªº°Êª«¼Ò«¬ ¬Ò¤ñ SND-1ªÌ ¦n«Ü¦h . ¶W¯Å¥é»sÃÄSNS¨t¦C¬O«ü°w¹ï¤w¨ì´Áªº¤¤¼Ï¯«¸g¨t²Î¯e¯fÃĪ«ªºAPI (¬¡©ÊÃĪ«¦¨¤À) , ²K¥[¦³À°§Uªº»²®Æ©Ò§Î¦¨ªºÃĪ« , ³z¹L¤ß®®ªº§Þ³N¥¥x , §ïµ½¸Óµ¥ÃĪ«§l¦¬©Î´£°ªÀø®Ä©Î°§C°Æ§@¥Î , ½²±Ð±Â»¡³o¬O«D±`¦³»ùȪº§Þ³N . IPO¤´¦bµû¦ô¤¤ , ¥x¡B¬ü¡B´ä¡Bº (¬ì³Ðª©)¬Ò¦b¦Ò¼{ , ¥xÆWªº¾÷·|©Î¦b«e± . ¶Ò¸ê¥H¦h±¦V¬°¤§ --- ¼W¸ê¡B IPO ©Î±ÂÅv . ±ÂÅv½Í§P¶i¦æ¤¤ , ¥ô¦ó²£«~³£¦³¥i¯à±ÂÅv , Ó¤H¥H¬°Y±ÂÅv©³©w , ¤ß®®ªºÁ{§É¶i«×±N·|¬ð¸²r¶i
¥H¤WºKn , Y¦³²¨º| ¡B»~¶Ç ¡B»~¸ÑªÌ , ¦³½Ð¤j®a¸É¥R«ü¥¿
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/2/28 ¤U¤È 07:02:57
²Ä 502 ½g¦^À³
|
½²±Ð±Â¤Ò¤Hªº«¢¦ò³Õ¤h½×¤å
healthpolicy.fas.harvard.edu/people/vivian-wu
¾Ç¦ì½×¤åÃD¥Ø¡G ¡§ºÞ²z¦¡ÂåÀø»P20¥@¬ö90¦~¥N¤£Â_ÅܤƪºÂå°|²£·~¡¨
²Ä¤@³¹±´°Q¤FºÞ²z¦¡ÂåÀøp¹º»PÂå°|¶i¦æ»ù®æ½Í§PªºÃÒ¾Ú¡CºÞ²z¦¡ÂåÀøp¹º¤¤Æ[¹î¨ìªº¸û§C»ù®æ¥i¯à»P¤TÓ°²³]¤@P¡G¡]1¡^¦¨¥»®t²§¡A¦]¬°¤@¨Çp¹º¨Ï¥Î¦¨¥»¸û§CªºÂå°|©Î¨ä±wªÌ¦bÂå°|¤ºÀò±o¤£¦Pµ{«×ªºÂåÀøªA°È; ¡]2¡^»ù®æª[µø¡A¨ã¦³¥«³õ¤O¶qªºÂå°|¹ï»Ý¨D¼u©Ê¸û¤jªºÁʶRªÌ¦¬¨ú¸û§Cªº»ù®æ; ¡]3¡^ºÞ²z¦¡ÂåÀøªA°Èªº»ù®æ½Í§P¡A»ù®æ¦]«OÀI¤½¥q¨ã¦³¤£¦Pµ{«×ªºÄ³»ù¯à¤O¦Ó¦³©Ò¤£¦P¡C¨Ï¥Î1994¦~¦Ü2000¦~´Á¶¡°¨ÂĽѶë¦{¹ê»ÚÂå°|»ù®æªº¿W¯S±ªO¼Æ¾Ú¶°¡A§Úµo²{¾¨ºÞ¦¨¥»®t²§©M»ù®æª[µø°²³]¸ÑÄÀ¤F¤ä¥Xªº¤@¨ÇÅܤơA
²Ä¤G³¹¤ÀªR¤FÂå°|¹ïÂåÀø«OÀI«¤j°]°È·l¥¢ªº©w»ù¦æ¬°¡C²{¦³ªº°²³]¨S¦³©ú½T¹w´ú³oºØ¾Ô²¤¦æ¬°¬O§_·|µo¥Í¡A©ÎªÌ¬O§_¦]©Ò¦³ÅvÃþ«¬¦Ó¤£¦P¡C¥»³¹¨Ï¥Î¤F¤@¶µ¦ÛµM¹êÅç - 1997¦~ªº¥¿Å¹wºâªk®×¡]BBA¡^¡A¨Ãµo²{¦bÄvª§§ó¿E¯Pªºªì©l¥«³õ¤¤ªºÂå°|³q¹L¦V¨p¤H«OÀI¤½¥q´£°ª»ù®æ¨Ó©è®ø¬ü¤¸ªºt¾á¡C¦¹¥~¡A³q¹L´£¨Ñ°Ó¾ã¦XÀò±o°Q»ùÁÙ»ùªºÂå°|¥H¤Î³q¹LºÞ²z¦¡ÂåÀøªA°È©ñ¼e´ë¹Dªº§V¤O¯à°÷¶i¤@¨B´£°ª»ù®æ¡C
²Ä¤T³¹¬ã¨s¤FÂå°|Ãö³¬¹ïÄvª§¹ï¤âªº»ù®æ¼vÅT¡C¦í°|ªA°Èªº»Ý¨D¦b¹L¥h¤G¤Q¦~¤¤¤@ª½¦b¤U°¡A¦P®É¦í°|¯f§É®e¶qµäÁY¬ù14¢H¡C³oºØ¯à¤O¤U°ªº«Ü¤j¤@³¡¤À¬O¥Ñ©óÂå°|Ãö³¬¡CÁöµMÂå°|Ãö³¬¦³§U©ó®ø°£¦h¾lªº³]¬I¡A¦ý¥¦Ì¤]´£°ª¤FƦsÂå°|ªº½Í§P¦a¦ì¡C¥»¤å¤ÀªR¤F1992¦~¦Ü1998¦~´Á¶¡Æ¦sªºÄvª§¹ï¤â¡Aµo²{¾aªñÃö³¬¦aÂIªºÂå°|¤ñ¥«³õ¤Wªº¨ä¥LÂå°|§ó¯à´£°ª¥L̪º½Í§P¦a¦ì¡C¦¹¥~¡A¸g¾ú¦h¦¸Ãö³¬ªº¦a°ÏªºÂå°|¯à°÷¹ê²{§ó¤jªº»ù®æ¼Wªø¡C (Google ½Ķ )
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/2/28 ¤U¤È 02:28:40
²Ä 501 ½g¦^À³
|
¶W¯Å¾Ç¦WÃÄ SNS¨t¦C , «Y³q¹L¤ß®®ªº§Þ³N¥¥x , §ïµ½¸Óµ¥¾Ç¦WÃĪºÃĪ«§l¦¬©Î´£°ªÀø®Ä©Î°§C°Æ§@¥Î ½²±Ð±Â»¡ «D±`¦³»ùÈ ¤w©óSeptember 4, 2018 Àò±o¬ü°ê±M§Q United States Patent 10,064,833 Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
¤µ¤é USPTO¤S¤½¶}¸Ó±M§QªºÂX(¸É)¥Rª©
United States Patent Application 20190060263 Kind Code A1 February 28, 2019
COMPOSITIONS CONTAINING BENZOATE COMPOUND AND TANNIC ACID FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
¦³¿³½ìªºªB¤Í ½Ð¦Û¦æ«e©¹°Ñ¦Ò¤ñ¹ï
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/2/28 ¤W¤È 09:27:49
²Ä 500 ½g¦^À³
|
½²±Ð±Â»¡ SND-5 ªº°Êª«¼Ò¦¡ ¤ñ SND-1 ¦n«Ü¦h ©Ò¥H ¤¤¬ü¦L¼Ú ³£¦³¥Ó½Ð
WO/2017/167168 COMPOSITIONS CONTAINING TANNIC ACIDS AND USES THEREOF WO International Application No.: PCT/CN2017/078361 Publication Date: 05.10.2017
Compositions Containing Tannic Acids and Uses Thereof US Publication Date: 05.04.2018
COMPOSITIONS CONTAINING TANNIC ACIDS AND USES THEREOF IN Publication Date: 11.01.2019
COMPOSITIONS CONTAINING TANNIC ACIDS AND USES THEREOF EP Publication Date: 06.02.2019
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p´²¤á10147972 |
µoªí®É¶¡:2019/2/27 ¤U¤È 01:41:17
²Ä 499 ½g¦^À³
|
¥i¯à¦³¨Ç¤Hµ¥¤£¤U¥h´N¥ý»{½ß½æ¥X¤F¡A¿ð¿ð¨S¦³®ø®§©Î¬O¶i«×¡C¤Ï¥¿¥H²{¦bªº»ù®æ¤jªÑªFÀH«K½æ³£ÁÈ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GYendis10145808 |
µoªí®É¶¡:2019/2/27 ¤U¤È 12:27:00
²Ä 498 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/2/18 ¤W¤È 10:40:46
²Ä 497 ½g¦^À³
|
»s¾¯¹Lµ{¤¤µo¥Í´¹«¬ÂàÅܪº·ÀI¦]¯À¥H¤Î¾÷¨î ¨Ó·½¡GÃÄ´ç ¡@2019-02-18 §@ªÌ¡Gmuzhang
med.sina.com/article_detail_103_2_60791.html
¤p¤À¤lÃĪ«¤À¤l±Æ¦C¤è¦¡¤£¦P±q¦Ó¨ã¦³¤£¦Pªº´¹«¬¡C¤£¦Pªº´¹«¬²z¤Æ©Ê½è¨ã¦³®t²§¡A¥]¬A±K«×¡B·»¸Ñ«×¡B¥iÀ£©Ê¡B¬y°Ê©Ê¬Æ¦Ü¤Æ¾Çéw©Êµ¥¡C¤£ºÞ¬O·sÃĶ}µo¡AÁÙ¬O¥é»sÃĶ}µo¹Lµ{¤¤¡A¹ïÃĪ«´¹«¬ªº¦Ò¹î¬O¥²¤£¥i¤ÖªºÀô¸`¡C¬°¤F«OÃÒÃÄ«~¦b¥Í²£©MÀx¦s¹Lµ{¤¤½è¶q¥i±±¡A»Ýn¹ï»s¾¯¹Lµ{¤¤«e«áªºÃĪ«´¹«¬¶i¦æ¦Ò¹î¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/2/11 ¤W¤È 11:37:38
²Ä 496 ½g¦^À³
|
ÁÂÁ¹ù¥S¤½¶} [ 108¦~·s¦~·s§Æ±æ : §Ú¹ïSND-7 ªº´Á«Ý ] liawbf.pixnet.net/blog/post/48772971
ªø½g½×¤å¯Åªº¤j§@ ±q¥NÁ¯gÔ¸s( MetS )³sµ² NMDAR , ¦A¨ìSND-7 ½×zÃøÀ´¨SÃö«Y , ¦hŪ´X¹M , ©Î³\´N·|¹³¤pªº¤@¼Ë , ±q©üÀYÂà¦V¨ì©ç¤â¥s¦n
¦A¦¸·PÁ¹ù¥Sªá¶O³o»ò¤j¤ß¤Oªº²±®b¤À¨É¤j®a Cliff¤j®¦¼w¤§«e¤]«Øij¤j®a[ ªÑ¥«¤£º¦½m¤º¥\ , ÃÛ¦n°¨¨Bµ¥®É¾÷ ] ´NÅý§ÚÌÃÛ¦n°¨¨Bµ¥Ô®É¾÷§a ! ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/27 ¤W¤È 11:28:57
²Ä 495 ½g¦^À³
|
Àò±o¬ð¯}©ÊÀøªk»{©w¹ï¤@Ó·sÃĪº·N¸q¦³¦h¤j¡H
¨Ó·½¡GÂåÃÄÅ]¤è ¡@2019-01-27 §@ªÌ¡GApril Chen
med.sina.com/article_detail_103_2_59892.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/25 ¤W¤È 10:50:58
²Ä 494 ½g¦^À³
|
¬Ý¬Ý§O¤H«ç»ò»¡? «·Å BTD
¥þ¤è¦ì¸ÑŪ¬ð¯}©ÊÀøªk»{©w¡GÃĪ«§Ö³t¤W¥«¦³±¶®| ¨Ó·½¡GCPhI»sÃĦb½u¡@2019-01-25 §@ªÌ¡G³Vd
Àò¬ð¯}©ÊÀøªk»{©w¦³þ¨Ç¦n³B¡H
«Ü¦hÃÄ¥ø¤£±¤ªá¶O¤j¶q¦¨¥»©M¤H¤O§Æ±æ¦Û¤vªºÃĪ«Àò±o¬ð¯}©ÊÀøªk»{©w¡A¨º»ò¡AÀò±o¬ð¯}©ÊÀøªk»{©w¬O¬°¤Fþ¨Ç¦n³B©O¡H
±qªø»·¤@ÂI¨Ó»¡¡A³Ì¤jªº¦n³B¬O¼f§å¥[³t¡I¾Ú±x¡AÀò±o¬ð¯}©ÊÃĪ«»{ÃÒªºÃĪ«¶}µo¥i¥H±o¨ì¥]¬AFDA©xû¦b¤ºªº§ó¥[±K¤Áªº«ü¾É¡A¤]´N¬O»¡¬ð¯}©ÊÀøªk»{©w¥i¥HÅý¥ø·~»P¬F©²¤§¶¡ªº·¾³q§ó¬°ºò±K¡A¦]¦¹¥i¥H«O»Ù¦b³Ìµu®É¶¡¤ºÀò±o¬ÛÀ³¼f§å¡C
±qªñ¤@ÂI¨Ó»¡¡A¥Ñ©óÀò±o¬ð¯}©ÊÀøªk»{©w¥i¥H³Q·í§@¬ÛÀ³ÃĪ«¤w¸g¦b¤@©wµ{«×¤WÀò±oFDA»{¥i¡A³o¹ï©óÃĪ«¤Î¥ø·~µLºÃ¬O¤@°w±j¤ß¾¯¡CªÑ²¼¼WÈ¡BÀò±o§ë¸ê¥H¤Î¬Fµ¦¶É¦V³£¬OIJ¤â¥i±oªº¦n³B¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gyuki10141394 |
µoªí®É¶¡:2019/1/24 ¤U¤È 09:46:30
²Ä 493 ½g¦^À³
|
¦U¦ì¤j¤j±ß¦w¡AÆ[¹î¤W§«ô¤ß®®1ªÑªÑªF¤H¼Æ¼W¥[800¦h¤H¡A½Ð±Ð¦U¦ì¤j¤j¬O¤°»òì¦]¡H ªþ¤W¤W¥«¤WÂd±ø¥ó¡AÀ³¸Ó¤£¬O¬°¤FªÑÅv¤À´²¡A³Â·Ð¤j®a¸Ñ´b¤@¤U¡A·PÁ sh823568.pixnet.net/blog/post/186736545-%E7%94%B3%E8%AB%8B%E4%B8%8A%E5%B8%82%E4%B8%8A%E6%AB%83%E7%9A%84%E6%A2%9D%E4%BB%B6 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/24 ¤U¤È 12:21:12
²Ä 492 ½g¦^À³
|
¹ù¥S³Ì·s½×¤å½àªR
DAAO¥Dn¸g¥Ñ²£¥ÍROS¦Ó«P¶i²ÓM¦Ñ¤Æ
liawbf.pixnet.net/blog/post/48782202
ì¨ÓCinnamon metabolite sodium benzoate (NaB) reduces the production of ROS ¤]¬O³oÓ¹D²z ÁÂÁ¹ù¥S ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/21 ¤U¤È 05:42:00
²Ä 491 ½g¦^À³
|
ÁÂÁ Cliff¤j®¦¼wªºÅW®b °ò¥»¬[ºc¦³¤F , ¸£µ¬´N²M·¡¦h¤F °²¦p±z¨SªÅ²âÅ¥³¯³Õ¤hªººtÁ¿ , ¨º²Ä¤@½gªº¤å³¹´N¤w§t¬A¤j³¡¤ÀªººtÁ¿¤º®e ¦³½Ð¤j®a²Ó²Ó«~À| ¨ä¤¤³¯³Õ¤h¦b Q&A ¯S§O±j½Õ §Üª¢©Ê ©M ¸£·½©Ê¯«¸gÀç¾i¦]¤l¡] BDNF ¡^
¥i³ßªº¬O ¤ß®®ªº NaBen ³£¦³³o¨âºØ¥\¯à
Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive, Reduces Microglial and Astroglial Inflammatory Responses www.ncbi.nlm.nih.gov/pmc/articles/PMC2862570/ ¥»¬ã¨s±´°Q¤F¦×®Û¥NÁª«f¥Ò»Ä¶u¡]NaB¡^¦b¤p½¦½è²ÓM©M¬P§Î½¦½è²ÓM¤¤ªº§Üª¢¯S©Ê¡C
Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: Therapeutic implications for neurodegenerative disorders www.ncbi.nlm.nih.gov/pmc/articles/PMC3663914/ f¥Ò»Ä¶u¡]NaB¡^¡A¤@ºØ¼sªx¨Ï¥Îªº¹«~¨¾»G¾¯©M FDA §å㪺§Ü¤HÃþ§¿¯À´`Àô»ÙꪺÃĪ«¡A¦b CNS ¤¤´£°ª¯«¸gÀç¾i¦]¤lªº¤ô¥[¨Ò¦p¸£·½©Ê¯«¸gÀç¾i¦]¤l¡] BDNF¡^©M¯«¸gÀç¾i¦]¤l-3¡]NT-3¡^]¡CNaB ¾¯¶q¨Ì¿à©Ê¦a»¤¾Éì¥N¤H¯«¸g¤¸( primary human neurons )©M¬P§Î½¦½è²ÓM¤¤ BDNF ©M NT-3 ªºªí¹F¡C
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GCliff10135274 |
µoªí®É¶¡:2019/1/21 ¤W¤È 09:27:33
²Ä 490 ½g¦^À³
|
ªÑ¥«¤£º¦½m¤º¥\¡AÃÛ¦n°¨¨Bµ¥®É¾÷¡C µ¹¦³¿³½ìªº¤H¡u¸É¸£¡v¡C
¤¤¬ã°|--¬ã¤§¦³ª« ¡u°O¾ÐÅÜ®t¡B¤ÏÀ³ÅܺC¡A¯«¸g²ÓM¥X¤F¤°»ò°ÝÃD¡H¡v ¡uresearch.sinica.edu.tw/neuron-disease/¡v
2016--¤¤¬ã°|105/11ª¾ÃÑÅW®b¡u¼Ä§ÚÃø®Æ- ¯«¸g°h¤Æ¯e¯f¤¤ªº¬P§Î½¦½è²ÓM¡v ¡uwww.youtube.com/watch?v=Qaz8rKEi3C8&feature=youtu.be¡v
2019/01/17 ¬ð¯}BBB ¡u¸£Àù±wªÌºÖµ¡I¬ð¯}¨¾Å@¸n ¦¨¥\¿é°e©`¦ÌÃĪ« ¶}±Ò¸£ÀùªvÀø¤§Æ_¡v ¡unewsletter.sinica.edu.tw/%E8%85%A6%E7%99%8C%E6%82%A3%E8%80%85%E7%A6%8F%E9%9F%B3%EF%BC%81%E7%AA%81%E7%A0%B4%E9%98%B2%E8%AD%B7%E7%BD%A9-%E6%88%90%E5%8A%9F%E8%BC%B8%E9%80%81%E5%A5%88%E7%B1%B3%E8%97%A5%E7%89%A9-%E9%96%8B%E5%95%9F/¡v
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/19 ¤U¤È 03:09:50
²Ä 489 ½g¦^À³
|
¦¤W ¤u°Ó®É³ø ·s¥úÂå°|¼ï¹Å©MÂå®v¼¶¼g¦³Ãöª`·N¤O¯Ê·l¹L°Ê¯g---attention deficit hyperactivity disorder (ADHD) ªº¤¶²Ð Åý¤H¾Ð°_½²±Ð±Â©MÂűбÂ...µ¥ ¦b2016/7 µoªíªº½×¤å Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children
journals.sagepub.com/doi/abs/10.1177/0269881116658986?journalCode=jopa
[ ºKn ]ªº²Ä¤@Ó¦r , ´N¬O¼gµÛ¼ï¹Å©MÂå®v©Ò¤¶²ÐªºªvÀøADHDÃĪ«---¤¤¼Ï¯«¸g¿³¾Ä¾¯ Methylphenidate Methylphenidate, a stimulant that activates dopaminergic and noradrenergic function, is an important agent in the treatment of attention deficit hyperactivity disorder (ADHD). ½×¤å½Íªº¬OSarcosine ( ¦Ù®ò»Ä )---¦b¦h°Ê¯gªº±¡ªp¤U¡A¦Ù®ò»Ä¥i¯à¬OªvÀøODD¯gª¬ªº·sÃÄ¡C ¦ý¬O¡A¤pªº«o¹ï³oÀÉ---¤¤¼Ï¯«¸g¿³¾Ä¾¯ Methylphenidate ¦³¿³½ì ¤pªº²q´ú , ³o¥i¯à¬O¹ù¥Sµ§¤U¦³Ãö¤ß®®¶W¯Å¾Ç¦WÃÄ SNS 1 ~ 7 ¤¤ªº¤@Àô ¤]´N¬O NaBen + ³æ¹ç»Ä + Methylphenidate ªº²Õ¦X , ¨ÓªvÀø¦h°Ê¯g¯gª¬ , [ Claims ]²Ä 8 ±ø ¥¿±ªí¦CªºÃĪ«¤¤¤]¦³ Methylphenidate ½×¤åµoªíªº¬O¦Ù®ò»Ä , Àò±o±M§Qªº¬O NaBen + ³æ¹ç»Ä , ¤]®¼¦³·N«äªº
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/19 ¤W¤È 08:15:34
²Ä 488 ½g¦^À³
|
¦W¡DÂå¡D°Ý¡D¶E¡Ðª`·N¤O¯Ê·l¹L°Ê¯g À³¤Î¦ªvÀø 2019¦~01¤ë19¤é 04:10 ¤u°Ó®É³ø ¤å¡þ¼ï¹Å©M¡]·s¥úÂå°|¨àµ£ºë¯«¬ì¥DªvÂå®v¡^
www.chinatimes.com/newspapers/20190119000431-260209
ª`·N¤O¯Ê·l¹L°Ê¯g¦b¥@¬É¦U°ê«Ä¤l¤¤´¶¹M¦s¦b¡A°ê¤º¤]°ª¹F20¦h¸U¦W¾ÇÄ֫ĵ£¿©±wª`·N¤O¤£¶°¤¤¹L°Ê¯g¡A¨ä¤¤¬ù¦³25¢H¯fµ£¡A¨ä¯gª¬¥i¯à©µ¦ù¦Ü«C¤Ö¦~©Î¦¨¤H¶¥¬q¡A¦ý¥þ¥x«o¶È¦³1¸U¦Wª`·N¤O¤£¶°¤¤¹L°Ê¯g¯fµ£´M¨D¥¿½TºÞ¹D´NÂåªvÀø¡AY®aªøµo²{«Äµ£¨ã¦³ª`·N¤O¤£¨¬¡B½Ä°Ê¡B¹L°Êµ¥¯gª¬¡AÀ³¥ß§Y«e©¹´NÂåµû¦ô©ÎªvÀø¡C
¬ã¨s«ü¥X¡Aª`·N¤O¤£¶°¤¤¹L°Ê¯g¯fµ£¤¤¬ù¦³11¢H¦P®É±w¦³§´·ç¤ó¯g¡A34¢Hªº¯fµ£§ó¨ã¦³µJ¼{²{¶H¡A³o¨Ç¦@¯f¯gª¬¹ï©ó«Äµ£¥¼¨ÓªºÓ©Ê¾i¦¨¡A¬Ò¦³ªø»·ªºt±¼vÅT¡A®aªø¤Î¾Ç®Õ¦Ñ®vÀ³ªÃ«ù¦P²z¤ß¡A³]¥ß¾A·íªº¦æ¬°ªvÀø¥Ø¼Ð¡A¤~¬O¨ó§U«Äµ£ªvÀøªºÃöÁä¦]¯À¤§¤@¡C
¦bÃĪ«ªvÀø¤è±¡A¥Ø«e¦³«D¤¤¼Ï¯«¸g¿³¾Ä¾¯¡]«ä¾U¡AAtomoxetine¡^§@¥Î¦b©ó´£°ª¸£¤¤¥¿µÇ¤W¸¢¯À¡A¡]¯à§ïµ½¸£¤¤¦h¤ÚÓiªº¿@«×¡^... ¤¤¼Ï¯«¸g¿³¾Ä¾¯¡]§Q¥L¯à¡B±M«ä¹F¡^¡AMethylphenidate«h¬°ªvÀø¸£¤¤¦h¤ÚÓiÃĪ«.
¤ß®®ªº±M§Q 10064833 2018¦~9¤ë4¤é §t¦³f¥Ò»ÄÆQ¤Æ¦Xª«©M³æ¹ç»Äªº²Õ¦Xª«¡A¥Î©óªvÀø¤¤¼Ï¯«¸g¨t²Î¯e¯f
[ Claims ] ²Ä 15 , 16 , 17 ±ø
15.¤@ºØ¦b±w¦³©ÎÃhºÃ±w¦³¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯f¯gªº¨ü¸ÕªÌ¤¤ , ¥Î¥H´î¤Ö¬¡°Ê¹L«×©Î®¾±Ï·Pı¹B°Ê»Ùꪺ¤èªk¡A©Òz¤èªk¥]¬A¦V©Òz¨ü¸ÕªÌ¬I¥ÎÅv§Qn¨D1ªº²Õ¦Xª« ¡C ( A method for reducing hyperactivity or rescuing sensorimotor deficit in a subject having or suspected of having a central nervous system (CNS) disorder, the method comprising administering to the subject the composition of claim 1. )
16.Åv§Qn¨D15ªº¤èªk¡A¨ä¤¤¤¤¼Ï¯«¸g¨t²Î¯e¯f¿ï¦Ûª`·N¯Ê³´¦h°Ê»Ùê¡Aºë¯«¤Àµõ¯g¡A««×§íÆ{¯g¡Aªüº¸¯ý®üÀq¯f¡AÂù¬Û±¡·P»Ùê¡A¤H®æ»Ùê¡A©â°Ê»Ùê¡A³Ð¶Ë«áÀ³¿E»Ùê¡A®£·W¯g¡A¦Û³¬¯gÃШt»Ùê¡Aªü´µ§B®æºî¦X¯g¡A¯Ü®zXºî¦X¼x¡A±j¢¯g¡ATouretteºî¦X¼x¡Aè§b¡A©¬ª÷´Ë¯f¡A¦ë§Ê¹y¯f¡A©]¶¡¿ò§¿¯g¡A²´Â¥µjÅË©M«DÅöíwµo§@¡C
17.Åv§Qn¨D16ªº¤èªk¡A¨ä¤¤CNS¯f¯g¬O¨ã¦³¦h°Ê¯g¯gª¬ªºCNS¯f¯g¡A¨ä¿ï¦Ûºë¯«¤Àµõ¯g¡AÂù¬Û±¡·P»Ùê¡Aª`·N¤O¯Ê³´¦h°Ê»Ùê¡A±j¢¯g¡A¹Ï¹p¯Sºî¦X¼x¡A¦Û³¬¯gÃШt»Ùê¡A¯Ü©ÊXºî¦X¼x¡A©¬ª÷´Ë¯f¡A¸ô©öÅéè§b©M¦Ñ¦~©Êè§b¡C
¤pµù :
ì¨Óª`·N¤O¯Ê³´¦h°Ê»Ùê¤]¬O¤@ºØCNS¯e¯f , ´¶¤Î²v¤]¤£§C ,,¥ú¬O¦b¥xÆW , ´N¦³ 20´X¸U«Äµ£±w¦³¦¹¯g ¦Ó¨ä¥LCNS¯e¯f¤]¦³¦hºØ¨ã¦³¦h°Ê¯g¯gª¬ , ³o¼Ë¬Ý°_¨Ó¥«³õ¤]¤£¤p Ãø©Ç½²±Ð±Ân¥t¦C¤@±ø³æ¿WªºÅv§Q½Ð¨D¶µ¨Ó«OÅ@ ±q¬Q¤éªº³ø¾É --- reducing brain homocysteine ( ¦P«¬¥b¯ÖÓi»Ä )levels , ªvÀøADªºf¥Ò»Ä¶u ¨ì¤µ¤éª`·N¤O¯Ê·l¹L°Ê¯gªº±MÄæ , ÁÙ¦³¤ß®®±M§QªºÀ³¥Î ÁÙ¦³ , ¦b[ Claims ]17¤¤ , ¤]Åã¥Üºë¯«¤Àµõ±wªÌ¤]¨ã¦³¦h°Ê¯g¯gª¬ , SND-11 ~ 13 À³¤]¥i¥HªvÀø¥¦ ¬Q¤µ³o¨â«h³ø¾É , Åý¤H¤£±o¤£¨ØªA½²±Ð±Âªº±M·~©M§V¤O ÁÂÁ½²±Ð±Â©M¤ß®®¹Î¶¤
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/18 ¤U¤È 07:38:05
²Ä 487 ½g¦^À³
|
¶¼¹¤¤´£°ªÁxÆP§t¶q¹ï§ÜÀ»³oºØ¡§¤£ªv¤§¯g¡¨¦³©_®Ä ¨Ó·½¡GCPhI»sÃĦb½u¡@2019-01-18 §@ªÌ¡G¸·¬¬õ
med.sina.com/article_detail_103_2_59447.html
ÁxÆP( choline ) ·|°§C¦P«¬¥b¯Ö®ò»Ä¡]homocysteine¡^ªº¤ô¥¡C¦P«¬¥b¯Ö®ò»Ä¬O¤@ºØ¥i¥H§@¬°±j®Ä¯«¸g¬r¯Àªº®ò°ò»Ä¡A¦³§U©ó¯«¸g¤¸ÅÜ©Ê¡B¾ý¯»¼Ë³J¥Õ¯f´³ªº§Î¦¨¡C¤w¦³¬ã¨sªí©ú¡A¦Ñ¦~è§b±wªÌªº¦P«¬¥b¯Ö®ò»Ä¤ô¥¤É°ª¡C Maternal choline supplementation ameliorates Alzheimer¡¦s disease pathology by reducing brain homocysteine levels across multiple generations.
³oÓ³ø¾É(ameliorates Alzheimer¡¦s disease pathology by reducing brain homocysteine levels )¤]¥i¥H³s¤W¤ß®®ªº SND-14 , SND-51
°Ñ¦Ò¸ê®Æ1: ¦×®Û¤Î¨ä¥NÁ²£ª«f¥Ò»Ä¶u¦bªüº¸¯ý®üÀq¯f°Êª«¼Ò«¬¤¤´î®zp21racªº¬¡¤Æ¨Ã«OÅ@°O¾Ð©M¾Ç²ß¡C www.ncbi.nlm.nih.gov/pubmed/26102198 [ oral feeding of cinnamon (Cinnamonum verum) powder and NaB suppressed the activation of p21rac and attenuated oxidative stress in the hippocampus of Tg mice as evident by decreased dihydroethidium (DHE) and nitrotyrosine staining, reduced homocysteine level and increased level of reduced glutathione. ]
°Ñ¦Ò¸ê®Æ2:
°ª¥b¯ÖÓi»Ä¡]^»y¡GHomocysteine¡A©ÎºÙ¬°¦P«¬¥b¯ÖÓi»Ä©Î¦P¥b¯ÖÓi»Ä¡^ ¦å²M¤º°ª¥b¯ÖÓi»Äªº°ª¤ô¥¬O¼ç¦b¤ß¦åºÞ¯e¯fªº¼Ð°O¡A¥¦§Y¬O³oºØ¯e¯f¤Î¤¤·ªº·ÀI¦]¯À¡C °ª¥b¯ÖÓi»Ä¦b°ª¿@«×ªº¦h×ô§Ü®ñ¤Æ¾¯¤U·|½Õ°¡A¦Ó¦h×ô§Ü®ñ¤Æ¾¯³Q»{¬°¬O¹ï¤ß¦åºÞ¨t²Î¤Î§K¬Ì¨t²Î¦³¬Y¨Ç°·±d¯q³B¡C¦h×ô§Ü®ñ¤Æ¾¯¥i¥H½Õ°¤ß¦åºÞ¯e¯fªº«n¤Æ¦Xª«¬¡©Ê®ñªº§Î¦¨¡C³z¹L°ª¥b¯ÖÓi»Äªº¦Û°Ê®ñ¤Æ¦¨¬¡©Ê®ñ·|¾ÉP¥Íª«·l®`¡C zh.wikipedia.org/wiki/%E9%AB%98%E5%8D%8A%E8%83%B1%E6%B0%A8%E9%85%B8
¦h×ô ºû°ò¦Ê¬ì¡A¦Û¥Ñªº¦Ê¬ì¥þ®Ñ zh.wikipedia.org/wiki/%E5%A4%9A%E9%85%9A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/14 ¤U¤È 04:04:18
²Ä 486 ½g¦^À³
|
¼fµû§¹²¦§Üºë¯«¤Àµõ¯g·sÃľ|©Ô¦èଧY±N³yºÖ°ê¤º±wªÌ ¨Ó·½¡GCPhI»sÃĦb½u¡@2019-01-14 §@ªÌ¡G¤pÃĤY ÆQ»Ä¾|©Ô¦èବO¤é¥»¦í¤Í»sÃĤ½¥q¶}µoªº¤@ºØ¨ã¦³Âù«§@¥Îªº«D¨å«¬§Üºë¯«¯fÃÄ¡A¹ï5-HT2A¨üÅé©M¦h¤ÚÓiD2¨üÅ駡¨ã¦³°ª«×¿Ë©M¤O¡C °ò©ó¤@¶µ¬°´Á6¶gªº¬ã¨sµ²ªG¡AFDA©ó2010¦~10¤ë28¤é§åã¤FÆQ»Ä¾|©Ô¦èତù¦b¬ü°êªº¤W¥«¥Ó½Ð¡A°Ó«~¦W¬°Latuda¡A±wªÌ¨C¤é¤fªA¤@¦¸¡A¥Î©óºë¯«¤Àµõ¯gªº¤@½uªvÀø¡C Ų©óºë¯«¤Àµõ¯gµo¯f¾÷²z©|¥¼§¹¥þÄÄ©ú¡B²{¦³ªvÀøÃĪ«Àø®Äªº§½¤Î¤£¨}¤ÏÀ³¡AÁ{§É»ÝnÀø®Ä§ó¦n¡B¤£¨}¤ÏÀ³§ó¤pªºªvÀøÃĪ«¡C°ê¤ººë¯«¬ìÂåÀø¸ê·½¯Ê¥F¡Aºë¯«ÃĪ«¥«³õ¼ç¤O¥¨¤j¡C
¤p·P·Q : ¬JµM§@ªÌ»{¬°¤¤°ê¤j³°ºë¯«¬ìÂåÀø¸ê·½¯Ê¥F¡Aºë¯«ÃĪ«¥«³õ¼ç¤O¥¨¤j¡C ´NÅý§Ú̦A¦¸¦^ÅU¤ß®®ªº SND-13 SND-13 ¤G(b) +¤T´ÁÁ{§ÉªºPrimary Outcome Measures ¥u¦³¤@¶µ : PANSS¶qªíªº¥§¡ÅÜ¤Æ [Positive and Negative Syndrome Scale (PANSS) [ Time Frame: 8 weeks after randomized treatment ] Mean change from baseline in PANSS total score]
¥i¨£±o PANSS¶qªí¹ïSND-13 ªº«n©Ê PANSS¶qªíªºµ²ºc , ¤À¬°4 Ó¤l¶° . ¥¿©Ê¯gª¬(P) 7 ¶µ . t©Ê¯gª¬(N) 7 ¶µ . ¤@¯ëºë¯«¯f²z(G) 16¶µ . ¨ä¥L(S) 3¶µ ¦@p 33¶µ , ¨C¶µ³Ì°ª7¤À(·¥«×ÄY«) , ³Ì§C1¤À(µL¯gª¬) , Á`¤À231¤À ( ¸Ô²Ó¶µ¥Ø½Ð°Ñ¹ù¥S³ø§i µù1 )
«·Å¹ù¥S2017¦~ºë¤ßªº¤j§@--- SND-13¤G´ÁÁ{§É³ø§i liawbf.pixnet.net/blog/post/47579859
³o¥÷³ø§iºë±mªº¤£¥u¥u¦³¼Æ¾Ú , PANSS¶qªí¤Î¨ä¥L 3 Ó¤l¶°¤]³£¤À§O¦³¨â²Õªº®t²§¤ñ¸û , Åý§Ṳ́@¥Ø¤FµMªº¬Ý¥X¦U¤l¶°ªºÀø®Ä , ¦n§@¬°µû¦ô2(b)+3´Áªº§Q¾¹ PANSS¶qªí¤Î¨ä¥L 3 Ó¤l¶°ªº®t²§¤ñ¸û , ºKn¦p¤U
1. PANSS¶qªí¨â²ÕÅܤƪº¤ñ¸û . NaBen ²Õ ¥Ñ 90.3 ¤À °¦Ü 71.7 ¤À ´î»´20.6 % . ¹ï·Ó²Õ ¥Ñ 87.3 ¤À °¦Ü 81.4 ¤À ´î»´6.8 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.53
2. ¥¿©Ê¯gª¬(P) . NaBen ²Õ ¥Ñ 20.6 ¤À °¦Ü 15.3 ¤À ´î»´25.7 % . ¹ï·Ó²Õ ¥Ñ 20.4 ¤À °¦Ü 18.8 ¤À ´î»´7.8 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.69
3. t©Ê¯gª¬(N) 7 ¶µ . NaBen ²Õ ¥Ñ 26.1 ¤À °¦Ü 20.8 ¤À ´î»´20.3 % . ¹ï·Ó²Õ ¥Ñ 24.8 ¤À °¦Ü 23.1 ¤À ´î»´6.9 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.19
4. ¤@¯ëºë¯«¯f²z(G) 16¶µ . NaBen ²Õ ¥Ñ 43.6 ¤À °¦Ü 35.7 ¤À ´î»´18.1 % . ¹ï·Ó²Õ ¥Ñ 42.2 ¤À °¦Ü 39.6 ¤À ´î»´6.2 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.16
¶µ2,3,4 ´N¬O²Ä1¶µªºPANSS¶qªíªº¤À©î ¥t¥~t©Ê¯gª¬¶qªíSANS¤À¼Æ . NaBen ²Õ ¥Ñ 59.2 ¤À °¦Ü 42.5 ¤À ´î»´28.2 % . ¹ï·Ó²Õ ¥Ñ 55.0 ¤À °¦Ü 51.3 ¤À ´î»´6.7 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.56
¨ä¥L¶µ¥Ø½Ð°Ñ¹ù¥S³ø§i(¥]§t»{ª¾¶µ¥Ø) §Ú̬ݨìPANSS¶qªí©M 3 Ó¤l¶° , pȳ£¤p©ó0.001 , ÁÙ¦³¶W°ª®ÄªGªº®ÄªG¶q ¤]Ãø©Ç½²±Ð±Â¥Î¥¦¨Ó¥D¥´ , ¦]¬°¥¦³Ì¯à¥Nªíºë¯«¤Àµõ¯g¾ãÅ骺Àø®Ä , ¤] ¬O NaBen ³Ì®³¤âªº ¯¬ºÖ¤ß®®ªº SND-13 ´Á¤¤¤ÀªR ©M 2(b)+3 ´ÁÁ{§É , ³£¯à¦p 2(a ) ´Á¤@¼Ë , ®³¨ìºë±m«GÄRªº¦¨ÁZ
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/13 ¤W¤È 09:53:39
²Ä 485 ½g¦^À³
|
¹ï SNS1-7 ¶W¯Å¾Ç¦WÃĪºÁp·Q liawbf.pixnet.net/blog/post/48763128
ÁÂÁ¹ù¥S¥H±M·~ªº©³Ä , ¬°§Ú̸ѪR¥h¦~9/10¤½¥q¶W¯Å¾Ç¦WÃÄ·s»D½Zªº¥i¯à·N²[ ¥HÃĪ«³q¹L¦å¸£«Ì»Ù ( BBB ) ªºÆ[ÂI , ¨ÓÁp·QSNS¨t¦C¥i¯àªº¼Ë»ª ¦^¥h«·Å¤½¥q·s»D½Z , ¤]Åý¤pªº´n¼Û ¦P¼Ë¤@½g·s»D½Z , ¦b±M·~©M«D±M·~¤§¶¡ªº²z¸Ñ , ³º¦³¤d¨½¤§§O§r!
¦A¦¸·PÁ¹ù¥Sªº¤À¨É , Åý§Ú̱o¥H¨£ÃÑSNS¥i¯àªº«Â¤O ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/11 ¤U¤È 04:10:55
²Ä 484 ½g¦^À³
|
¬ì¾Ç®a´¦¥Ü¤j¸£½Õ¸`©ÊT²ÓM«P¶i¯«¸g¨t²Î«ì´_¾÷¨î ¨Ó·½¡G ¥Íª«¨¦ ¡@2019-01-11
med.sina.com/article_detail_103_1_58974.html
¦b¤@¶µ·sªº¬ã¨s¤¤¡A¨Ó¦Û¤é¥»¼yÀ³¸q¹Ñ¤j¾Ç©Mªñ½B¤j¾Çªº¬ã¨s¤Hûµo²{¦bµo¥Í¯Ê¦å©Ê¤¤·«á¡A¤j¶qªºTreg²ÓM¦b¤p¹«¤j¸£¤¤°ï¿n¡A³o«P¶i¤FºC©Ê¯Ê¦å©Ê¸£·l¶Ë´Á¶¡ªº¯«¸g«ì´_¡C
¬ÛÃö½×¤å Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. www.ncbi.nlm.nih.gov/pubmed/30602786
«n¥[¤jªº¾ÇªÌ Terrence Town ±µµÛ´£¥Xµû½× www.alzforum.org/papers/brain-regulatory-t-cells-suppress-astrogliosis-and-potentiate-neurological-recovery ¥»³ø§i´£¨Ñ¤F¤@Ó´I¦³¬}¹î¤Oªº®Ø¬[¡A¥H¸Ñ¨MTregs§Î¦¡ªº¾AÀ³©Ê§K¬Ì¦p¦ó¦b¯Ê¦å©Ê¸£¤¤¤Þ°_§K¬Ì¥\¯à¡C³oºØ¾÷¨î¬O§_¤]¥i¥H¦bADªºI´º¤U¹B§@¡H«D±`¥i¯à - ¬ã¨sTregs¤§¶¡ªº¬Û¤¬§@¥Î¡A¥H¤Î¥i¯àªº¨ä¥LT²ÓM¨È¸s©M¾ý¯»¼Ë³J¥Õ-£]/ tau¯f²z¾Ç¡AÅãµM¬O¥²nªº¡C
¦Ó§Ú̬ݹLªº¤@½g¦³Ãöf¥Ò»Ä¶uªº½×¤å Sodium Benzoate, a Food Additive and a Metabolite of Cinnamon, Modifies T Cells at Multiple Steps and Inhibits Adoptive Transfer of Experimental Allergic Encephalomyelitis europepmc.org/articles/pmc1976122
¹êÅç©Ê¹L±Ó©Ê¸£¯áÅ誢¡]EAE¡^¬O¦hµo©Êµw¤Æªº°Êª«¼Ò«¬¡C... NaB³q¹L¥Í²z¤W¥i@¨üªº¶¼¥Î¤ôµ¹ÃÄ¡A§ïµ½¨üÅé¤p¹«¤¤EAEªºÁ{§É¯gª¬©M¯e¯f¶i®i¡A¨Ã§í¨î¨ÑÅé¤p¹«¤¤P¸£ª¢©ÊT²ÓMªº²£¥Í¡C²Õ´¾Ç¬ã¨sªí©ú¡ANaB¦³®Ä§í¨îEAE¤p¹«¯áÅ褤³æ®Ö²ÓMªº®û¼í©M²æÅèÀT¡C ¦]¦¹¡ANaBÁÙ§í¨î«Pª¢¤À¤lªºªí¹F¨Ã¨ÏEAE¤p¹«ªºCNS¤¤ªºÅèÀT°ò¦]ªí¹F¥¿±`¤Æ¡C ¦¹¥~¡A§ÚÌÆ[¹î¨ìNaB±NÅèÀTÆP©Ê³J¥Õ¤ÞµoªºT²ÓM±qTh1ÂàÅܬ°Th2¼Ò¦¡¡A´I¶° ( enriched ) ½Õ¸`©ÊT²ÓM¸s¡A¨Ã¤U½ÕT²ÓM¤¤¦UºØ±µÄ²¤À¤lªºªí¹F¡C Á`¤§¡A§Ú̪ºµ²ªGªí©úNaB¦b¦hÓ¨BÆJ¤¤×¹¢P¸£ª¢T²ÓM¡A¨Ã¥BNaB¥i¯à¦b¦hµo©Êµw¤Æ¤¤¨ã¦³ªvÀø«n©Ê¡C
¤p·P·Q: f¥Ò»Ä¶u¥i¥H´I¶° ( enriched ) ½Õ¸`©ÊT²ÓM ( Treg ) ¨Ì¤é¥»¾ÇªÌªº¬ã¨s µo²{¦b¯Ê¦å©Ê¤¤·«á¡A¤j¶qªºTreg²ÓM¦b¤p¹«¤j¸£¤¤°ï¿n¡A³o«P¶i¤FºC©Ê¯Ê¦å©Ê¸£·l¶Ë´Á¶¡ªº¯«¸g«ì´_¡C ³o·|¤£·|¦p«n¥[¤j¾ÇªÌ©Ò»¡±o©MAD¬ÛÃö---¦bAD±wªÌªº¤j¸£¤¤ , f¥Ò»Ä¶u(SND-14)¤]´I¶° ( enriched ) ½Õ¸`©ÊT²ÓM ( Treg ) , ²£¥Í¯«¸g«OÅ@(©Î«ì´_)ªº§@¥Î ¦b¹ù¥S©Ò»`¶°ªºf¥Ò»Ä¶uªº½Ñ¦h¥\¯à¤¤ ( liawbf.pixnet.net/blog/category/2056459 ) ¤S¼W²K¤@¶µ¾÷Â઺¨ÒÃÒ?! SND-14 ¦h¤è¦ì¦aªvÀøAD , Åý¤H±H¤©«p±æ
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p©¯¹B10141538 |
µoªí®É¶¡:2019/1/10 ¤U¤È 11:01:00
²Ä 483 ½g¦^À³
|
ÁÂÁ²q·Q¤j...Cliff¤j...¥H¤Îªø´Á´£¨Ñ¬ÛÃö¸ê°Tªº¤j¤jÌ... ±M§Qªñ¤@¦~³°Äòªº³q¹L¤Î¥Ó½Ð§ó·sªº±M§Q...ȱo´Á«Ýªº¥¼¨Ó... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/10 ¤U¤È 07:55:21
²Ä 482 ½g¦^À³
|
¬Ý§¹¤F±M§Q¤å¥ó , ¤´µM§Ô¤£¦í¦V¤j®a³ø§i
In the learning phase, high dosage of ¤Æ¦Xª« enhances the learning after MK-801 induced learning deficit. In the memory phase, the high dose of ¤Æ¦Xª« treatment completely ameliorated the memory deficit while ¦Ù®ò»Ä is not effective. Therefore, ¤Æ¦Xª« treatment is much superior as compared with ¦Ù®ò»Ä to recover memory deficit induced by the MK-801 treatment.
ªþµù : ¦Ù®ò»Ä ´N¬O¹ï«äı¥¢½Õ¯g¤]¦³Àø®Äªº sarcosine , ²{³Q¤ß®®®³¨Ó¸ÕÅç MDD ªºÁ{§É¤T´Á ¤Æ¦Xª« ©hÁô¨ä¦W
¦Ù®ò»ÄªvÀø«äı¥¢½ÕªºÁ{§É³ø§i 1. ¥Ì®ò»ÄÂà¹B³J¥ÕI§í»s¾¯N-¥Ò°ò¥Ì®ò»Ä¡]¦Ù®ò»Ä¡^¥[¤J§Üºë¯«¯fÃĤ¤¥Î©óªvÀøºë¯«¤Àµõ¯g¡C www.ncbi.nlm.nih.gov/pubmed/15023571 2. ¤@¶µÀH¾÷¡AÂùª¼¡A¦w¼¢¾¯¹ï·Óªº¦Ù®ò»Ä¡]N-¥Ò°ò¥Ì®ò»Ä¡^©MD-µ·®ò»Ä²K¥[ªvÀøºë¯«¤Àµõ¯gªº ¤ñ¸û¬ã¨s academic.oup.com/ijnp/article/13/4/451/712753
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/10 ¤U¤È 03:11:22
²Ä 481 ½g¦^À³
|
¤ß®®¤S¥Ó½Ð±M§Q ¥»¦¸®¤¤£¶K¤º®e ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/9 ¤U¤È 03:54:35
²Ä 480 ½g¦^À³
|
SAGE±N¹J«l¼Ä ? AXSOME««×¼~Æ{¯g·sÃĤG´Á¼Æ¾Ú¬°§ë¸ê¤H²K«H¤ß ªÑ»ù¨â¤Ñ¤«¼Q 237 % www.genetinfo.com/investment/featured/item/22718.html
Axsome Therapeutics«Å¥¬AXS-05¦b««×§íÆ{¯gªº2´Á¸ÕÅ礤Àò±o¥Dn²×ÂI globenewswire.com/news-release/2019/01/07/1681055/0/en/Axsome-Therapeutics-Announces-AXS-05-Achieves-Primary-Endpoint-in-Phase-2-Trial-in-Major-Depressive-Disorder.html
»P¬¡©Ê¹ï·Ó¬Û¤ñ¡AMADRSµû¤ÀÅã¥Ü²Îp¾ÇÅãµÛ©Ê§ïµ½¡]¥Dn²×ÂIp <0.001¡^
§íÆ{¯gª¬ªº§Ö³t§ïµ½¦b²Ä¤@©P¤ºÅã¥Ü¥X¤ñ¬¡©Ê¹ï·Ó²Õ¨ã¦³²Îp¾ÇÅãµÛÀu¶Õ¡]CGI-I¤Wp = 0.045¡^
¦b¦hÓ¦¸n²×ÂI¤WÆ[¹î¨ìAXS-05»P¬¡©Ê¹ï·Ó²Õªº§ïµ½¡A¥]¬A47¢HªºAXS-05±wªÌ»P16¢Hªº¬¡©Ê¹ï·Ó²Õ±wªÌªº½w¸Ñ²v¡]p = 0.004¡^
¼Æ¾Ú¤ä«ùAXS-05¦bªvÀø©è§Ü©Ê§íÆ{¯g©MMDD¶i¤@¨Bµo®i¤è±ªº«ùÄòµo®i
¼ç¦bªº¤@¬y¤fªANMDA¨üÅé«ú§Ü¾¯¡A¨ã¦³¦h¼Ò¦¡¬¡©Ê¡A¥Î©óªvÀø§íÆ{¯g
¯Ã¬ù¡A2019¦~1¤ë7¤é¡]¥þ²y·s»D¤¤¤ß¡^ - Axsome Therapeutics¡AInc¡C¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GAXSM¡^¬O¤@®aÁ{§É¶¥¬q¥Íª«»sÃĤ½¥q¡A¶}¾v¥Î©óªvÀø¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯e¯fªº·sÀøªk¡A¤µ¤Ñ«Å¥¬AXS -05¡A¨ã¦³¦h¼Ò¦¡¬¡©Êªº·s«¬¤fªA¬ã¨sNMDA¨üÅé«ú§Ü¾¯¡A¦b««×§íÆ{¯g¡]MDD¡^ªºASCEND 2´Á¸ÕÅ礤²Å¦X¹w©wªº¥Dn²×ÂI¨ÃÅãµÛ§ïµ½§íÆ{¯gª¬¡CASCEND¬ã¨s¬O¤@¶µÀH¾÷¡AÂùª¼¡A¥D°Ê±±¨î¡A¦h¤¤¤ßªº¬ü°ê¸ÕÅç¡A¨ä¤¤80¦W½T¶E¬°¤¤«×¦Ü««×MDDªº¦¨¦~±wªÌ±µ¨üAXS-05ªvÀø¡]45 mg¥k¬ü¨Fªâ/ 105 mg¦w«D¥Lଡ^¡A©Î¬¡©Ê¤ñ¸û¾¯¦w«D¥Lଡ]105²@§J¡^¡A¨C¤é¨â¦¸¡A¦@6¶g¡C
»P¦w«D¥Lବۤñ¡AAXS-05³q¹LÃÒ©ú»Xô°¨§Q - Åsberg§íÆ{µû©w¶qªí¡]MADRS¡^Á`¤À¦b6©PªvÀø´Á¡]Á`ÅéªvÀø®ÄªG¡^¤¤ªº¥§¡È±o¨ì°ª«×²Îp¾ÇÅãµÛ©Ê°§C¡A¹F¨ì¹w©wªº¥Dn²×ÂI¡]p < 0.001¡^¡C¦b²Ä6¶g¡AAXS-05Åã¥ÜMADRSÁ`¤À´î¤Ö17.2¤À¡A¦Ó¦w«D¥L଴î¤Ö12.1¤À¡]p = 0.013¡^¡CAXS-05¨³³t´î¤Ö§íÆ{¯gª¬¡AÃÒ©ú¦b²Ä1¶gÁ{§ÉÁ`Åé¦L¶H§ïµ½¶qªí¡]CGI-I¡^¤W¦w«D¥Lପº²Îp¾ÇÅãµÛ§ïµ½¡]p = 0.045¡^¡C±q²Ä1¶g¶}©l¡AAXS-05¦bMADRSÁ`¤À¤WÀò±o¤F¶W¹L¦w«D¥Lପº¼ÆÈÀu¶Õ¡A¦b²Ä2©P¹F¨ì²Îp¾ÇÅãµÛ©Ê¡A¨Ã¦b¦¹«áªº©Ò¦³®É¶¡ÂI«O«ù¡C¦b²Ä6¶g¡A ...
ªþµù : ¦w«D¥Lଡ]°ê»Ú«D±M§QÃÄ«~¦WºÙ¡GBupropion ) ¬O¤@ºØ¥Dn§@¬°§Ü§íÆ{ÃÄ©M§ÙµÒÃĨϥΪºÃĪ«¡B¤]¥i¥Î§@ªvÀøª`·N¤O¤£¨¬¹L°Ê¯gªº²Ä¤G½uÃÄ«~»P¤¤¼Ï¯«¸g¨ë¿E¾¯¦X¨Ö¨Ï¥Î¡A©Î§@¬°¤¤¼Ï¯«¸g¨ë¿E¾¯ªº´À¥N¤è®×¡C ¦w«D¥Lଦb¬ü°ê¬O³Ì±`¥Îªº§Ü§íÆ{ÃĤ§¤@¡A¦b¨ä¥L³\¦h^»y°ê®a¥ç¬O¦p¦¹¡C
¥k¬ü¨Fªâ¡]Dextromethorphan¡^¡A¤S¦W¥k¥Ò¶Ü³ä¡A^¤å²ºÙDM©ÎDXM¡A¬O¤@ºØÂí«yÃĪ«¡A¥¦ªº²B·Í»ÄÆQ±`¥Î©óÃÄ«~¤¤¡C¦b³¡¤À°ê®a±`³Qª«½èÀݥΡC ¬ü°ê¹«~¤ÎÃĪ«ºÞ²z§½¦b1958¦~§åã¥k¬ü¨Fªâ¥i¤£»ÝÂå¥Í³B¤è¦Ó§@¬°Âí«yÃĵo°â¡C·í®É³Ì¼sªx¨Ï¥Îªº«yÃÄ¥i«Ý¦]¦³³QÀݥΪº¥i¯à©Ê¡A¤]¥i¦¨Å}¡C¥k¬ü¨Fªâ¦b³o¨Ç¤è±Áö¤ñ¥i«Ý¦]¦³©Ò§ïµ½¡A¦ý¤]¦³ª«½è¨Ì¿àªº¥i¯à©Ê¡C
¤pµû : AXS-05 ·|¤£·|¤ñ SAGE-217 ¦n? ±N¨Ó¦A»¡§a ! AXS-05 ¤S¬O¨å«¬ªº ¨âºØÂÂÃĪº²Õ¦X¡]45 mg¥k¬ü¨Fªâ/ 105 mg¦w«D¥Lଡ^¡AÀu©ó³æ¾¯¦w«D¥Lଡ]105²@§J¡^ªº¨Ò¤l ³o©M¤ß®®ªº SND-12 , SND-13 , ¶W¯Å¾Ç¦WÃÄ »á¦³²§¦±¦P¤u¤§§®
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/9 ¤W¤È 11:49:47
²Ä 479 ½g¦^À³
|
Alector¥Ó½Ð¯Ç´µ¹F§J¤W¥«±Mª`ªvÀø°h¦æ©Ê¸£³¡¯e¯f ¨Ó·½¡G³ÐŲ¶× ¡@2019-01-09
med.sina.com/article_detail_103_1_58818.html
Alector¤@®a±Mª`©óªvÀø°h¦æ©Ê¸£³¡¯e¯f¡]¦pªü¯÷®üÀq¯f¡^ªº¥Íª«§Þ³N¤½¥q¡A¤é«e¤w¦b¯Ç´µ¹F§J»¼¥æIPO¥Ó½Ð¡A¥Ø¼ÐÄw¶°1.5»õ¬ü¤¸¡A¬°¨ä§Y±N¶}®iªº¤HÅé¸ÕÅç´£¨Ñ¸êª÷¡C
¾Ú¸Ó¤½¥qªº©ÛªÑ»¡©ú®Ñ¡AAlector»{¬°¡A³y¦¨¯«¸g°h¦æ©Ê¯e¯fªº®Ú¥»ì¦]¦b©ó¤j¸£¤¤ªº§K¬Ì²ÓM¥X²{°ÝÃD¡C¸ÓÆ[ÂI±N¬D¾Ô¤@¨Çªø´Á¦s¦bªº²z½×¡X¡X§Yªü¯÷®üÀq¯fªº³J¥Õ½è-¾ý¯»¼Ë³J¥Õ£]©Mtau¡A©¬ª÷´Ë¯fªº£\-¬ðIJ®Ö³J¥Õ¡A¥H¤ÎÃBù®¸Ã¨§b¡]FTD¡^©M¦ÙµäÁY°¼¯Áµw¤Æ¯g¡]ALS¡^¤¤ªºTDP-43¡A¬O³y¦¨¯e¯fªº®Ú¥»ì¦]¡C
Alector±Mª`©ó¤p½¦½è²ÓM¡A³o¬O¤@ºØ§K¬Ì²ÓM¡A¬°¯«¸g¤¸´£¨ÑÀç¾i¡A¡§¦Y¡¨²ÓM¸H¤ù©M¯f²z³J¥Õ¡C®Ú¾ÚAlectorªº¸ÑÄÀ¡A³o¨Ç²ÓM·|ÀHµÛ¦~ÄÖªº¼Wªø¦Ó´c¤Æ¡A±q¦Ó°§C¤F¥¦Ìµo´§¦³¯q©M«OÅ@§@¥Îªº¯à¤O¡C¸Ó¤½¥qªí¥Ü¡A¨äÃĪ«°w¹ï»P¯«¸gÅܩʬÛÃöªº°ò¦]¬ðÅÜ¡A³o¥i¯à·|´î½w¬Æ¦Ü°fÂà¤j¸£§K¬Ì²ÓMªº´c¤Æ¡C
Alector¦b©ÛªÑ»¡©ú®Ñ¤¤ªí¥Ü¡G¡§³q¹L«ì´_¤j¸£¤¤°·±dªº§K¬Ì¥\¯à¡A§Ú̬۫H¥i¥H¦P®É©è®ø¾ÉP¯«¸gÅܩʪº¦hºØ¯f²z¡C¡¨
...
Alectorªºªü¯÷®üÀq¯fÃĪ«AL002©MAL003¡A¬O»P¦ã§Bºû¦X§@¶}µoªº¡C®Ú¾Ú¨óij¡A¦ã§Bºû¹w¥I¤F2.05»õ¬ü¤¸¡A¨Ã¹ïAlector¶i¦æ¤F2000¸U¬ü¤¸ªºªÑÅv§ë¸ê¡C®Ú¾ÚÃĪ«¶}µoªº¶i®i¡AAlector¦³Åv§QÀò±oÀò±o°ª¹F9.85»õ¬ü¤¸ªº¨½µ{¸O¥I´Ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/8 ¤W¤È 11:00:06
²Ä 478 ½g¦^À³
|
§Ü²£«á§íÆ{¯gÃĪ«Sage-217 ¤@¦p¹w´Á ¹F¨ì3´ÁÁ{§É²×ÂI
Sage§Ü§íÆ{ÃĪ«¹F¨ì3´ÁÁ{§É²×ÂI ¨Ó·½¡GÃÄ©ú±d¼w¡@2019-01-08
med.sina.com/article_detail_100_2_58709.html
GABA¨t²Î¬O¤j¸£©MCNS¤¤ªº¥Dn§í¨î©Ê«H¸¹³q¸ô¡A¥¦¹ïCNS¥\¯àªº½Õ¸`¨ã¦³«n·N¸q¡CSAGE-217¬O¤@´Ú¿ï¾Ü©Ê°w¹ï¬ðIJ©M¬ðIJ¥~GABA¨üÅ骺¤U¤@¥N¥¿¦V§Oºc½Õ¸`¾¯¡A¦Ó¥B¦³µÛ¾A¦X¤fªAªºÃÄ¥N°Ê¤O¾Ç¯S¼x¡CSAGE-217¦³±æ³q¹L¹ïGABA¨t²Îªº½Õ¸`¡A¬°««×§íÆ{¯g¡]MDD¡^©MPDD±wªÌ±a¨ÓºÖµ¡C
Á{§É¼Æ¾ÚºKn ½Ð°Ñì³ø¾É
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/6 ¤U¤È 05:58:48
²Ä 477 ½g¦^À³
|
¤ß®®¦b±M§Q±ÂÅvªº«°T¤¤¯S§OÂI¥X ¶W¯Å¾Ç¦WÃÄ (SNS¨t¦C ) , ©w¦³¨ä«nªº·N¸q ªG¤£¨äµM , ¦b¤pªº§V¤O¾ã²z¤@¨Ç¤åÄm«á ÁôÁô¬ù¬ù¥i¥H¬Ý¥X½²±Ð±Â¦b¯«¸g»â°ì¥ÎÃĪº¥þ¤è¦ì§G§½ ¦bÁp¦X¥ÎÃĤW , §Ú̦ü¥G¬Ý¨ì¤FÃĮĥ[¦¨»P´î§C°Æ§@¥ÎªºÂù«¦n³B ¦ÓªvÀø¯e¯f¤£¬O´N¦b¼W¥[Àø®Ä©M´î»´°Æ§@¥Î³o¨âºØ®Ä¥Î¤¤ , °l¨D¥ÎÃĪº¬ü¦n¶Ü ?!
½²±Ð±Âªº®v¥S§ÌDarrick T. Balu ±Ð±Â ¦b¥Lªº¤@½g¤å³¹¤¤
The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment www.ncbi.nlm.nih.gov/pmc/articles/PMC5518924/#R94
In schizophrenia, there are also disturbances to the GABAergic, cholinergic, and dopaminergic neurotransmitter systems (Coyle, Balu, Benneyworth, Basu, & Roseman, 2010; Lisman et al., 2008), as well as disruptions to astrocytes and white matter integrity (Mighdoll, Tao, Kleinman, & Hyde, 2015). Furthermore, there is convincing evidence that the immune system and oxidative stress play key roles in the pathophysiology of schizophrenia (Leza et al., 2015). Thus, schizophrenia likely results from various combinations of environmental disruptions in brain development and numerous genetic vulnerabilities. These etiological complexities imply that no single pharmacological approach will treat all aspects of the illness nor be effective for all patients with schizophrenia.
½Í¤Î NMDAR¦b«äı¥¢½Õªº¨¤¦â . disturbances to the GABAergic, cholinergic, and dopaminergic neurotransmitter systems (Coyle, Balu, Benneyworth, Basu, & Roseman, 2010; Lisman et al., 2008) . disruptions to astrocytes and white matter integrity (Mighdoll, Tao, Kleinman, & Hyde, 2015). . There is convincing evidence that the immune system and oxidative stress play key roles in the pathophysiology of schizophrenia (Leza et al., 2015).
¥t¦³§@ªÌ¤]»¡¨ì NMDA©M¦h¤ÚÓi¡GÀ³¥Î©ó¬Û¤¬§@¥Î¨üÅé¨t²Îªº¦hºØ¾÷¨î www.ncbi.nlm.nih.gov/books/NBK5280/
N-¥Ò°ò-D-¤Ñ¥V®ò»Ä¡]NMDA¡^©M¦h¤ÚÓi¡]DA¡^¨üÅé¤Î¨ä¬Û¤¬§@¥Î±±¨îµÛ§¹¾ã¤j¸£¤¤¥O¤HÃø¥H¸m«Hªº¦hºØ¥\¯à¡A¥B·í¨ä²§±`®É¡A³o¨Ç¬Û¤¬§@¥Î§Î¦¨³\¦h¯e¯fªº°ò¦¡C³o¨Ç¨üÅé¬Û¤¬§@¥Î»P½Ñ¦p¹B°Ê±±¨î¡A»{ª¾©M°O¾Ð¡A¯«¸g°h¦æ©Ê¯e¯f¡Aºë¯«¤Àµõ¯g©M¦¨Å}µ¥¦hºØ¥\¯à¬ÛÃö¡C
¤£¥u«äı¥¢½Õ¯g¦p¦¹ ªü¯÷®üÀq¯g¨üÁxÆP¯à(cholinergic), ¦h¤ÚÓi¯à(dopaminergic) ÁÙ¦³ª¢¯g(immune system) ®ñ¤ÆÀ³¿E(oxidative stress)¼vÅT¥ç¤£«Ý¨¥ ´N³s¼~Æ{¯g¤]¬O¦p¦¹
¦h¤ÚÓi¦b§íÆ{¯g¯f²z¥Í²z¾Ç¤¤ªº§@¥Î miami.pure.elsevier.com/en/publications/the-role-of-dopamine-in-the-pathophysiology-of-depression ª¢¯g¦b§íÆ{¯g¤¤ªº§@¥Î¡G±q¶i¤Æ©R¥O¨ì²{¥NªvÀø¥Ø¼Ð www.ncbi.nlm.nih.gov/pmc/articles/PMC5542678/ §íÆ{¯g¬O§_»P®ñ¤ÆÀ³¿E¼W¥[¦³Ãö¡H¨t²Îµû»ù©MîPµÑ¤ÀªR www.sciencedirect.com/science/article/pii/S0306453014003655
³o·íµM²o¯A«Ü¦hªvÀø¾÷Âà¬Û»²¬Û¦¨ªº°ÝÃD ´N¹³½²±Ð±Â¦b±M§Q½Ð¨D¶µ²Ä8±ø©Ò¦CÁ|ªº³\¦hÁp¦XªvÀøªºÃĪ«©M¾AÀ³¯g ¤@ÃĦh¥Îªº±¡ªp·íµM¦b©Ò¦h¦³ . «äı¥¢½Õ¯g : cariprazine, brexpiprazole ¡K «Ü¦h . ¼~Æ{¯g : Fluoxetine , Duloxetine , Trazodone , Mirtazapine , Moclobemide , Bupropion , paroxetine , sertraline , reboxetine ¡K . ªü¯÷®üÀq¯g : Memantine , Donepezil , Rivastigmine ¡K . ¤Úª÷´Ë¤ó¯g : selegiline ¡K . ª`·N¤O¤£¨¬¹L°Ê¯gADHD : dextroamphetamine , clonidine , guanfacine , bupropion ¡K . ¦Û³¬¯g : Methylphenidate , Aripiprazole , Atomoxetine ¡K . Åöíw¯g : Lamotrigine ¡Kµ¥ ¦b±M§Q½Ð¨D¶µ¤¤ , ¤´¥H·§¬Aªº¤è¦¡«O¯dµÛÁp¦X¥ÎÃĪº¼u©Ê¤Î«OÅ@ Compositions containing benzoate compound and tannic acid for treating central nervous system disorders patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=AND&d=PTXT&s1=%22TSAI,+Guochuan+Emil%3B%22&OS=%22TSAI,+Guochuan+Emil;%22&RS=%22TSAI,+Guochuan+Emil;%22
1. A composition, comprising a benzoate compound and an excipient, wherein the excipient comprises tannic acid, or a pharmaceutically acceptable salt thereof, wherein the benzoate compound and the tannic acid are at a ratio of 100:1 to 1:100 by weight in the composition, and wherein the composition comprises about 100 mg to about 1,200 mg of the benzoate compound and about 2.0 to about 1,200 mg of the tannic acid.
7. The composition of claim 1, further comprising an additional therapeutic agent for a central nervous system (CNS) disorder.
8. The composition of claim 7, wherein the additional therapeutic agent for the CNS disorder is selected from the group consisting of cariprazine, brexpiprazole, butyrophenone, phenothiazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, promethazine, thioxanthene, chlorprothixene, flupenthixol, thiothixene, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, asenapine, paliperidone, aripiprazole, lamotrigine, droperidol, pimozide, butaperazine, carphenazine, eemoxipride, piperacetazine, sulpiride, acamprosate, tetrabenazine, vilazodone, levomilnacipran, fluoxetine, paroxetine, escitalopram, citalopram, sertraline, fluvoxamine, venlafaxine, milnacipram, duloxetine, mirtazapine, mianserin, reboxetine, bupropion, amitriptyline, nortriptiline, protriptyline, desipramine, trimipramine, amoxapine, clomipramine, doxepin, tranylcypromine, selegiline, trazodone, nefazodone, phenelzine, lamatrogine, lithium salts, topiramate, gabapentin, carbamazepine, oxacarbazepine, valporate, maprotiline, mirtazapine, brofaromine, moclobemide, isoniazid, iproniazid, amphetamine, mixed salts amphetamine, modafinil, desoxyn, methamphetamine, cocaine, arecoline, dexmethylphenidate, dextroamphetamine, methylphenidate, lisdexamfetamine dimesylate, atomoxetine, clonidine, guanfacine, arecoline, pemoline, donepezil, tacrine, rivastigmine, memantine, physostigmine, arecoline, selegiline, riluzole, tannic acid, and Ginkgo Biloba extract. 15. A method for reducing hyperactivity or rescuing sensorimotor deficit in a subject having or suspected of having a central nervous system (CNS) disorder, the method comprising administering to the subject the composition of claim 1.
¥Ñ²Ä¤@±ø¤£»â°ìªºÅn¬A , ¨ì²Ä¤C±øCNS»â°ìªº·§¬A , ¦A¨ì²Ä¤K±øªº¥¿±ªí¦C , ¤T««OÅ@¾AÀ³¯gÁp¦Xªº½d³ò ÁÙ¦³ÃB¥~µo²{ªº , ¦bCNS¯e¯f»â°ì¥Î¥H reduce hyperactivity or rescue sensorimotor deficit ¥\¯àªº±M§Q ¬Ý°_¨Ó , ²Ä15±ø¬O¥t¥~¿W¥ßªº±M§Q½Ð¨D¶µ , ©Î¬°CNS¯e¯f»â°ì±`¨£ªº¯f¼x ,¦]¦¹¯S§O¥t¥ß±M§Q«OÅ@
³o¨ÇÀ³¥Î ( NaBen + ³æ¹ç»Ä ) ªºÀø®Ä¯S©Ê , ¥]¬A . DAAO §í¨î¾¯ ( NMDAR¼W±j ) . ¼W±j»{ª¾ . ¦h¤ÚÓi¯àªº¨}©Ê¬Û¤¬§@¥Î , ´£¤ÉÃÄ®Ä . §Üµoª¢§@¥Î . §Ü®ñ¤Æ§@¥Î ¥¿²Å¦X³o¨Ç¾AÀ³¯gªº¾÷Âà , ©Î¥i¹F©ó 1 + 1 > 2 ªº®ÄªG±d¯q³B
f¥Ò»Ä¶uªº°·±d¯q³B www.selfhacked.com/blog/sodium-benzoate-some-preservatives-block-inflammation-and-autoimmune-disease/ f¥Ò»Ä¶u¡A¹«~²K¥[¾¯©M¦×®Û¥NÁª«¡A¦h¨B×¹¢T²ÓM¡A§í¨î¹êÅç©Ê¹L±Ó©Ê¸£¯áÅ誢ªº¹LÄ~Âಾ www.ncbi.nlm.nih.gov/pmc/articles/PMC1976122/ ¹êÅç©Ê¹L±Ó©Ê¸£¯áÅ誢¡]EAE¡^¬O¦hµo©Êµw¤Æªº°Êª«¼Ò«¬¡C§Ú̪ºµ²ªGªí©úNaB¦b¦hÓ¨BÆJ¤¤×¹¢P¸£ª¢T²ÓM¡A¨Ã¥BNaB¥i¯à¦b¦hµo©Êµw¤Æ¤¤¨ã¦³ªvÀø«n©Ê¡C
³æ¹ç»Äªº§@¥Î¡A¥i±¤ª¾¹Dªº¤H¤Ó¤Ö¤F kknews.cc/zh-tw/health/gzgbz58.html
¥H¤W¬O½Í¨ì¼W¶iÀø®Äªº§@¥Î ¦A¨Ó½Í½Í´î»´²{¦sºë¯«¯e¯fÃĪ«ªº°Æ§@¥Î
§ÚÌ¥ý¨Ó¬Ý¬Ý¦¨¤jÂå°|精神¬ì李嵐´@Âå®vªº 精神¬ìÃĪ«¤¶²Ð docsplayer.com/20760589-%E7%B2%BE%E7%A5%9E%E7%A7%91%E8%97%A5%E7%89%A9%E4%BB%8B%E7%B4%B9.html
§Ü精神¯f¾¯(antipsychotics)
. 歷¥v¤W²Ä¤@Ó§Ü精神¯f¾¯¬OCPZ (chlorpromazine)¡Aµoªí©ó1950年¥N¡A¦Û·í®É°_¦Ü1990年¥N¥H«e¦³³\¦h§Ü精神¯f¾¯³Q¦X¦¨¤Î¤WÉ]¡A³o¨Ç²Ä¤@¥NÃĪ«ªº¥Dnªv療®ÄªG¬°±±¨î¥¿©Ê精神¯f¯g狀¡A¦ý®e易³y¦¨´ÕÅé¥~®|¯gÔ¸s(EPS, extra-pyramidal symptoms)¡C²ÎºÙ¬°¡u¶Ç²Î«¬©Î¨å«¬§Ü精神¯f¾¯¡v(conventional or typical antipsychotics)
. 1990年¥N¥H«á¤WÉ]ªÌÄÝ©ó²Ä¤G¥N§Ü精神¯f¾¯¡A³o¨Ç·s«¬©Î²Ä¤G¥NªºÃĪ«³Q²ÎºÙ¬°¡u«D¨å«¬§Ü精神¯f¾¯¡v(atypical antipsychotics)¡A¥¦Ì»P²Ä¤@¥NÃĪ«³Ì¤jªº°Ï§O¦b©óEPS¸û¤Ö¡A¥B°£了¥¿©Ê精神¯f¯g狀¥H¥~¡A¹ï©ó精神¤À裂¯g±wªÌ±`見¤§t©Ê¯g狀¤Î»{ª¾¥\¯à¯Ê³´¥i¯à¦³ªv療®ÄªG¡C
²Ä¤@¥N§Ü精神¯f¾¯ºØ類
. Phenothiazine: chlorpromazine (wintermine¡AÃ¥L¯v), triflupromazine (flurazine¡A´I祿ÀR), fluphenazine (flucan¡A復±d) . Thioxanthenes: thioridazine (melleril¡A¬ü立廉) . Dibenzoxazepines . Dihydroindole . Butyrophenones: haloperidol (haldol¡A¦n度) . Diphenylbutylpiperidine ²Ä¤@¥N§Ü精神¯f¾¯°Æ§@¥Î ¥Ñ¦h¤ÚÓiªýÂ_¤Þ°_
. À@Åé¥~®|¯g狀¸s(EPS): ¥]¬A¦Ù¦×ºò±i異±`¡BÀR§¤不¯à¡B¤Ú金´Ë¤ó¯e¯f(¦Ù¦×»øµw¡B行°Ê½wºC¡B¤â§Ýµ¥²{¶H) ªv療¤è¦¡: °±¥Î©Î降§C§Ü精神¯f¾¯¾¯量¡A¨Ö¥Î§ÜÁxÆP§@¥Î¾¯(¦ptrihexylphenidyl¡Bbiperidin)¡A©Î¥[¤W¦h¤ÚÓi«P¶i¾¯(¦pamentadine)¡C¥t¤]¥i¨Ï¥Îf¤G´á¤G´á¥(benzodiazepine)來µÎ½w¡C
. ¿ðµo©Ê不¦Û¥D¹B°Ê: µo¥Í¦b¼L¤Ú¡B¦ÞÀY¡B¤U¤Ú¡B¥|ªÏ¡A¬Æ¦ÜÂß·FÀV³¡ªº°Ê§@¡A¯f¤H不Â_°µ©CÄZ狀¡B¦ÞÀY«½Æ¦R¥X¡B¹ª¼L¡B¯w²´¡B°µ°Áyµ¥¡C©Î«½ÆÁqªÓ¡BÂß·F·nÂ\¡B¤â«ü¸}³k不³W«h©Ê©â°Ê¡C ©|¥¼¦³¦³®Äªv療¤è¦¡¡C
¿ðµo©Ê¹B°Ê»Ùê¡]TD¡^¬O¥Ñ©óªø´ÁªA¥Î¸û¤j¾¯¶q§Üºë¯«¯fÃĪ«¤Þ°_ªº¤@²Õ¦Ù¸s¤£¦Û¥Dªº¸`«ß©Ê«½Æ¹B°Ê¡Aµo¥Í²v¦]ÃĪ«ºØÃþ¡B¾¯¶q¡BªAÃÄ´Á©M¦~ÄÖµ¥¦Ó¤£¦P¡C¸ê®ÆÅã¥Ü¡A¦~ÄÖ¡Ö50·³±wªÌTDµo¥Í²v°ª¹F50%¡C¿ðµo©Ê¹B°Ê»Ùê¦h¬°¤£¥i°f©Ê·l®`¡A¦Ó¥BªvÀø¸û¬°§xÃø¡A¦]¦¹¹w¨¾Åã±o¤Q¤À«n¡C ¿ðµo©Ê¹B°Ê»Ùê¡]TD¡^¤SºÙ¿ðµo©Ê¦h°Ê¯g¡B«ùÄò©Ê¹B°Ê»Ùê¡A¬O¤@ºØ¯S®í¦Ó«ù¤[ªºÀ@Åé¥~¨t¤ÏÀ³¡A¥Dn¨£©óªø´ÁªA¥Î¤j¾¯¶q§Üºë¯«¯fÃĪº±wªÌ¡A°¸¨£©óªø´ÁªA¥Î§Ü§íÆ{ÃÄ¡B§Ü¾_Ÿ³Â·ôÃÄ¡B§ÜÅöíwÃÄ©M§Ü²Õ´ÓiÃĪº±wªÌ¡C ¦UºØ§Üºë¯«¯fÃħ¡¥i¤Þ°_TD¡A¦Ó¥H¬t¾Ä¤DÀR¡]Fluphenazine¡^¡B¤T¬t©Ô嗪¡]Stelazine¡^©M¬t哌¥m¾J¡]Haloperidol¡^µ¥§t¬t¤¸¯Àªº§Üºë¯«¯fÃħó±`¨£¡C§Üºë¯«¯fÃÄ©ÒPªº¿ðµo©Ê¹B°Ê»Ùê¦bºë¯«¬ìÁ{§É¤W¬O¤@Ó¤ñ¸û´Æ¤âªº°ÝÃD¡A¤£¶È¼vÅT±wªÌªº¥Í¬¡½è¶q¡A¬Æ¦Ü¥i¦M¤Î±wªÌ¥Í©R¡C
. §Ü²Õ´ÓiªýÂ_§@¥Î: ¤Þ°_Å髼W¥[ ¡K ²Ä¤G¥N§Ü精神¯f¾¯ . ²Ä¤G¥N§Ü精神¯f¾¯ªº¥Dnªv療®ÄªG來¦Û¦å²M¯À¤Î¦h¤ÚÓi§ÜÅ餧«ú§Ü§@¥Î(©Ò¥HºÙ¬°Serotonin-Dopamine Antagonists¡ASDA)¡F¦¹¥~¡Aclozapine¤Î»P¨ä¤Æ¾Çµ²ºc¡AÃÄ理§@¥Î類¦üªºÃĦpolanzapine¡Bquetiapineµ¥²ÎºÙMARTAs(Multiple-Acting Receptor Targeted Anti- psychotics )¡A¦Ó§Ü精神¯f¾¯³Ì·sªº¬ã¨s¬Oµo®idopamine system stabilizers¡C
. ¨Ì¾Ú¬ü°ê精神¬ìÂå¾Ç·|¥Xª©¤§¡u精神¤À裂¯gªv療·Ç«h¡v¡Aclozapine ¥i¯à³y¦¨agranulocytosis ¦ý療®Ä³Ì¨Î¡A列¬°²Ä¤G©Î²Ä¤T½uÃÄ¡A¨ä¥Lªº§Ü精神¯f¾¯¬Ò¥i§@¬°精神¤À裂¯gªv療ªº²Ä¤@½uÃĪ«¡C
²Ä¤G¥N§Ü精神¯f¾¯ºØ類 ¤ÀÄÝ©ó¤T¤j類ÃÄ理©Ê½èÂkÄÝ¡G . ¦å²M¯À-¦h¤ÚÓi«ú§Ü¾¯(SDAs)¡G risperidone (理«ä¥²§´¡Arisperdal)¡Aziprasidone (geodon¡Aõ«ä)兩ºØ¡C
. 神¸g¦h«¨üÅé§@¥Î¾¯類(MARTAs)¡G clozapine (¥iP律¿õ¡Aclozaril)¡Aolanzepine (zeprexa¡A金µÐÂÄ)¡Aquetiapine (seroquel¡A«ä樂±d)¡A©Mzotepine (lodopine¡Aµ¸¿w¥)µ¥¡C
. ¿ï¾Ü©Ê¦h¤ÚÓi²Ä¤G©M²Ä¤T«¬¨üÅé«ú§Ü¾¯: amisulpride (solian¡Aº利¦w)
. ³¡¤À©Ê¦h¤ÚÓi¨üÅé«P¶i¾¯¤Î¦å²M¯À1A¨üÅé«P¶i¾¯»P2A¨üÅéªýÂ_¾¯: aripiprazole (abilify¡A¦w立復)
²Ä¤G¥N§Ü精神¯f¾¯°Æ§@¥Î ¦h¤ÚÓi§@¥Î¤Þ°_¤§»Ùê . À@Åé¥~®|¯gÔ¸s¡G risperidone ÀH¾¯量¼W¥[®É¸û©úÅã¡Aziprasidone¡Bolanzepine¦b°ª¾¯量¤U¤~·|¡Aquetiapine¡Bclozapine¡Bzotepine©Mamisulpride·ÀI¸û§C¡C
. °£了¦h¤ÚÓi§@¥Î¥~¡AÄÝ©ó¦h«¨üÅé§@¥Î¾¯類ªºÃĪ«¡A¤ñ°_¦å²M¯À- ¦h¤ÚÓi«ú§Ü¾¯ ¡A¦³¸û©úÅ㪺§ÜÁxÆP¤Î§Üªý´Ói§@¥Î¡C
. Å髼W¥[¡G¥Hclozapine©Molanzepine¸û©úÅã¡Azotepine¦¸¤§¡Aquetiapine¡Brisperidone¸û»´·L¡Aziprasidone¡Bamisulpride©Maripiprazole´X¥G不·|¡C
. ¦å糖¤ÎÅé¯×ªÕ¡]¤T»Ä¥Ìªo¯×¡^½Õ¸`異±`¤Î糖尿¯f§Î¦¨¡G©MÅ髼W¥[¤§¶É¦V¬Û¦ü¡C
. ¤ß¹q¾É»Ùê(©µªø): ¦å²M¯À-¦h¤ÚÓi«ú§Ü¾¯¸û©úÅã¡A¤×¨ä¥Hziprasidone¦MÀI©Ê³Ì°ª¡C¥i¯à³y¦¨¤ß律不¾ã¡C
¥Ñ¤W±ªº¤¶²Ð §Ú̪¾¹D¦@¦Pªº°Æ§@¥Î¤j¬ù¦³¤T¶µ . À@Åé¥~®|¯gÔ¸s ( EPS ) . ¿ðµo©Ê不¦Û¥D¹B°Ê (Tardive dyskinesia ) . Å髼W¥[ ¤Î ¦å糖¤ÎÅé¯×ªÕ¡]¤T»Ä¥Ìªo¯×¡^½Õ¸`異±`¤Î糖尿¯f§Î¦¨ ¤£ª¾±M§Q¤å¥ó¤¤reducing hyperactivity or rescuing sensorimotor deficitªº§@¥Î ¬O§_©MÀ@Åé¥~®|¯gÔ¸s¤Î¿ðµo©Ê不¦Û¥D¹B°Êªº°Æ§@¥Î¬ÛÃö? Y¥i¥H´î»´ , ±N¬O¬ü¨Æ¤@¼Î ¥t¥~¹ï©óÅ髼W¥[ ¤Î ¦å糖¤ÎÅé¯×ªÕ¡]¤T»Ä¥Ìªo¯×¡^½Õ¸`異±`¤Î糖尿¯f§Î¦¨ªº°Æ§@¥Î NaBen ©M ³æ¹ç»Ä ³£¥i¥H°§CÁx©T¾J ³æ¹ç»Ä¤]¥i¥Î¥H¹w¨¾©MªvÀøT2D ( II«¬¿}§¿¯f ) ¤Î¨ä¬ÛÃöªºªÎD¯g
³æ¹ç»Ä¨ë¿E¸²µå¿}Âà¹B¨Ã§í¨î3T3-L1²ÓM¤¤ªº¯×ªÕ²ÓM¤À¤Æ academic.oup.com/jn/article/135/2/165/4663627 ªÎD¬OXºî¦X¼x©MII«¬¿}§¿¯f¡]T2D¡^ªº¥Dn¦MÀI¦]¯À¡CµM¦Ó¡A¤j¦h¼Æ°¿}ÃĪº§Ü¿}§¿¯fÃĪ«¤]·|«P¶iÅ髼W¥[¡AÁöµM´î»´T2Dªº¤@ºØ¯gª¬¡A¦ý¦P®É¤S¥[«¾ÉPT2Dªº¥Dn¦MÀI¦]¯À¡C¯×ªÕ²ÓMªº¤À¤Æ©M¼W´Þ¯×ªÕ¥Í¦¨¬O¾ÉPÅ髼W¥[©MªÎDªº¥Dn¾÷¨î¡C ³o¨Çµ²ªGªí©úTA¥i¥Î©ó¹w¨¾©MªvÀøT2D¤Î¨ä¬ÛÃöªºªÎD¯g¡C
¬ï´¡Âø¶Ãªº±Ôz , ¥u¦b»¡©ú ¤ß®®ªº¶W¯Å¾Ç¦WÃĨt¦C , ¬J¥iÁp¦X¨âªÌÀø®Ä , ¤S¥i¬Û¹ï´î»´¥Ø«e¥ÎÃĪº°Æ§@¥Î ½²±Ð±Â¥Ñ±M·~¾ÇÃÑ©Òl¥Íªº³Ð·N , ¤Sµo²{ ( NaBen + ³æ¹ç»Ä ) »P¤§°t¦X ¹ê¦b¬O³Ð·sªº²Õ¦X
¤pªº¤í¯Êª¾ÃÑ°ò¦ªº¬ïÆwªþ·| , ©Î¥¼ªí¹F¤½¥q³Ð·sªºì·N ¦³¥¢·q·N ¬è½Ð¤j®aªº«ü¾É«ü¥¿»P¸É¥R ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/5 ¤U¤È 07:43:57
²Ä 476 ½g¦^À³
|
ÁÂÁ¹ù¥S¤À¨É³Ì·s¤å³¹
Âűб¬ã¨s¹Î¶¤¦A¦¸µoªíMDD¤§NMDAR¦³Ãö°ò¦]ªí¹F¤§±Ú¸s¬ã¨s®t²§
liawbf.pixnet.net/blog/post/48753153
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/3 ¤U¤È 06:30:14
²Ä 475 ½g¦^À³
|
¨â½g¤å³¹¨Ñ°Ñ
1. ºë¯«¤Àµõ¯g¤¤¨¦®ò»Ä©MGABA¥¢½Õªº¦¬ÀÄ©Ê
§@ªÌ¡GSarah A. Monaco¡AAustin A. Coley©MWen-Jun Gao
www.intechopen.com/books/schizophrenia-treatment-the-new-facets/the-convergence-of-glutamate-and-gaba-dysregulation-in-schizophrenia
µ²»y»¡¨ì ¥¼¨Óªº¬ã¨s¦³¥²n¶i¤@¨B¯}¸ÑNMDA¥\¯à´î°h¬O§_¥ý©óGABA¯à¯Ê³´¡A¤Ï¤§¥çµM
2. The impact of NMDA Receptor hypofunction on GABAergic interneurons in the pathophysiology of schizophrenia
Samuel M. Cohen,1 Richard W. Tsien,1 Donald C. Goff,2,3 and Michael M. Halassa1,2,*
www.ncbi.nlm.nih.gov/pmc/articles/PMC4724170/
Evidence that hypo-NMDA states and GABA dysfunction contribute to the schizophrenia phenotype at multiple levels.
GABA deficits secondary to NMDAR hypofunction
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2019/1/3 ¤U¤È 01:14:24
²Ä 474 ½g¦^À³
|
^°ê¾ÇªÌªº½×¤å
ºë¯«¤Àµõ¯g¤¤ªº¨¦®ò»Ä©M¦h¤ÚÓi¡G21 ¥@¬öªº³Ì·s¶i®i
www.ncbi.nlm.nih.gov/pmc/articles/PMC4902122/
¤º®eºKn :
. ¬ã¨sµo²{¡A»P¹ï·Ó²Õ¬Û¤ñ¡Aºë¯«¤Àµõ¯g±wªÌ¦h¤ÚÓiÄÀ©ñÅãµÛ¼W¥[¡A¦b±wªÌ¤¤©ñ®g©Ê¥Ü踪¾¯ªº§ïÅܵ{«×¤j¬ù¥[¿¡A¨Ã¥B§ïÅܵ{«×»Pºë¯«¯f¯gª¬ªº´c¤Æµ{«×¬ÛÃö¡C
. ¸£¤¤ªº¿³¾Ä©Ê¯«¸g¶Ç»¼¥Dn¬O¨¦®ò»Ä¯à¡A¨¦®ò»Ä¯à¯«¸g¤¸§Q¥Î¦ûÁ`¸£¥NÁ¬¡©Êªº60¢H¦Ü80%¡C¨¦®ò»Ä¯à¯«¸g¶Ç»¼³q¹L¥NÁ«¬©MÂ÷¤l«¬¨¦®ò»Ä¨üÅéµo¥Í¡A¾¨ºÞ¤w¯A¤Î³\¦h¨¦®ò»Ä¨üÅé¡A¦ý¥Dnªº°²³]¬ONMDA¨üÅé¥\¯à»Ùꬰ¥Dn°Ñ»PªÌ¡C
. ¨ãÅé¦Ó¨¥¡ANMDA¨üÅé«ú§Ü¾¯¤w³QÃÒ©ú°§C¤FGABA¯à¤¤¶¡¯«¸g¤¸¥\¯à , §Î¦¨¥h§í¨î¤Æ , ¾ÉPÀ@Åé²ÓMµo©ñ¼W¥[¡C¦³¤H´£¥X¥¦Ì¥i¯à¹ïGABA¯«¸g¤¸¤Wªí¹FªºNMDA¨üÅé¨ã¦³Àu¥ý§@¥Î¡C¥t¤@ºØ°²³]«h¬ONMDA¨üÅé«ú§Ü¾¯»¤¾Éªº¬¡©Ê®ñ¤ô¥Åܤƥi¯à¬O³oºØ¾÷¨îªº®Ö¤ß²Õ¦¨³¡¤À¡A¦]¬°°§C¶W®ñ¤Æª«¤ô¥·|ªý¤î´âÓi଻¤¾Éªº¤¤¶¡¯«¸g¤¸¬¡°ÊÅܤơC¦¹¥~¡A§í¨î¬¡©Ê®ñª«½è§Î¦¨ªýÂ_¤FNMDA¨üÅé«ú§Ü¾¯¦b°Êª«¤¤ªº¦æ¬°®ÄÀ³¡C( NaBen ¤]¥i´î°ROS (¬¡©Ê®ñ) Cinnamon metabolite sodium benzoate (NaB) reduces the production of ROS and the activation of p21rac in microglia.) . ¦h¤ÚÓi©M¨¦®ò»Ä°²»¡ªº¾ã¦X .. NMDA¥\¯à´î°h©M¬ðIJ«e¦h¤ÚÓi¥\¯à»Ùꪺ²Õ¦X¥i¥H´£¨Ñºë¯«¤Àµõ¯gªº©Ò¦³Á{§É¤è±ªº³Ì¨Î¸ÑÄÀ¡C .. ºë¯«¤Àµõ¯g¤¤©Ò¨£ªº¦h¤ÚÓi¥\¯à¥i¯àÄ~µo©ó§ïÅܪº¨¦®ò»Ä¯à¥\¯à¡]McGuire µ¥¡A2008¡^¨¦®ò»Ä¯à©M¦h¤ÚÓi¯à³q¸ô¤§¶¡ªº¬Û¤¬§@¥Î , ¦p¹Ï©Ò¥Ü www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=4902122_emss-66264-f001.jpg
. ¦h¤ÚÓi©M¨¦®ò»Ä°Ñ»Pºë¯«¤Àµõ¯g¦³¨âºØ¥i¯àªº¸ÑÄÀ¡C¤@Ó¬O¥¦Ì¬O³oºØ¯e¯fªº¤£¦P¨È«¬ªº°ò¦¡A»P³ÌªñªºªvÀø@Ãĩʵ²ªG¤@P¡C¥t¤@Óºî¦X°²³]¡A¥¦¥i¥H¸ÑÄÀ¬ðIJ«e¦h¤ÚÓiªº¶§©Ê¯gª¬¡A¥H¤Î¨¦®ò»Äªº³±©Ê©M»{ª¾¯gª¬¡C
¥Ø«e«äı¥¢½Õªº¥ÎÃÄ , ³£¬O°w¹ï¦h¤ÚÓi©M¦å²M¯À¨Ó§@¥Î NaBen «h¬O°w¹ï NMDA ¨Ó¥[±j «e±ªº±Ôz´N¬O¦h¤ÚÓi©M¨¦®ò»Äªº¬Û¤¬§@¥Î , ©Îµo´§¤ôÀ°³½ ³½À°¤ôªº¨}©Ê¼vÅT´`Àô SND-13 ´N¬O½²±Ð±Âªº³Ð·N , §â¨âªÌ¥[¦b¤@°_ªvÀøªº³Ç§@ ®ÄªG¦n¤£¦n©O ? §ÚÌ¥un¬Ý SND-13 ¤G(a)´Áªº¼Æ¾Ú , ¥[¤W¥Î³oӼƾÚÀò±o FDAªº«C·ý , ®³¨ì¤F BTD , ´N¥i²¤ª¾¤@¤G ³o½g½×¤å©Î³\À°§U§Ú̹ï SND-13 { add-on } ªºÁp¦X¾÷¨î¦³¤@Ó°ò¦ªº»{ÃÑ Åý§Ú̦b§ë¸ê¤§¾l , ¤]¦³ª¾ÃѤWªº¦¬Ã¬
Google½Ķ©M·QªkY¦³¿ù , ·q½Ð«ü¾É«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GCliff10135274 |
µoªí®É¶¡:2018/12/28 ¤W¤È 12:20:53
²Ä 473 ½g¦^À³
|
¤p©¯¹B¤j ¥¿¦n¬ù¦b¤@¦~«e¡A¤]´N¬O2018¦~¤¸¥¹¥»ª©¤]´¿°Q½×¹LRS-D7³o´Ú¬ãµo¤¤·sÃÄ¡C ´N¦b¥»ª©¡upage 2¡v¡G¡u2018/1/1 ¤W¤È 12:49:00²Ä 247 ½g¦^À³¡v 2018¤¸¥¹¤pÂI¤ß¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/27 ¤U¤È 08:12:38
²Ä 472 ½g¦^À³
|
Janssen ªº¬ãµo¤HûA. Ahnaou, H. Huysmans, T. Van de Casteele, and W. H. I. M. Drinkenburgµ¥¤H ¦b2017/12µoªí¤@½g½×¤å
Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity
www.ncbi.nlm.nih.gov/pmc/articles/PMC5802558/
¥L̥Φh¤ÚÓi¯à¿E°Ê¾¯¡]f¤þÓi¡^©MN-¥Ò°ò-D-¤Ñ¥V®ò»Ä¡]NMDA¡^¨üÅé«ú§Ü¾¯¡]PCP©MMK801¡^¦b¤£¦P¥Ö½è°Ï°ì¼ÒÀÀ¶§©Ê¯gª¬©M»{ª¾¯Ê³´¬ÛÃöÂZ°Êªººôµ¸®¶Àú ¨Ã¥Î«D¨å«¬§Üºë¯«¯fÃÄolanzapine, risperidone, and clozapine ¨Ó¥¿±`¤Æ¥\¯à¥¢½Õªº®¶Àú
In the combined treatments, antipsychotics attenuated NMDA antagonist-induced abnormalities in functional network oscillations and connectivity, whose effects on motor behavior is mechanistically related. These results suggest that pharmacologically induced disruption of cortical gamma oscillations and network connectivity in rats is a candidate model to study dysfunctional oscillatory patterns described in positive and negative symptoms of schizophrenia. The efficacy of antipsychotics to rescue cortical network oscillatory patterns is in line with the idea that glutamatergic and dopaminergic systems play a role in maintaining the integrity of cortical circuits.
¤pªº¦n©_ªº¬O ¥L̦³¨S¦³§âf¥Ò»Ä¶u¥[¶i¨Ó , °µ¤@Ó add-on ªº¤è¦¡ , ¨Óµû¦ô¬Ý¬Ý¥LÌ©Ò»¡ªºglutamatergic and dopaminergic systems play a role in ¡K ©Î³\¨S¦³ , ¤]©Î³\¦³ , ¥u¬OÁô¦Ó¤£µo , ¤S©Î¤wµo , ¥u¬O¤pªº¨S§ä¨ì ¦³½Ðª¾±¡ªº¤j¤j¸É¥R«ü¾É«ü¥¿
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p©¯¹B10141538 |
µoªí®É¶¡:2018/12/27 ¤W¤È 10:54:07
²Ä 471 ½g¦^À³
|
ªñ¤é¬Ý¨ì»O¤j²£¾Ç¦X§@Á`¤¤¤ß¦bNMDA¨üÅé½Õ¸`¾¯·s¬ã¨s§Þ³N... --------------------------------------------------------------------------------- µo©ú¦WºÙ¡GNMDA¨üÅé½Õ¸`¾¯ µo©ú¤H¡G´¿¦t»ñ±Ð±Â¡B¿à¤å±]±Ð±Â¡B¼B´¼¥ÁÂå®v¡BJ®ü°êÂå®v¡B®]¥ò»Ê±Ð±Â¡B ¼B¥ÉÄR¬ã¨sû ³æ¦ì¡G°ê¥ß»OÆW¤j¾Ç¥ÍÂå¹q¤l»P¸ê°T¾Ç¬ã¨s©Ò¡B¤ß²z¾Ç¨tº[¬ã¨s©Ò¡BÂå¾Ç°|ºë ¯«¬ì¡B°ê¥ß¥æ³q¤j¾ÇÀ³¥Î¤Æ¾Ç©Ò¡B°ê®a½Ã¥Í¬ã¨s°|¯«¸g¤Îºë¯«Âå¾Ç¬ã¨s¤¤¤ß¡C ²¾ú¡Gwww.csie.ntu.edu.tw/~yjtseng/ ¥«³õ¤Î»Ý¨D¡G¥@¬É¤W¦³1%ªº¤H¤f±w¦³«äı¥¢½Õ¯g¡A±wªÌ´¶¹M·|¨ü¥¿©Ê¡Bt©Ê¡B »{ª¾¥\¯à¥¢½Õ¡B»P±¡ºü¥¢½Õµ¥¯gª¬¼vÅT¡C¥Ø«e¥«³õ¤W¥u¦³¥i¥H§ïµ½¥¿©Ê»P±¡ºü¯g ª¬ªºÃĪ«¡At©Ê©M»{ª¾¥\¯à¥¢½Õ¯gª¬¦Ü¤µ¤´µLÃÄ¥iªv¡C §Þ³NºKn:¥Ø«e¹Î¶¤¤w³]p¥X¤@¨t¦C¥iªvÀø«äı¥¢½Õ¯gt©Ê¯gª¬ªº¤p¤À¤lÃĪ«¡A ³z¹L¼W¥[NMDA¨üÅ骺¬¡©Ê¨Ãª½±µªº§ïµ½«äı¥¢½Õ¯g»{ª¾¥\¯à»Pt©Ê¯gª¬¡A¨ä¤¤ ½s¸¹RS-D7¬O§Ú̪º³Ì¨ÎÔ¿ïÃĪ«¡A¥i¥Î©óªvÀø¯«¸g¨t²Î¬ÛÃö¯e¯fªº¾AÀ³¯g¡C Àu¶Õ:ÃĪ«¦w¥þ©Ê°ª¡B¤w²¤Æ¦X¦¨¨BÆJ¡B°Êª«¼Ò«¬ÃĮݪ¡B¤w¦³Á{§ÉÅçÃҩʸê®Æ¡C Ävª§²£«~:SyneuRxªºSodium benzoate¦P¼Ë¬ONMDA¨üÅé½Õ¸`¾¯¥Ø«e¦bPhase II¶¥ ¬q¡C ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ªñ´X¦~¶V¨Ó¶V¦hªº¥xÆW¬ã¨s¹Î¶¤§ë¤JNMDA¨üÅé½Õ¸`¾¯¤§¬ã¨s... ³o¤]¥Nªí¨«¦b«eÀYªº¤ß®®¹Î¶¤¦¨¥\¾÷²v¶V¨Ó¶V°ª...
°Ñ¦Ò¨Ó·½:file:///C:/Users/Administrator/Downloads/%E6%8A%80%E8%A1%93%E6%8E%A8%E5%BB%A3%E8%A1%A8-NMDA%E5%8F%97%E9%AB%94%E8%AA%BF%E7%AF%80%E5%8A%91%20(2).pdf
¥H¤W¸ê°T~~¨Ñªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/25 ¤W¤È 10:51:30
²Ä 470 ½g¦^À³
|
¾ú¨Ó³Ì¤j³W¼Ò¬ã¨s¡G³\¦h±`¨£ÃĪ«¥i¯à¤Þ°_¼~Æ{¯g 2018-12-25 10:44Áp¦X³ø °OªÌ§d¤é§g¢¬§Y®É³ø¾É
udn.com/news/story/6813/3556451
©Ò¦³ÃĪ«³£¦³¼ç¦b¥i¯à¤Þµo¤£¨}°Æ§@¥Î¡A¦Ó¼~Æ{¯g¬O±`¨£°Æ§@¥Î¤§¤@¡C®Ú¾Ú¡m¬ü°êÂå¾Ç·|´Á¥Z¡n6¤ëµoªí¤@¶µ¬ã¨sÅã¥Ü¡A¦³¤T¤À¤§¤@¬ü°ê¤H¥Ø«eªA¥ÎÃĪ«¥i¯à¤Þ°_±¡ºü»Ùê¡C¨ä¥L¬ã¨s¤]¦³Ãþ¦üµo²{¡A¬ü°êÂå¾Ç·|¬ã¨s«h¬O¾ú¨Ó³Ì¤j³W¼Ò¬ã¨s¦¨ªG¡C
¬ã¨s¤Hûµo²{¡A¬ù¦³200ºØ³B¤èÃĪ«¡A¥]¬A¦Ñ¦~¤H±`¥ÎÃĪ«¡A¨Ò¦p¥Î©óªvÀøG»Ä¬ÛÃö¯e¯fªº²BÂ÷¤lÀ°®úªýÂ_¾¯(proton pump inhibitor¡A²ºÙPPI)¡A¥H¤ÎªvÀø°ª¦åÀ£ªº£]¨üÅéªýÂ_ÃÄ(Beta blocker¡^¡A¥i¯à¾ÉP¼~Æ{¯g¡CôÛ¤ñ¨È¤j¾Ç¼Ú¤åÂå¾Ç¤¤¤ßºë¯«¯f¾Çº[¬y¦æ¯f¾Ç±Ð±Â¶ø¶O´Ë(Mark Olfson)ªí¥Ü¡A¦ý³\¦hÂå¥Í¥i¯à¤£ª¾¹D¡A±`¥Î³B·ÃĪ«»P¼W¥[±¡ºü¥¢±±·ÀI¦³Ãö¡C
¬ã¨s«ü¥X¡A¤H̪A¥ÎÃĪ«¶V¦h¡A¼W¥[¼~Æ{·ÀI¶V°ª¡C¹ï©ó¤@¨ÇªA¥Î¦hºØÃĪ«ªº¦Ñ¦~¤H¡A¥i¯à¦³§ó¦h¾÷²v¨ü¨ìÃĪ«°Æ§@¥Î¼vÅT¡C¦ý¶ø¶O´Ë¤]»¡¡A§Y¨ÏªA¥ÎÃĪ«»P¼~Æ{¦³Ãö¡A¤]¤£¤@©w¬O³y¦¨¼~Æ{ì¦]¡A¦]¬°¤j¦h¼ÆªA¥ÎÃþ¦üÃĪ«ªº¤H¡A¨Ã¥¼¿©±w¼~Æ{¯g¡C
¯Ã¬ù¦è©`¤s¨Ì§¢Âå¾Ç°|ºë¯«¾Ç±Ð±Â¸ëªL§J(Igor Galynker)ªí¥Ü¡A¦³®ÉÔ¡A¤H̦b¶}©lªAÃÄ«e´Nµo¥Í¼~Æ{¡A©Î¬O¦UºØ°·±dª¬ªp¾ÉP¼~Æ{¡C¨Ò¦p¥b¼Æ¥H¤W¦³ºC©Ê¯kµhªÌ©ö±w¼~Æ{¡A¦]¬°·Pª¾¯kµhªº¤j¸£³¡¤À¤]·|¼vÅT±¡ºü¡C¥H¤U¬O¥i¯à¾ÉP¼~Æ{ªºÃĪ«¡G
1. £]¨üÅéªýº¢¾¯©M¦åºÞºò±i¯ÀÂà´«酶§í»s¾¯(¦åÀ£ÃĪ«)¡Gmetoprolol¡Batenolol¡Benalapril»Pquinapril¡C
2. §Ü¼~Æ{ÃĪ«¡GªÙ¦±ªL(Zoloft»P¾Ç¦WÃÄ)¡B¦è酞´¶Äõ(Celexa)¡B¤G´á¥(Wellbutrin)¡Bªü¦Ì´ÀªLµ¥¡C
3. §ÜļÆ{ÃÄ¡Galprazolam (Xanax)¡Bclonazepam (Klonopin)¡Bdiazepam (Valium)¡Blorazepam (Ativan )¥H¤Îsedative zolpidem (Ambien )¡C
4. ¾~¤ùÃþÃĪ«¡]Opioid¡^¡G²B¥iଲզXÃĪ«(Lorcet¡BNorco¡BVicodin»P¨ä¥L¾Ç¦WÃÄ)¡Btramadol (ConZip)¡C
5. ¥Ö½èÃþ©T¾J¡Gprednisone»P¨ä¥L¡C
6. Ãĩж}¬[ÃĪ«²BÂ÷¤lÀ°®úªýÂ_¾¯(PPI)G»Ä»s¾¯¡Gomeprazole (Prilosec, Zegerid) ¡Besomeprazole (Nexium)¡Bantacids ranitidine (Zantac and generic)¥H¤Îfamotidine (Pepcid)µ¥¡C
7. ¹L±Ó»P®ð³ÝÃĪ«¡G¶}¬[Zyrtec¥H¤Î³B¤èÃĪ«montelukast (¦pSingulair)¡C
8. §ÜÅöíw¯gÃĪ«(Anticonvulsants)¡Ggabapentin (Neurontin)¡Btopiramate (Topamax)¡C
9. ¶Pº¸»X¡G»Û¿E¯Àestradiol (Delestrogen¡BElestrin¡BEstroGel)¡B¤fªA¶¯©Ê¨rÃĪ«finasteride (Proscar¡BPropecia)¡C
¦P®É¡AªA¥ÎÃĪ«®É¡A¶·¦P®ÉºÊ±±±¡ºü¡BÀˬdªA¥ÎÃĪ«¤º®e¡B±K¤ÁÃöª`ªA¥Îªº·sÃÄ¡B¸ß°Ý¦³Ãö§ó´«ÃĪ«¸ê°T¡A©Î¿Ô¸ßÂå¥Í¡A¦Ò¼{¥Í¬¡¤è¦¡¡A¨Ò¦p§Ö¨B¨«¸ô¥i§ïµ½¤[§¤¤£°ÊªÌªº¼~Æ{±¡ªp¡C
¼~Æ{ÃĪ«ªº¾÷·|? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/24 ¤U¤È 06:54:56
²Ä 469 ½g¦^À³
|
½LÂI| 2018¦~10¤jÃĪ«Á{§É¬D¾Ô¡GAD¬ãµo²×¤î²v³Ì°ª ¤å³¹°Ñ¦Ò¨Ó·½¡GDown but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018 ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-12-24 ·s®öÂåÃĽsĶ/newborn
med.sina.com/article_detail_103_2_58011.html
¦^ÅU2018¦~¡AÂåÃĦæ·~¨ú±o¤F«Ü¦h¦¨´N¡A¦ý¤]±Á{µÛ«Ü¦h¬D¾Ô¡C¥H¤U¬OBiospaceºô¯¸¦C¥Xªº2018¦~³Ì¤Þ¤Hª`¥Øªº¤Q¤jÃĪ«Á{§É¬D¾Ô¡G
1¡Bpioglitazone 1¤ë25¤é¡AªZ¥Ð»sÃÄ»P¦X§@¹Ù¦ñZinfandel¸g¹L¤¤´Á¤ÀªR«á©ñ±ó¤F¬°´Á5¦~ªºTOMORROWÁ{§ÉIII´Á¬ã¨s¡A¸Ó¬ã¨s¥¿¦bµû¦ôpioglitazoneªvÀøªüº¸¯ý®üÀq¤ó¯g¡]AD¡^¤Þ°_ªº»´«×»{ª¾»Ùê¡C
2.BI-409306 2¤ë9¤é¡A«kªL®æ®ï®æ¿««Å¥¬BI-409306¥¼¯à¹F¨ì¥Dn²×ÂI¡A±N²×¤îII´ÁÁ{§É¶}µo¡C¸ÓÃĬO¤@ºØPDE9§í»s¾¯¡A¥Î©óªvÀøºë¯«¤Àµõ¯g©MAD±wªÌªº»{ª¾·l®`©M°O¾Ð»Ùê¡A¦b¨âÓ³æ¿WªºÁ{§É¬ã¨s¤¤§¡¥¼¯àÅã¥Ü¥XÀu©ó¦w¼¢¾¯ªº»{ª¾Àu¶Õ¡C
3¡Bverubecestat 2¤ë14¤é¡AÀq¨FªF«Å¥¬²×¤îverubecestatªvÀø«eÅX´ÁADªº¤j«¬III´ÁÁ{§É¬ã¨sAPECS¡]protocol 01 9 ¡^¡C¥~³¡¼Æ¾ÚºÊ´ú©eû·|¡]eDMC¡^¦b§¹¦¨¤@¶µÁ{®É¤¤´Á¤ÀªR«á«Øij²×¤î¸Ó¬ã¨s¡AºÙ¨ü¯qªº¥i¯à©Ê¨Ã¤£¤j©ó·ÀI¡C¦Ó¦b2017¦~2¤ë14¤é·í¤Ñ¡A¸Ó¤½¥q«Å¥¬²×¤îverubecestatªvÀø»´¦Ü¤¤«×ADªº¤j«¬III´ÁÁ{§É¬ã¨sEPOCH¡]protocol 017¡^¡C³o¤]·N¨ýµÛ¡AverubecestatªvÀøADªºIII´ÁÁ{§É¶µ¥Ø¤w§¹¥þ²×¤î¡Cverubecestat¬O¤@ºØ£]-¾ý¯»¼Ë³J¥Õ«eÅé³J¥Õµõ¸Ñ酶1¡]BACE1¡^¤p¤À¤l§í»s¾¯¡C
4¡Bozanimod 2¤ë28¤é¡A·s°ò¦hµo©Êµw¤Æ¯g¡]MS¡^¤fªAÃĪ«ozanimod·sÃĥӽС]NDA¡^¦¬¨ì¬ü°êFDAªº©Úµ´¨ü²z³qª¾®Ñ¡]RFL¡^¡A¦ÓFDAµ¹¥Xªº©Úµ´¨ü²z²z¥Ñ©~µM¬O¸ÓÃÄNDA¤¤ªº«DÁ{§É©MÁ{§ÉÃIJz¾Ç³¡¤À¡AÁnºÙ¸Ó³¡¤ÀÃÒ¾Ú¤£¨¬¥HÄ~Äò¹ï¨ä¶i¦æ¼f¬d¡C ¤µ¦~6¤ë¡A·s°ò©Ó»{¿ù»~¡A¦ý±N¿ù»~Âk©S©ó¤l¤½¥qReceptos¡COzanimod¬O·s°ò´Á±æ«Ü°ªªº«á´ÁºÞ½uÃĪ«¡A
¦b2015¦~¥H72»õ¬ü¤¸¦¬ÁÊReceptos«áÀò±o¡C
2017¦~5¤ë²Ä2ÓÃöÁä©ÊIII´ÁRADIANCEªº¿n·¥¼Æ¾Ú¥XÄl¤§«á¡A·s°ò¦b2017¦~©³´£¥æ¤FozanimodªºNDA¡C¤µ¦~10¤ë¡A·s°ò¤½§G¤F¨Ó¦ÛIII´ÁSUNBEAM©MRADIANCE B³¡¤À¬ã¨sªº¨â¶µ¨Æ«á¤ÀªR¿n·¥¼Æ¾Ú¡A¨Ãªí¥Ü±N©ó2019¦~¦A¦¸´£¥æ¥Ó½Ð¡C
5¡Bepacadostat 4¤ë6¤é¡AIncyte¤½¥q©ÜÅS¨äIDO1ÃĪ«epacadostat»PÀq¨FªFPD-1¸~½F§K¬ÌÀøªkKeytrudaÁp¦X¥ÎÃĤè®×¦b¶Â¦â¯À½F III´ÁÁ{§É¬ã¨s¡]ECHO-301/KEYNOTE-252¡^¤¤¥¼¯à¹F¨ì¥Dn²×ÂI¡C
6¡Bazeliragon 4¤ë10¤é¡AvTv Therapeutics¤½¥q«Å¥¬azeliragonªvÀø»´«×ADªºIII´ÁSTEADFASTÁ{§É¬ã¨s¥¼¯à¹F¨ì¦@¦P¥DnÀø®Ä²×ÂI¡C¸Ó¬ã¨s¥Ñ¨âÓ¿W¥ß¦ý¬Û¦PªºÂùª¼¡B¦w¼¢¾¯¹ï·ÓPart A©MPart B²Õ¦¨¡CPart A¼Æ¾ÚÅã¥Ü¡A±µ¨üazeliragonªvÀøªº±wªÌªüº¸¯ý®üÀq¤ó¯gµû¦ô¶qªí-»{ª¾¤l¶qªí¡]ADAS-cog¡^¬Û¹ï°ò½u¤U°4.4¤À¡BÁ{§Éè§bµû©w¶qªí¡]CDR-sb¡^¬Û¹ï°ò½u¤U°1.6¤À¡A¦w¼¢¾¯²Õ¤À§O¤U°3.3©M1.6¡C³o¨ÇÅܤƦbÁ{§É¤W¨Ã¤£ÅãµÛ¡CAzeliragon¬O¤@ºØ·s«¬¤fªARAGE¬¡©Ê¤p¤À¤l§í»s¾¯¡A¬O¤½»{ªºªý¤î¸£¨üÅéRAGE¡]±ß´Á¿}¤Æ²×²£ª«¨üÅé¡^ªº³Ì¥ý¶iÃĪ«¡CvTv¤½¥q»{¬°¡AªýÂ_RAGE¥i¥H3ºØ¤è¦¡§ðÀ»AD¡G¯}ÃaAD¾ý¯»¼Ë³J¥Õ¤ù¬qªº»W¿n¬r©Ê¡F´î½w»P¨ä¬ÛÃöªºtau³J¥Õ¤À¸Ñ¡F´î¤Ö¤j¸£ª¢¯g¡C
7¡Bcobimetinib 4¤ë11¤é¡Aù¤ó©MExelixis¼È°±Âಾ©Êµ²ª½¸zÀù II´ÁÁ{§É¬ã¨sMODUL±wªÌ©Û¶Ò¡Aì¦]¬O¦³4¨Ò±wªÌ±µ¨üù¤óPD-L1¸~½F§K¬ÌTecentriq»PExelixis¤½¥qMEK§í»s¾¯Cotellic¡]cobimetinib¡^Áp¦XªvÀø«á¦º¤`¡C¤µ¦~5¤ë¤¤¦¯¡ATecentriq+Cotellic²Õ¦XÀøªk¦bªvÀø¬J©¹±µ¨ü¦Ü¤Ö¨â½ü¤ÆÀø¥¢±Ñªºµ²ª½¸zÀù±wªÌIII´ÁÁ{§É¬ã¨sIMblaze370¤¤Àø®Ä¤£¼Ä«ô¦Õ¹v¦VÃĪ«Stivarga¡]regorafenib¡^¡CCotellic¬O¤@ºØ¤fªA¤p¤À¤lMEK§í»s¾¯¡AMEK¬O¤@ºØ³J¥Õ¿E酶
8¡Batabacestat 5¤ë18¤é¡A±j¥ÍºX¤U·¨´Ë²×¤îatabacestat¡]¤@ºØBACE§í»s¾¯¡^ªvÀøADªºÁ{§É¶µ¥Ø¡C¦¹¦¸²×¤îì¦]¬O¦w¥þ©Ê°ÝÃD¡A¦Ó¤£¬OÀø®Ä¤è±¡C¦bÁ{§É«eAD±wªÌ¤¤¶}®iªºIIb/III´Á¬ã¨sEARLY¥H¤Î¦b¤@¶µII´Áªø´Á¦w¥þ©Ê¬ã¨s¤¤§¡Åã¥Ü¡A±wªÌ¨x酶¤É°ª¡CEARLY¬ã¨s©ó2015¦~±Ò°Ê¡Aìp¹º¦b2024¦~µ²§ô¡C
9¡BExondys 51 9¤ë21¤é¡ASarepta Therapeutics¤½¥q§ù¤ó¦ÙÀç¾i¤£¨}¯g¡]DMD¡^ªvÀøÃĪ«Exondys 51¤W¥«¥Ó½Ð³Q¼Ú¬wÃÄ«~ºÞ²z§½¡]EMA¡^»é¦^¡Cȱoª`·Nªº¬O¡A¦b¬ü°êºÊºÞ¤è±¡AFDA¦b¯A¤Î¸Ó¾÷ºc¤º³¡½Ä¬ð¡B´CÅé³ø¾É¡B°ê·|ijû¥H¤ÎDMD±M®a¤p²Õµo¥X¤½¶}«H¥ó´°«P§å㪺¿E¯Pª§°«¤§«á¡A©ó2016¦~9¤ë§åã¤FExondys 51¡C´£¥æµ¹EMAªº¥Ó½Ð¬O°ò©ó¹ï12¨Ò7-13·³DMD¨k«Ä¶}®iªº¨â¶µÁ{§É¬ã¨s¡C ¦b¬ü°ê¡AExondys 51ªº»ù®æ¼ÐÅÒ°ò©ó±wªÌÅé«¡A¤j¬ù¬°¨C¦~30¸U¬ü¤¸¡C
10¡BALKS5461 11¤ë2¤é¡AFDAªº¨âÓÅU°Ý©eû·|§ë²¼§_¨M¤FAlkermes¤½¥qªº§íÆ{¯gÃĪ«ALKS5461¡C¨ãÅé¦Ó¨¥¡A©eû·|¥H21:2ªº§ë²¼µ²ªG¤Ï¹ï§åã¸ÓÃÄ¡A¦P®É¥H20:3ªº§ë²¼µ²ªG»{¬°Alkermes¤½¥q¨S¦³´£¨Ñ¤ä«ùALKS5461Àø®Äªº¹ê½è©ÊÃÒ¾Ú¡C ¤µ¦~4¤ë¡A¸ÓÃÄNDA¦¬¨ìFDAªº©Úµ´¨ü²z³qª¾®Ñ¡A¸Ó¾÷ºc»{¬°NDA¤¤©Ò¯Ç¤JªºÁ`ÅéÀø®ÄÃÒ¾Ú¤£¨¬¡An¨D¶}®i§ó¦hªºÁ{§É¸ÕÅç¥H¤ä«ù«·s´£¥æ¡C¤§«áAlkermes¤½¥q´£¥X¤W¶D¡A¦ÓÀH«áFDA¤]§ïÅܤF¥D·N¡A«·s¨ü²z¤FALKS5461ªºNDA¡APDUFA¥Ø¼Ð¤é´Á¬°2019¦~1¤ë31¤é¡CÁöµM¨âӿԸߩeû·|³£±j¯P¤Ï¹ï¡A¦ý¨ä·N¨£¹ïFDA¨Ã¨S¦³ªk«ß¬ù§ô¤O¡A¤]´N¬O»¡¸Ó¾÷ºc¦b°µ¥X³Ì²×¼f¬d¨M©w®É¨S¦³¥²n¿í´`¿Ô¸ß©eû·|ªº«Øij¡A¦ý¦pªGFDA§åã¤F¸ÓÃĪ«¡A±N¥O¤H·P¨ìÅå³Y¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/24 ¤U¤È 06:34:35
²Ä 468 ½g¦^À³
|
©¬ª÷´Ë·sÃÄ¡I¥ª±Û¦h¤Ú§l¤J¯»INBRIJAÀòFDA§åã ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-12-24
med.sina.com/article_detail_103_2_58020.html
¤é«e¡AAcorda »sÃÄ«Å¥¬¡A¬ü°ê¹«~©MÃĪ«ºÞ²z§½¡]FDA¡^§åãINBRIJA¥Î©ó±µ¨ü¥d¤ñ¦h¤Ú/¥ª±Û¦h¤ÚªvÀøªº©¬ª÷´Ë¯fÃö³¬´Á¡] OFF ¡^¶¡·²©ÊªvÀø¡C
INBRIJA¬O¤@´Ú«K©ó±wªÌ¦Û¤v¾Þ§@ªº§l¤J¦¡¥ª±Û¦h¤Ú¡A¥Î©óªvÀø¥Ø«e¦b¨Ï¥Î¥d¤ñ¦h¤Ú/¥ª±Û¦h¤Úªº©¬ª÷´Ë¯f±wªÌÃö³¬´Á¯gª¬¡CINBRIJA§Q¥ÎAcordaªºARCUS¥¥x¶}µo¡A¦®¦b¦VªÍ³¡´£¨Ñºë½T¾¯¶qªº¥ª±Û¦h¤Ú°®¯»»s¾¯¡C¤fªAÃĪ«»Ýn¥ý³q¹L¸zG§l¦¬¦A¨ì¹F¤j¸£¡A©Ò¥H°_®Ä¹Lµ{·|¦³ÅܤơC¦Ó§l¤J¦¡ªvÀø¥i¥H³q¹LªÍ³¡¶i¤J¨Åé¡Aª½¹F¤j¸£¡A¶¹L¤F®ø¤Æ¨t²Î¡C
©¬ª÷´Ë¯f¬O¥Ñ©ó¬Y¨Çt³d²£¥Í¦h¤ÚÓiªº¯«¸g¤¸³vº¥³à¥¢¦Ó¤Þ°_ªº¶i¦æ©Ê¯«¸g°h¦æ©Ê¯e¯f¡A·|¾ÉP¤@¨t¦C¯gª¬¡A¥]¬A¹B°Ê¨ü·l¡B¦Ù¦×»øµw©M¾_Ÿ¡C¥Ø«e¡A¥d¤ñ¦h¤Ú/¥ª±Û¦h¤Ú¾¯¶q¬O©¬ª÷´Ë¤ó¯g¤fªAªvÀø¼Ð·ÇÃĪ«¡C¡§¶}-Ãö²{¶H¡¨¡]ON-OFF¡^¬O©¬ª÷´Ë¯f¤HÃĪ«ªvÀø«á´Áªº¨Ãµo¯g¡C¡§¶}¡¨¬O«üÃĪ«ªvÀø¹ï¯f¤H°_¨ì©úÅ㪺ªvÀø®ÄªG¡A¯f¤H¯à¹B°Ê¡F ¡§Ãö¡¨¬O«ü¯f¤H¦b±µ¨üªvÀø¤@¬q®É¶¡«á¹B°Ê¯à¤O³à¥¢¡A³o¬O¥Ñ©ó¤fªA¤§¶¡ªº§C¤ô¥¦h¤ÚÓi¤Þ°_ªº¡C³oºØÅܤƳt«×¥i¥H«D±`§Ö¡A¨Ã¥B¬O¤£¥i¹w´úªº¡C¯f¤H§Î®e¯f±¡ªºÅܤƴN¹³¬O¹q·½ªº¶}¡BÃö¤@¼Ë¡A©Ò¥HÁ{§É¤W§Î¹³¦aºÙ³oºØ²{¶H¬°¶}-Ãö²{¶H¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/24 ¤U¤È 06:30:08
²Ä 467 ½g¦^À³
|
ÆF¥_ºë¯«¤Àµõ¯g·sÃÄRexulti¤J¼Ú¬w¥«³õ ¨Ó·½¡G ¥Íª«¨¦ ¡@2018-12-24
med.sina.com/article_detail_100_1_58033.html
¤¦³ÁÃÄ¥øÆF¥_¡]H.Lundbeck¡^ªñ¤é«Å¥¬¡A±N©ó2019¦~1¤ë1¤é¦b·ç¤h±À¥XRexulti¡]brexiprazole¡^¡A¥Î©óªvÀøºë¯«¤Àµõ¯g¦¨¤H±wªÌ¡C¸Ó¤½¥q±N¦b2019-2020¦~´Á¶¡³°Äò¦b¨ä¥L¼Ú¬w°ê®a±À¥X¸ÓÃÄ¡C
brexpiprazole¬O¤@ºØ¨C¤é¤@¦¸ªº²Ä¤G¥N¡]«D¨å«¬¡^¤fªA§Üºë¯«¯fÃĪ«¡A¥Ñ¤j¶ïµo²{¡A¥ÑÆF¥_©M¤j¶ïÁp¦X¶}µo¡C¦b¬ü°ê¥«³õ¡Abrexpiprazole¡]«~µP¦WRexulti¡^©ó2015¦~7¤ëÀò§å¡A»²§UªvÀø««×§íÆ{¯g¡]MDD¡^¦¨¤H±wªÌ¥H¤ÎªvÀøºë¯«¤Àµõ¯g¦¨¤H±wªÌ¡C¦b¼Ú·ù¡Abrexpiprazole©ó2018¦~7¤ë©³Àò§å¡AªvÀøºë¯«¤Àµõ¯g¦¨¤H±wªÌ¡C
ºë¯«¤Àµõ¯g¡]schizophrenia¡^¬O¤@ºØºC©Ê¡BÄY«ªººë¯«°·±d»Ùê¡A©¹©¹P´Ý¡F±wªÌ¥i¯à¥X²{»{ª¾¡B±¡ºü¡B¦æ¬°¤è±ªº§ïÅÜ¡A¨ä¤¤¦k·Q©M¤Ûı¬O³Ì±`¨£ªº¯gª¬¡Cºë¯«¤Àµõ¯gªº¯fµ{¤@¯ë¾E©µ¡A§e¤Ï´_µo§@¡B¥[«©Î´c¤Æ¡A³¡¤À±wªÌ³Ì²×¥X²{°I°h©Mºë¯«´Ý¯e¡A¦ý¦³ªº±wªÌ¸g¹LªvÀø«á¥i«O«ù²¬Â¡©Î°ò¥»²¬Â¡ª¬ºA¡C
¥Ø«e¡ARexultiªvÀø««×§íÆ{¯g¡]MDD¡^©Mºë¯«¤Àµõ¯gªº½T¤Á§@¥Î¾÷¨î©|¤£©ú¤F¡A¸ÓÃĪºÀø®Ä¥i¯à¬O³q¹L5-HT1A¨üÅé©M¦h¤ÚÓiD2¨üÅ骺³¡¤À¿E°Ê¾¯¬¡©Ê¡B¦å²M¯À5-HT2A¨üÅ骺«ú§Ü¾¯¬¡©ÊÁp¦X¤¶¾É¡C¦¹¥~¡ARexulti°£¤F¹ï³o¨Ç¨üÅéªí²{¥X°ª¿Ë©M¤O¡]¦¸¯Ç¼¯º¸¡Asubnanomolar¡^¡A°w¹ï¥h¥ÒµÇ¤W¸¢¯À£\1B/2C¨üÅé¤]ªí²{¥X°ª¿Ë©M¤O¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/18 ¤U¤È 05:59:32
²Ä 466 ½g¦^À³
|
½²±Ð±Â½×¤å¶° Publications by authors named Guochuan Tsai
www.pubfacts.com/author/Guochuan+Tsai
1. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.
...
57. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/12 ¤U¤È 06:07:21
²Ä 465 ½g¦^À³
|
SND-11 , SND-12 , SND-13 , SND-14 ªº¥Î³~±M§Q³£®³¨ì¤F
10,149,845 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical 10,098,861 Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof 10,039,730 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical 9,675,604 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical 9,649,304 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
³o¥NªíµÛ ·íÃÄÃÒ®³¨ì¥H«á , ¥Îf¥Ò»Ä(ÆQ)¨ÓªvÀø«äı¥¢½Õ¯g ¥¢´¼¯g »´«×»{ª¾»Ùê , ¤ß®®¾Ö¦³±MÄÝÅv , ¥L¼t¤£±o¨Ï¥Î ¦Ó¥B±M½æ´Á¤]¥i¥Ñì¨Óªº 3¦~ 5¦~ ©Î 7¦~ , ¤j´T¸õ¤É¨ì±M§Q´Áº¡(³Ì¤j20¦~,¹ê°È¤W©Î¦³¤Q¨Ó¦~) ³o¹ï¤@ÀÉ·sÃĦӨ¥ , ±M½æ´Á©µªøµ¥©ó¬O¾P°â°ª®p´Áªº©µªø , ¹ï·sÃĤ½¥qªºÀò§Q§U¯q , §ó¦³¦p¸Às¦b¤Ñ¦h¦h¦~ ³o¬OÓ¤Hªº¸ÑŪ , µMY¦³©Ò¿ù»~ , ¤]½Ð¤j®a«ü¾É«ü¥¿
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/11 ¤U¤È 05:41:02
²Ä 464 ½g¦^À³
|
¹ù¥S¤S¦³·s±M¤åµoªí
Frontiers Molecular Biosciences 107¦~11¤ë , ¤wDAAO¬°¥DÃD ¥X¥Z±´°Q
liawbf.pixnet.net/blog/post/48719601
¹ù¥S¨Ã¹ï¨ä´£¥X5ÂI«n«ä¦Ò ÁÂÁ¹ù¥S¤À¨É ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/11 ¤U¤È 02:49:38
²Ä 463 ½g¦^À³
|
¹ï¤£°_ §ó¥¿³sµ²
patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22Tsai%3B+Guochuan+Emil%22.INNM.&OS=IN/%22Tsai;+Guochuan+Emil%22&RS=IN/%22Tsai;+Guochuan+Emil%22 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/11 ¤U¤È 02:43:02
²Ä 462 ½g¦^À³
|
®¥³ß ½²±Ð±ÂèèÀò±of¥Ò»Ä(ÆQ)¥Î©óªvÀø¥¢´¼¯g©Î»´·L»{ª¾»Ùꪺ¬ü°ê±M§Q
United States Patent 10,149,845 December 11, 2018
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Inventors: Tsai; Guochuan Emil (Pasadena, CA)
patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=34&f=G&l=50&co1=AND&d=PTXT&s1=Tsai.INNM.&OS=IN/Tsai&RS=IN/Tsai
²q´ú NaBen Áö¤wÀò±oFDA®Öã¶i¦æADªºÁ{§É , µM¿ð¥¼¶i¦æ ©Î³\½²±Ð´N¬O¦bµ¥«Ý®³¨ì³oÓ±M§Q«á , ¤~nµÛ¤â¦¬®×§a?!
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/12/7 ¤U¤È 12:37:07
²Ä 461 ½g¦^À³
|
쥻©óApril 26, 2018 ¤½¶}ªº±M§Q¥Ó½Ð °µ¤FY¤z×¥¿ ¤S«·s¤½¶}
United States Patent Application 20180346400 December 6, 2018
POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF
Abstract The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2.theta. of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2.theta. of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer¡¦s disease).
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/11/15 ¤U¤È 11:36:14
²Ä 460 ½g¦^À³
|
ªþ±a説©ú¡G Lurasidone¡]LATUDA¡^ ªvÀø¦¨¤H©M«C¤Ö¦~(13¦Ü17·³)ªº«äı¥¢½Õ¯g¡F²Ä¤@«¬Âù·¥©Ê¯e±w¤§Æ{¯gµo§@(¬°´Á¤»¶g¤§³æ¤@Àøªk©Î°t¦X¾YÆQ©Îvalproate¤§»²§UÀøªk)
³o¤SÅý¤H¹ï SNS¨t¦C±H¤©«p±æ ¦p¦PNRX-101ÂùÃÄÁp¦X¤@¼Ë¡A²£¥Í 1 + 1 ¤j©ó 2 ªºÀø®Ä
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/11/15 ¤U¤È 11:22:59
²Ä 459 ½g¦^À³
|
§ÚÌ°Q½×¹LªºNRX-101 FDA±Â¤©²Ä¤@´Ú°w¹ï¦Û±þ©ÊÂù¬Û§íÆ{¯g¤fªAÃĪ«¬ð¯}©ÊÀøªk»{ÃÒ
¨Ó·½¡G°Ê¯ßºô ¡@2018-11-15 §@ªÌ¡GMailman med.sina.com/article_detail_103_2_55953.html
NRX-101¬O¤@ºØ¥Ñ©T©w¾¯¶qªºD-Àôµ·®ò»Ä¡]DCS¡^(NMDA«ú§Ü¾¯)¤Îlurasidone²Õ¦¨ªº¤fªAÃĪ«²Õ¦X¡A¨ã¦³5-HT2a¨üÅé«ú§Ü¾¯¬¡©Ê¡C»P¦¹«e§å㪺©Ò¦³§Ü§íÆ{ÃĪ«¬Û¤ñ¡ADCS¯à´£°ª¨âºØ¯«¸g»¼½èªº¤ô¥¡A§Y¨¦®ò»Ä©M¨¦®ò酰Ói¡]Glx¡^
NeuroRx¥Ø«e¥¿¦bSPA¤U¶i¦æ¤@¶µÃöÁ䪺2b/3´ÁÁ{§É¸ÕÅç¡A§Y³q¹L¹ï¤ñ¨C¤é¤fªANRX-101Àøªk»P¼Ð·ÇªvÀø¡]lurasidone¡^¡A¨ÓªvÀø¦b´âÓiପì©léw«áªºÄY«Âù¬Û§íÆ{©M«æ©Ê¦Û±þ·N©À±wªÌ¡C
www.neurorxpharma.com/tablet/nrx-100nrx-101-overview.html
·P·Q¡G SNA-1 ÃÄ®ÄÀò±oÃÒ¹ê ¥t¥~¡A¬Û¦Pªº·Qªk¡A³o·|¥[³t«P¦¨J&J esketamine ©M SNG-12 ©Î SNA-1 ªº¦X§@¶Ü¡H §Æ±æ¤ß®®¥[§ÖÁ{§É¸}¨B
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/11/9 ¤W¤È 10:17:26
²Ä 458 ½g¦^À³
|
f¥Ò»Ä¾Y f¥Ò»Ä + ¾Y Âù¥\®Ä¶Ü?
±M§Q¤º¤å§i¶D§ÚÌ Finally, lithium benzoate unexpectedly showed better pharmacokinetic features and therapeutic efficacies as compared with sodium benzoate and lithium chloride in combination. »Pf¥Ò»Ä¶u©M´â¤Æ¾Yªº²Õ¦X¬Û¤ñ¡Af¥Ò»Ä¾Y¥X¥G·N®Æ¦aÅã¥Ü¥X§ó¦nªºÃÄ¥N°Ê¤O¾Ç¯S¼x©MªvÀø¥\®Ä¡C
¦CÁ|f¥Ò»Ä¾Y¥\®Ä . Lithium benzoate successfully rescued neuron toxicity induced by 3-nitropropionic acid (3-NP), which is known to induce mitochondria dysfunction, oxidative stress, and reactive oxygen species overproduction . enhanced spare respiratory capacity for mitochondria function, which plays an important role in various CNS disorders; ameliorated disease progression in an amyotrophic lateral sclerosis (ALS) animal model . protected neurons from oxygen and glucose deprivation . reduced cell death and behavior disability from toxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) either alone, or in combination with 3-NP . protected neuron damages caused by amyloid-£] peptides . lithium benzoate was observed unexpectedly to alleviate pain . Finally, lithium benzoate unexpectedly showed better pharmacokinetic features and therapeutic efficacies as compared with sodium benzoate and lithium chloride in combination
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! Y¦³¤£§´ , ·Ð½Ðª©¥D¤j¤j³w¤©§R°£ ÁÂÁÂ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/11/9 ¤W¤È 09:13:35
²Ä 457 ½g¦^À³
|
¹ï¤£°_! ¸É¥R¤@¤U±M§Q¥Ó½Ð
USE OF LITHIUM BENZOATE FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
November 8, 2018
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/11/9 ¤W¤È 08:58:23
²Ä 456 ½g¦^À³
|
f¥Ò»Ä¾Y f¥Ò»Ä + ¾Y Âù¥\®Ä¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/11/8 ¤W¤È 08:58:42
²Ä 455 ½g¦^À³
|
¤½¶}¸ê°TÆ[´ú¯¸«¤j°T®§¤½§i
(6575)¤ß®®¥»¤½¥q»PSIMPEX PHARMA PRIVATE LIMITEDñqSNA1 505(b)(2)¸z·»¿õ¾¯¤§¥Í²£¤Î¾P°â¨óij
1.¨Æ¹êµo¥Í¤é:107/11/07 2.«´¬ù©Î©Ó¿Õ¬Û¹ï¤H:SIMPEX PHARMA PRIVATE LIMITED 3.»P¤½¥qÃö«Y:µL¡C 4.«´¬ù©Î©Ó¿Õ°_¨´¤é´Á(©Î¸Ñ°£¤é´Á):107/11/07 5.¥Dn¤º®e(¸Ñ°£ªÌ¤£¾A¥Î):¥»¤½¥q©e°USIMPEX PHARMA PRIVATE LIMITED¥Í²£»s³yÃÄ«~¡A¤Î¥¼¨Ó¦L«×¡B¿W¥ß°ê®a°ê¨ó(CIS Countries)¡B«D¬wªk»y¨t°ê®a(Africa Francophone Countries)¡BªF«n¨È°ê¨ó(South East ASEAN Countries)¤§¦X§@¾P°â¡C 6.¨î±ø´Ú( ¸Ñ°£ªÌ¤£¾A¥Î):µL¡C 7.¹ï¤½¥q°]°È¡B·~°È¤§¼vÅT(¸Ñ°£ªÌ¤£¾A¥Î):¹ï¤½¥qªøµu´ÁÀç¹B¨ã¦³¥¿±ªº¼vÅT¡C 8.¨ãÅé¥Øªº(¸Ñ°£ªÌ¤£¾A¥Î): ¥Í²£SNA1Ãøªv«¬««×¼~Æ{¯g(Treatment-Resistant Depression)Á{§É¹êÅç¥ÎÃÄ¡A¤Î©Ý®i¥¼¨Ó¤Wz¦a°Ï¤§®ü¥~¥«³õ¡ASNA1¤]¦P®É¬OªvÀøµ²®Ö¯f¤§¥ÎÃÄ¡C 9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¥¼«OÃÒ¥¼¨Ó¨ú±oÃÄÃҤξP°â¤@©w¯à¦¨¥\¡A¦¹µ¥§ë¸ê·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/11/7 ¤W¤È 11:02:12
²Ä 454 ½g¦^À³
|
^±M®a:§Ü疱¯lÃĹw¨¾ªü¯÷®üÀq¯g ¥xÆW¹êÅçÀòÃÒ©ú 2018-11-07 01:21¤¤¥¡ªÀ °Ò¹ý´µ¯S6¤éºî¦X¥~¹q³ø¾É udn.com/news/story/6812/3465572?from=udn_ch1cate5_pulldownmenu
¤ß®®ÃĪ«ªº¥D¦¨¥÷ f¥Ò»Ä¶u ³æ¹ç»Ä , ³£¦³§Üµß §Ü¯f¬rªº¥\¯à Y hsv ¬° AD ªº¦¨¦]¤§¤@ , ¬O§_¬°f¥Ò»Ä¶u ³æ¹ç»ÄªvÀø AD ´£¨Ñ¥t¤@ªvÀø¾÷Âà ? ¦³½Ð¤j®aµo´§Google¥\¯à , §ä§ä¬Ý¬O§_¦³¦¹¥\®Ä ? Áö¹ù¥S¤wÀ°§Ú̾ã²z¤ß®®ÃĪ«¹ïªvÀøADªº²³¦h¾÷Âà µMY¤ß®®ÃĪ«¹ï¦¹hsv¦³ªvÀø¥\®Ä , °Z¤£¦b¦hºÞ»ô¤U¤¤¤S¼W²K¤@¼Î¬ü¨Æ ?
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/10/24 ¤U¤È 07:51:50
²Ä 453 ½g¦^À³
|
¹ù¥Sªº·s§@
10710 ¬ã¨s§Ö°T...
liawbf.pixnet.net/blog/post/48648474
ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/10/23 ¤U¤È 03:41:54
²Ä 452 ½g¦^À³
|
®¥³ß¤ß®® SND-51´I¶°»s³Æ¤èªk ¤µ¤éÀò±o¬ü°ê±M§Q
Enrichment methods for preparing tannic acid compositions
United States Patent 10,105,378 October 23, 2018
»s³Æ§t³æ¹ç»Äªº²Õ¦Xª«¡]¨Ò¦p¡AÃĪ«²Õ¦Xª«¡AÀç¾i²Õ¦Xª«©ÎÂå¾Ç¹«~²Õ¦Xª«¡^ªº¤èªk¡A¯S§O¬O¨ã¦³Àu²§®Ä¤O¡A¯Â«×©M¦w¥þ©Êªº´I§t³æ¹ç»Ä¸sªº¨º¨Ç¡C¥»¤åÁÙ´£¨Ñ¤F§t¦³³æ¹ç»Äªº²Õ¦Xª«¡A¨ä¥Î©ó§í¨îD-®ò°ò»Ä®ñ¤Æ酶©M/©Î¥Î©óªvÀøCNS¯f¯g©MªÎD¯g¡A¥]¬A¿}§¿¯f¡A°ª¦å¿}¯g¡A°ª¯×¦å¯g©Î°ªÁx©T¾J¦å¯g¡C
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/10/20 ¤W¤È 11:51:28
²Ä 451 ½g¦^À³
|
¹ù¥S¥ÑGlobaldata¬ã½Õ³ø§iªºÁÍ¶Õ , ¨Ó½×z SND-14 ( NaBen ) ªvÀø AD ªº¦h±¬Û¾÷Âà
liawbf.pixnet.net/blog/post/48640176
ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/10/18 ¤U¤È 03:29:07
²Ä 450 ½g¦^À³
|
¹ù¥S¤Sµ¹§ÚÌ SNG-12 ( sarcosine )ªvÀø¾÷Â઺¬ã¨s¦õÃÒ
¹ï¥I¼~Æ{¯g ¬¡¤Æ¾¢Ói»Ä¯à¨t²Î , ¦³«á³]¤§²z
liawbf.pixnet.net/blog/post/48639666
ÁÂÁ¹ù¥S ÁÂÁ¤j®a ! |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 1201 ~ 1300 «h¦^ÂÐ >> |